Addictive Behavior,Excluded: Patients whose use of alcohol or drugs is sufficient to impair compliance with protocol requirements.
Addictive Behavior,Current substance or alcohol use disorder as determined by the SCID or by positive drug toxicology results
Addictive Behavior,Subjects who consume >14 alcoholic drinks per week.
Addictive Behavior,Excessive consumption of xanthine-based beverages
Addictive Behavior,History of drug abuse or use of illegal drugs: use of soft drugs (marijuana  pot) within 3 months of the screening visit or hard drugs (cocaine  PCP  crack)within 1 year of the screening visit
Addictive Behavior,Non-smokers.
Addictive Behavior,Smokers may participate  but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules
Addictive Behavior,Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [ 1 Unit = 150mL of wine  360 mL of beer  or 45mL of 40% alcohol])
Addictive Behavior,Use of soft drugs ( such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine  phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug at screening.
Addictive Behavior,Subject has been a nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months
Addictive Behavior,subjects who have discontinued smoking or the use of nicotine/nicotine containing products for at least approximately 3 months may be enrolled in the study at the discretion of the investigator
Addictive Behavior,Current use of tobacco products including cigarettes  cigars  pipes  or chewing tobacco  current participation in a smoking cessation program  or discontinuation of smoking within 3 months prior to screening
Addictive Behavior,Exclusion Criteria: Consumption greater than 14 alcoholic drinks per week
Addictive Behavior,alcoholism  drug addiction  acute withdrawal from chemical dependency  psychiatric disease)
Addictive Behavior,Be current smokers of cigarettes (past 7 days)
Addictive Behavior,History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than fourteen units of alcohol per week
Addictive Behavior,History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day
Addictive Behavior,Inebriated
Addictive Behavior,or abstinence
Addictive Behavior,Patients who are currently cigarette smokers.
Addictive Behavior,Smokes at least 20 cigarettes per day (1 pack per day)
Addictive Behavior,Smoking
Addictive Behavior,Smoking  alcohol intake (more than 2 drinks/week)
Addictive Behavior,Use other forms of tobacco like cigars or chewing tobacco or are using anything else to help them quit smoking
Addictive Behavior,Subjects who are  appear to be  or are known  current or former drug addicts or alcoholics.
Addictive Behavior,History of drug abuse during prior twelve months
Addictive Behavior,History of smoking  alcoholism  and use of illicit drugs
Addictive Behavior,Patient has a history of substance abuse within the past year.
Addictive Behavior,Have been a smoker in the past 12 months
Addictive Behavior,Have smoked an average of at least 10 cigarettes/day in the preceding year  with < 3 month total abstinence period
Addictive Behavior,Subject is a nonsmoker or has not used nicotine-containing products for 6 months prior to study start
Addictive Behavior,Existing Substance abuse
Addictive Behavior,Use of any tobacco products in the 6 months proceeding drug administration.
Addictive Behavior,Abuse alcohol or drugs.
Addictive Behavior,Abuse alcohol or require drugs which  in the opinion of the investigator  may increase the risk of pancreatitis.
Addictive Behavior,Abuse drugs or alcohol.
Addictive Behavior,abusive drug or alcohol consumption.
Addictive Behavior,alcohol high consumption
Addictive Behavior,Alcohol or drug abuse
Addictive Behavior,Are known to have had a substance abuse (drug or alcohol) problem within the previous 3 years
Addictive Behavior,Self-reported level of motivation to stop smoking >=  7  on a scale of 1-to-10
Addictive Behavior,Subjects who consume > 14 alcoholic drinks per week
Addictive Behavior,Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
Addictive Behavior,has a history of alcohol or drug abuse within the past year
Addictive Behavior,Have had at least one HIV risk behavior (unprotected sexual activity  sharing injection drug needles without following CDC guidelines for needle-cleaning  sexual activity while under the influence of drugs or alcohol) during the three-month period prior t
Addictive Behavior,History of alcoholism or drug abuse within 12 months of the study.
Addictive Behavior,History of significant alcohol abuse or drug abuse within one year prior to the screening visit.
Addictive Behavior,Patients with excessive alcohol consumption or alcoholism that would be contraindicated with the use of acetaminophen.
Addictive Behavior,Subjects who have a history of alcohol or drug abuse within 1 year of study entry
Addictive Behavior,The presence of alcoholism or drug abuse within the past year
Addictive Behavior,history of smoking within 2 years of surgery  or
Addictive Behavior,alcohol consumption > 14 drinks per week
Addictive Behavior,Exclusion Criteria: Meets criteria for current abuse or dependence for any alcohol or illicit substance within the past month
Addictive Behavior,Chronic alcohol or illicit drug use
Addictive Behavior,Drug or alcohol abuse within 12 months of enrollment.
Addictive Behavior,had a history of alcohol or substance abuse within 12 months of enrolment
Addictive Behavior,History of drug or alcohol abuse or dependence
Addictive Behavior,Ingestion of alcohol within 1 week of the first dose of study medication.
Addictive Behavior,Recent history of drug and/or alcohol abuse
Addictive Behavior,Recent history of drug or alcohol abuse.
Addictive Behavior,Subject consumes more than 3 alcoholic beverages per day
Addictive Behavior,Subject consumes more than 6 caffeinated beverages per day
Addictive Behavior,Active substance abuse or dependence
Addictive Behavior,Active substance abuse or illegal drug use.
Addictive Behavior,Active substance abuse.
Addictive Behavior,Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine)
Addictive Behavior,Substance abuse
Addictive Behavior,Substance abuse or dependence within the past 3 months  except for nicotine
Addictive Behavior,Have a history of drug abuse in the past 2 years and/or positive finding on urinary drug screening  other than prescribed medication.
Addictive Behavior,History of drug abuse or use of illegal drugs: soft drugs (marijuana) within 3 months prior to the screening visit or hard drugs (cocaine  PCP  crack) within 1 year prior to the screening visit or positive urine drug screen at screening
Addictive Behavior,Recent history of drug abuse or use of illegal drugs: soft drugs (marijuana  pot) use within 3 months of the screening visit and hard drugs (cocaine  PCP  crack) use within 1 year of the screening visit
Address,Residing in Bandiagara for the duration of the study
Address,Residence in skilled nursing facility
Address,Subjects living too far from participating center or unable to return for follow-up visits
Address,All patients presenting to Mayo Clinic  Jacksonville  Florida for a screening  surveillance colonoscopy  and/or a diagnostic and surveillance upper endoscopy  will be eligible based on inclusion and exclusion criteria
Address,Live within 10 miles of UCLA
Address,Patient who live and can be located in the Kintampo District.
Address,Reside within zip codes corresponding to the lowest performing schools in the broad Miami area
Address,Residing in Lambarene for the duration of the study
Address,Living in an area where Arthritis Foundation aquatic programs were offered
Address,A rural population in the middle belt of Ghana
Address,Eligible patients will be offered entry into the study on the day of the procedure in the hospital GI or Mayo Clinic Jacksonville endoscopy suites.
Age,Inclusion Criteria: Inborn at Brigham and Women's Hospital  Boston
Age,Inclusion Criteria: Healthy men or women 18 years of age or older
Age,Inclusion Criteria: Male & Females aged 65 and older
Age,Inclusion Criteria: Male and female outpatients 18 years of age or older.
Age,Inclusion criteria: Male and female patients aged above ten years.
Age,Inclusion Criteria: Male and female subjects must be at least 45 years old at the time of consent.
Age,Inclusion Criteria: Male or female 12-70 years of age (inclusive).
Age,Inclusion Criteria: Men and women >= 18 years of age
Age,Inclusion Criteria: Men or women aged 60-85  inclusive
Age,Key Inclusion Criteria: Female and male subjects must be 18 to 65 years of age
Age,Men or women ages greater than or equal to 55 years
Age,Inclusion Criteria: all patients above 18 years
Age,Inclusion Criteria: Male or female subjects 18 to 65 years inclusive.
Age,Age group 6-25 years.
Age,Inclusion Criteria: 18 and 45 years
Age,Must be 18 or over
Age,Any subject over 18 years of age 
Age,18- 45 years old
Age,18 years of age and older
Age,18 years of age or older
Age,18 years of age.
Age,18 years or older
Age,18-80 years of age
Age,Patients must be in the age range of 40 to 80 years.
Age,age < 18 years
Age,age < 21
Age,Age <18 years or >80 years
Age,age = or > than 70 years
Age,Age > 18 years
Age,Age > 18 years.
Age,Age > 60 years
Age,Age >18years
Age,Age >4.0 to <10.0 years
Age,Age >= 18 years
Age,Age  >= 6 years.
Age,Age 18 - 80 Years
Age,age 18 to 65 years
Age,age 18-65 years
Age,Age 21 to 60 years (inclusive).
Age,Age  >= 18 years.
Age,Age between 35 and 75 years.
Age,Age less than 18
Age,Age limits (see below)
Age,Age of at least 18 years and 75 years or less
Age,Age older then 18 years of age.
Age,Age over 18 years
Age,Age over 50 years
Age,Aged 55 to 75
Age,Ages 18 - 60 years old
Age,Ages 18-80
Age,Ages Eligible for Study: 1 Month to 18 Years
Age,Ages Eligible for Study: 1 Year and older
Age,Ages Eligible for Study: 1 Year to 18 Years
Age,Ages Eligible for Study: 10 Years and older
Age,Ages Eligible for Study: 11 Months to 14 Months
Age,Ages Eligible for Study: 11 Years to 16 Years
Age,Ages Eligible for Study: 11 Years to 18 Years
Age,Ages Eligible for Study: 12 Years and older
Age,Ages Eligible for Study: 12 Years to 70 Years
Age,Ages Eligible for Study: 13 Years and older
Age,Ages Eligible for Study: 13 Years to 17 Years
Age,Ages Eligible for Study: 13 Years to 18 Years
Age,Ages Eligible for Study: 15 Years to 18 Years
Age,Ages Eligible for Study: 15 Years to 45 Years
Age,Ages Eligible for Study: 16 Years and older
Age,Ages Eligible for Study: 16 Years to 70 Years
Age,Ages Eligible for Study: 18 Years and older
Age,Ages Eligible for Study: 18 Years to 24 Years
Age,Ages Eligible for Study: 18 Years to 25 Years
Age,Ages Eligible for Study: 18 Years to 26 Years
Age,Ages Eligible for Study: 18 Years to 35 Years
Age,Ages Eligible for Study: 18 Years to 40 Years
Age,Ages Eligible for Study: 18 Years to 45 Years
Age,Ages Eligible for Study: 18 Years to 50 Years
Age,Ages Eligible for Study: 18 Years to 55 Years
Age,Ages Eligible for Study: 18 Years to 60 Years
Age,Ages Eligible for Study: 18 Years to 65 Years
Age,Ages Eligible for Study: 18 Years to 70 Years
Age,Ages Eligible for Study: 18 Years to 75 Years
Age,Ages Eligible for Study: 18 Years to 76 Years
Age,Ages Eligible for Study: 18 Years to 80 Years
Age,Ages Eligible for Study: 18 Years to 85 Years
Age,Ages Eligible for Study: 18 Years to 90 Years
Age,Ages Eligible for Study: 18 Years to 95 Years
Age,Ages Eligible for Study: 19 Years and older
Age,Ages Eligible for Study: 19 Years to 39 Years
Age,Ages Eligible for Study: 19 Years to 50 Years
Age,Ages Eligible for Study: 19 Years to 90 Years
Age,Ages Eligible for Study: 2 Years to 10 Years
Age,Ages Eligible for Study: 20 Years and older
Age,Ages Eligible for Study: 20 Years to 30 Years
Age,Ages Eligible for Study: 20 Years to 60 Years
Age,Ages Eligible for Study: 20 Years to 64 Years
Age,Ages Eligible for Study: 20 Years to 80 Years
Age,Ages Eligible for Study: 21 Years and older
Age,Ages Eligible for Study: 21 Years to 50 Years
Age,Ages Eligible for Study: 21 Years to 60 Years
Age,Ages Eligible for Study: 21 Years to 75 Years
Age,Ages Eligible for Study: 21 Years to 89 Years
Age,Ages Eligible for Study: 25 Years to 65 Years
Age,Ages Eligible for Study: 28 Weeks to 33 Weeks
Age,Ages Eligible for Study: 3 Months to 12 Years
Age,Ages Eligible for Study: 3 Months to 18 Years
Age,Ages Eligible for Study: 3 Years and older
Age,Ages Eligible for Study: 30 Years and older
Age,Ages Eligible for Study: 30 Years to 70 Years
Age,Ages Eligible for Study: 35 Years to 75 Years
Age,Ages Eligible for Study: 4 Years to 9 Years
Age,Ages Eligible for Study: 40 Years and older
Age,Ages Eligible for Study: 40 Years to 80 Years
Age,Ages Eligible for Study: 45 Years and older
Age,Ages Eligible for Study: 45 Years to 60 Years
Age,Ages Eligible for Study: 5 Years to 65 Years
Age,Ages Eligible for Study: 50 Years and older
Age,Ages Eligible for Study: 50 Years to 80 Years
Age,Ages Eligible for Study: 55 Years and older
Age,Ages Eligible for Study: 55 Years to 75 Years
Age,Ages Eligible for Study: 55 Years to 85 Years
Age,Ages Eligible for Study: 6 Weeks to 14 Weeks
Age,Ages Eligible for Study: 6 Years to 13 Years
Age,Ages Eligible for Study: 6 Years to 18 Years
Age,Ages Eligible for Study: 6 Years to 20 Years
Age,Ages Eligible for Study: 6 Years to 25 Years
Age,Ages Eligible for Study: 60 Years and older
Age,Ages Eligible for Study: 60 Years to 80 Years
Age,Ages Eligible for Study: 60 Years to 85 Years
Age,Ages Eligible for Study: 60 Years to 89 Years
Age,Ages Eligible for Study: 65 Years and older
Age,Ages Eligible for Study: 75 Years and older
Age,Ages Eligible for Study: 9 Years to 15 Years
Age,Ages Eligible for Study: up to 21 Years
Age,Ages Eligible for Study: up to 24 Hours
Age,Ages Eligible for Study: up to 3 Months
Age,Ages Eligible for Study: up to 3 Years
Age,Ages Eligible for Study: up to 59 Months
Age,Ages Eligible for Study: up to 6 Years
Age,All patients must be aged 18 years and older.
Age,Are at least 13 years old 
Age,Are at least 16 years old 
Age,Are between the ages of 18 and 70 years of age  inclusive.
Age,Be 18 years of age or older.
Age,Be 18 years old or older.
Age,Be a male or female at least 18 years of age 
Age,Be at least 18 years of age
Age,Be between the ages of 18 and 45 years old  inclusive
Age,Between 18 and 55 years of age
Age,Boys and girls between the ages of 9-15.
Age,Children ten years and below (to be catered for in the child antimalarial efficacy studies mentioned above).
Age,Criteria for children 15 months to 12 years of age
Age,Exclusion Criteria: < 18 years of age
Age,Exclusion Criteria: Age <21 years*
Age,Exclusion Criteria: age > 75 years
Age,Exclusion Criteria: Age less than 18 years
Age,Exclusion Criteria: Individuals younger than 11 years and older than 18 years
Age,Exclusion Criteria: Patient is less than 18 years of age
Age,Exclusion Criteria: Patient less than 18 years of age
Age,For all: Age 15-18
Age,In addition  they must meet all of the following criteria: be at least 18 years of age
Age,Inclusion Criteria: 10 years or older
Age,Inclusion Criteria: 18 to 85 years of age
Age,Inclusion Criteria: 18 years of age and older
Age,Inclusion Criteria: 18 years to 75 years of age
Age,Inclusion Criteria: 18-65 years of age
Age,Inclusion Criteria: age <= 75 years
Age,Inclusion Criteria: Age > 1 year
Age,Inclusion Criteria: Age > 18
Age,Inclusion Criteria: age > 18 years
Age,Inclusion Criteria: Age > 60 years
Age,Inclusion Criteria: Age >= 18 years
Age,Inclusion Criteria: Age 1 to 5 years old
Age,Inclusion Criteria: Age 18-45 years
Age,Inclusion Criteria: Age 18-55 years inclusive at the time of screening
Age,Inclusion Criteria: Age 19 and older
Age,Inclusion Criteria: Age 21-89
Age,Inclusion Criteria: Age 40 to 80 years  inclusive.
Age,Inclusion Criteria: Age greater than 18
Age,Inclusion Criteria: Age greater than 18 and less than 90
Age,Inclusion Criteria: Age is 18 and older.
Age,Inclusion Criteria: Age over 18 years
Age,Inclusion Criteria: Age: 18-80 
Age,Inclusion Criteria: aged 65 years or older
Age,Inclusion Criteria: Ages 18 to 100
Age,Inclusion Criteria: Are aged 55-85 years  inclusive
Age,Inclusion Criteria: Boys and girls ages 9-15
Age,Inclusion Criteria: Children between 6 and 18 years
Age,Inclusion Criteria: Must be between 21 and 50 years of age
Age,Inclusion Criteria: patients >18 years old
Age,Inclusion Criteria: patients aged 75 years old or more
Age,Inclusion Criteria: Subject is between 18 and 55 years of age
Age,Patient greater than or equal to 18 years of age
Age,Patient must be > 18 years of age.
Age,Patients must be >=  18 years of age.
Age,Patients must be older than one year of age
Age,Patients who are younger than 18 years of age
Age,Subject is >=  18 years old.
Age,Subject may be of any age
Age,Subjects must be >= 18 years and <= 75 years of age.
Age,Subjects must be >=18 years and <=75 years of age.
Age,Subjects up to 65 years of age may be enrolled in Panels B and C
Age,Under 18 years of age
Age,Under the age of 19
Age,Exclusion Criteria: Under 18
Allergy,Had a history or presence of dermal hypersensitivity
Allergy,A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to Exelon or to other cholinergic compounds  .  pilocarpine  bethanechol  tacrine  velnacrine  donepezil  metrifonate  or physostigmine)
Allergy,Exclusion Criteria: Hypersensitivity to the active ingredient or one of the components of the drug
Allergy,Exclusion Criteria: Sensitivity to immune globulin preparations or any benzodiazepine
Allergy,History of hypersensitivity or intolerability to either desloratadine or fexofenadine or other antihistamines.
Allergy,history of hypersensitivity to active or inactive excipients of tamoxifen and Zoladex
Allergy,History of hypersensitivity to bupropion or the nicotine transdermal patch (NTP)
Allergy,History of hypersensitivity to the investigational products or to drugs with similar chemical structures
Allergy,History of hypersensitivity to zolpidem  eszopiclone  or flurazepam.
Allergy,Hypersensitivity or idiosyncratic reaction to buspirone HCl
Allergy,Hypersensitivity to any component of ZYFLO CR
Allergy,Hypersensitivity to didanosine (ddI).
Allergy,Hypersensitivity to Irbesartan.
Allergy,Hypersensitivity towards any component of degarelix or mannitol
Allergy,hypersensitivity or idiosyncratic reaction to buspirone HCl.
Allergy,Known history of sensitivity to cyclogyl and/or proparacaine HCL 0.5%
Allergy,Known hypersensitivity to alfuzosin
Allergy,Known hypersensitivity to any study drug component.
Allergy,Known hypersensitivity to Argatroban or related compounds.
Allergy,Known hypersensitivity to AZT.
Allergy,Known hypersensitivity to estrogens  progestins  or other ingredients of Totelle
Allergy,Known hypersensitivity to IV or oral ganciclovir.
Allergy,Known hypersensitivity to murine or chimeric antibodies.
Allergy,Known hypersensitivity to the study drugs.
Allergy,No hypersensitivity to trastuzumab (Herceptin??)
Allergy,Patient has hypersensitivity to gabapentin.
Allergy,Patients who are sensitive or allergic to aspirin.
Allergy,Patients with the following are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
Allergy,Polyene hypersensitivity 
Allergy,Subjects who have known hypersensitivity to HMG-CoA reductase inhibitors.
Allergy,Patients with the following conditions or symptoms are excluded: Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
Allergy,Intolerance to Losartan therapy
Allergy,Allergic to insulin
Allergy,Allergy against niacin oder other ingredient of niaspan
Allergy,Allergy to DHA (Omega 3) or Vitamin D
Allergy,Allergy to fluorescein
Allergy,Allergy to lactose.
Allergy,Allergy to trial required medications
Allergy,Are allergic to study drugs or any ingredient in them.
Allergy,Exclusion Criteria: allergy to dairy proteins
Allergy,Food allergies to the study food
Allergy,Have an allergy to soybean oil and/or eggs
Allergy,History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Allergy,History of allergic reactions or anaphylaxis to immunizations or to any vaccine component
Allergy,History of allergic reactions to cabergoline or ergot derivatives
Allergy,History of allergic reactions to heparin
Allergy,History of allergic reactions to heparin  doxycycline  or other related drugs
Allergy,History of allergic reactions to heparin  propranolol  or other related drugs.
Allergy,history of allergies to lidocaine
Allergy,History of allergy to any of the proposed treatment or its alternatives  i.e
Allergy,History of allergy to vaccines components
Allergy,History of drug allergy of clinical significance in the opinion of the investigator.
Allergy,History of serious allergic reaction to any substance  requiring hospitalization or emergent medical care  
Allergy,History of serious allergic reactions to any substance  requiring hospitalization or emergent medical care
Allergy,History of serious allergic reactions to any substance  requiring hospitalization or emergent medical care or history of allergy to vaccines components
Allergy,Known allergies to aspirin  clopidogrel bisulphate (Plavix??) and ticlopidine (Ticlid??)  heparin  or stainless steel
Allergy,Known allergies to the same class of drug and/or allergies to eggs
Allergy,Known allergy to tetracycline.
Allergy,No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drug
Allergy,Patient with known allergy to iodine  iodine containing drugs or contrast agent
Allergy,Patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib  boron or mannitol.
Allergy,Patients with a history of allergic reaction to an intra-articular injection or avian products.
Allergy,Patients with known allergies to acetaminophen  lidocaine  hyaluronans  or avian products.
Allergy,Reported allergy to egg proteins  chicken proteins or any other constituent of the vaccine.
Allergy,Subject has a documented allergy to radiographic contrast that cannot be pre-treated.
Allergy,Subject has a documented allergy to the device materials.
Allergy,Subject has multiple and/or severe allergies to drugs or food
Allergy,Subjects who have a clinically significant history of food or drug allergy.
Allergy,You are allergic to amitriptyline or duloxetine.
Allergy,Known previous intolerance to zidovudine (AZT) at 500 mg/day.
Allergy,Subject has documented intolerance to BOTH heparin and Angiomax.
Allergy,History of grade 3 or worse intolerance to 500-600 mg/day AZT.
Allergy,Known intolerance or inefficacy to either drug.
Bedtime,Usual bedtime between 21:00 and 01:00
Bedtime,habitual bedtime between 9:00 pm and 1:00 am. 
Bedtime,reports habitual bedtime earlier than 9 pm or later than 1 am > 2 times per week 
Bedtime,regular sleep habits  including bedtime between 9 pm and midnight. 
Bedtime,self-report bedtimes that do not vary by > two hours on five nights per week 
Bedtime,sleep onset latency and / or bedtime resistance 
Bedtime,over the last three months for >= 5 nights per week  must have a normal bedtime of between 9 pm and 1 am and a time in bed of >= 7 hours 
Bedtime,patient's bedtime is between 9 pm and 1 am 
Bedtime,habitual bedtime should be determined by sleep history as between 9:00 pm and 12:00 am as determined by sleep history prior to randomization
Bedtime,have regular bedtime (within 1 hour) for 1 week prior to travel. 
Bedtime,usual bedtimes between 9:00 pm and midnight. 
Bedtime,patients who experience rls symptoms requiring treatment after 17:00 but prior to bedtime.
Bedtime,the subject has a history of the following sleep characteristics during the past three months or more at visit 1: bedtime between 22:00-00:00 h on >= five nights per week 
Bedtime,the patient has a habitual bedtime between 2100 and 2400. 
Bedtime,patient's usual bedtime is between 9 p. m 
Bedtime,their sleep schedule will include a typical bedtime of between 9:00 p. m
Capacity,Anticipated availability for blood draw 4-6 weeks following 3rd vaccine dose
Capacity,Ability to tolerate oral therapy.
Capacity,Are unable to take medications by mouth.
Capacity,Recent evidence of or history of significant psychiatric illness that may have compromised the subject's ability to comply with the study requirements
Capacity,Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Capacity,Inability to communicate or cooperate with the investigator because of a language problem  poor mental status  or impaired cerebral status.
Capacity,Available for the duration of the study.
Capacity,Available to participate in follow-up for the duration of study (13 months)
Capacity,Available to start intervention within 6 weeks
Capacity,Available for 12 months of follow-up and able to complete study assessments as per clinician judgment
Capacity,Parent/legal representative able to attend all scheduled visits and comply with all trial procedures.
Capacity,Subject is unable to refrain from or anticipates the use of any medication (with the exception of metformin or sulfonylurea agents)  including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks until the post-study v
Capacity,Are available for at least 8 weeks.
Capacity,Must be able to adhere to the study visit schedule and other protocol requirements
Capacity,Patients who are able to tolerate ICD programming as specifically prescribed in the study protocol
Capacity,Clinically significant disorder including excessive alcohol or drug abuse that may interfere with trial participation or influence the conclusion of the trial as judged by the investigator
Capacity,Mental incapacity or language barrier precluding adequate understanding or cooperation
Capacity,Adequate vision and hearing to participate in study assessments.
Capacity,Can communicate verbally or with assistive device
Capacity,Available to participate in follow-up for the duration of study (14 months)
Capacity,Any reason which  in the opinion of the medical subinvestigator  would prevent the subject from participating in the study
Capacity,Exclusion Criteria: can not answer a written questionaire
Capacity,Patients who are unable to complete quality of life questionnaires
Capacity,Patients who can perform the 50-foot walk test without the support of crutches or other assistive devices  except for canes
Capacity,Patients who cannot perform the 50-foot walk test without the support of crutches or other assistive devices  except for canes
Capacity,Able to follow 3-stage commands
Capacity,Able to recall 2/3 objects after 30 minutes
Capacity,Can swallow capsules
Capacity,Difficulty to swallow study medication.
Capacity,Patients will be excluded from this study for the following reasons: If they are unable to walk several blocks for whatever reason
Capacity,Capable of completing a 3-day food intake diary with instruction
Capacity,Difficulty to swallow study medication
Capacity,Must be able to swallow pills
Capacity,Able to understand the nature of the study and what will be required of them.
Capacity,Ability to walk 30 feet without assistance (cane and leg bracing is permitted).
Capacity,Exclusion Criteria: Patient not being able to walk
Capacity,Subjects must understand the dosing schedule.
Capacity,Able to perform 6 minute hall walk
Capacity,Able to self-administer study medication by subcutaneous injection or caregiver available to administer study medication.
Capacity,Able to take oral medications
Capacity,Exclusion Criteria: Patients who are unable to walk several blocks regardless of the reason will be excluded from all the trials  .  arthritis  stroke  claudication).
Capacity,Patients unable to or with any psychiatric illness that would prevent them to legally comprehend the details and nature of the study.
Capacity,Caregiver available to assist with the device every day (unless subject capable of using it independently
Capacity,Diaphragmatic weakness such that patients are unable to tolerate supine position  or swallowing impairment such that patients are unable to maintain nutrition without use of gastrostomy.
Capacity,Subject is unable to respond to external questions and stimuli and to exert a pressure with the contralateral hand.
Capacity,The participant must also be able to correctly rank the following three levels of pain from highest to lowest: 1) falling from a 2-story building and breaking both ankles  2) stubbing one's toe and 3) getting bitten by a mosquito.
Capacity,Unable to take oral medication reliably.
Capacity,Patient or family inability to understand or cooperate with study procedures
Capacity,Patient must be able to attend all required follow-up visits at the study center.
Capacity,You must be able to visit the doctor's office once a week for ten (10) weeks.
Capacity,Exclusion Criteria: Patients who are unable to walk several blocks for any reason.
Compliance,patients who  for whatever reason(eg  confusion  infirmity alcoholism) are unlikely to comply with trial requirements
Compliance,Ability to comply with the requirements of the entire study
Compliance,Intellectual  emotional  and physical ability to comply with oral medication.
Compliance,Capability of complying with study protocol.
Compliance,Patient must be able to comply with treatment regimen.
Compliance,Patients must be able to comply and understand the use of a diary
Compliance,Be able to comply with all study procedures
Compliance,Able to comply with all required study procedures and schedule
Compliance,The subject  in the opinion of the principal investigator  is unlikely to comply with the study protocol or is unsuitable for any other reason.
Compliance,Unlikely to comply with follow-up protocol
Compliance,Unlikely to comply with the study protocol and prescribed treatment or is unsuitable for any other reason in the opinion of the investigator
Compliance,Patient must complete the pre-treatment quality of life questionnaires.
Compliance,Will not engage in direct patient care until immunization scab falls off (around 21 days or 3 weeks after vaccination) if health care worker
Compliance,Subject cannot stop taking any of their current prescription or non-prescription medications during the study
Compliance,Inclusion Criteria: Adherence to prior or current HAART was or is being compromised  or HAART was discontinued/interrupted due to nausea/vomiting
Compliance,Inability to comply with study and follow-up procedures.
Compliance,Other condition that in the opinion of the PI would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
Consent,No serious medical or psychiatric illness preventing informed consent or intensive treatment  
Consent,Ability to provide written informed consent and/or assent.
Consent,Ability to voluntarily provide written informed consent prior to treatment.
Consent,Able to provide consent
Consent,Be able to give informed consent.
Consent,Be capable of reading and understanding patient information materials and giving written informed consent.
Consent,Capable of consent
Consent,Exclusion Criteria: Inability to give written informed consent.
Consent,Exclusion Criteria: Inability to provide informed consent
Consent,If they are unable to provide informed consent because of cognitive deficits
Consent,Inability to provide consent
Consent,Patient must be able to provide informed consent.
Consent,Patients must be able to provide informed consent
Consent,Patients must be able to provide informed consent within the one week after the procedure.
Consent,Patients who are able to give informed consent
Consent,Patients who are mentally incompetent and cannot sign a Patient Informed Consent form or comply with the study
Consent,Patients who are unable to provide consent.
Consent,Patients who are unable to provide informed consent.
Consent,Unable to provide consent
Consent,Women able to consent for themselves
Consent,Women unable to consent for themselves
Consent,Exclusion Criteria: Failure to provide an informed consent
Consent,Informed consent: Each patient must be completely aware of the nature of his/her disease process and must willingly give consent after being informed of the procedure to be followed  the experimental nature of the therapy  alternatives  potential benefits
Consent,Parent or guardian willing to provide informed consent
Consent,Parental non-consent
Consent,Patient or guardian available to give written informed consent.
Consent,Patients must have the following: Parent or guardian available to give written informed consent.
Consent,Patients must sign study-specific informed consent prior to study entry.
Consent,Unable to obtain or refusal to consent prior to surgery
Consent,(2) Ability and willingness to provide signed  witnessed informed consent.
Consent,Any reason which  in the opinion of the Medical Sub- Investigator  would prevent the subject from participating in the study.
Consent,Patients who in the judgment of the clinician are likely to violate the protocol regulations or unlikely to complete the study for any reason.
Consent,If under legal age  must have legal guardian who is able to give consent
Consent,Exclusion Criteria: unable to provide informed consent
Consent,Inability to provide informed consent signed.
Consent,Inability to provide informed consent.
Consent,Must be able to give written informed consent
Consent,Persons lacking consent capacity
Consent,Consent of parent or guardian if less than 18 years of age.
Consent,Consent of patient and parent or guardian if less than 18 years of age.
Consent,An informed consent obtained from the patient or his/her guardian and assent for children
Consent,Consent of patient and/or care giver (in the case of children)
Consent,Subject (or legal representative) understands the nature of the procedure and provides informed consent  prior to enrollment in the study.
Consent,Evidence of signed and dated informed consent document (by the patient or a legal guardian) indicating that the patient and/or the legal guardian has been informed of all pertinent aspects of the trial.
Consent,Meets the eligibility requirements for registration  .  within certain time windows from annual visits  having signed informed consent for Respiratory Ancillary Study [RAS]  at a site which has concurrent Institutional Review Board [IRB] approval for RAS)
Consent,Signed ICF
Consent,Signed  informed parental consent if patient is less than 18.
Consent,Written informed consent will be obtained from each subject and/ or parent or guardian of the subject before the blood-sampling visit of each year
Consent,Absence of informed consent 
Consent,All patients must have given signed  informed consent prior to registration to the study.
Consent,Confirmed written informed consent
Consent,Consent not signed
Consent,Consent obtained before first dose of PCV-7 is given
Consent,Exclusion Criteria: Informed consent not obtained
Consent,Exclusion Criteria: No provision of informed consent
Consent,Inability to obtain signed informed consent from a parent or legal guardian.
Consent,Inclusion Criteria: Patient has provided informed consent.
Consent,Inclusion Criteria: Patient has provided IRB-approved written informed consent prior to conducting any study-related procedures
Consent,Inclusion Criteria: Patients having given their written informed consent  prior to participating in the trial.
Consent,Inclusion Criteria: provision of informed consent
Consent,Inclusion Criteria: Written informed consent
Consent,Inclusion Criteria: Written informed consent prior to any study related procedures
Consent,Inform consent
Consent,informed consent
Consent,Informed consent from the patients or authorized representatives must be obtained in writing enrollment into the study
Consent,Informed consent must be obtained from all subjects prior to beginning therapy
Consent,informed consent signed
Consent,Informed consent signed by the parent
Consent,Must sign an informed consent form
Consent,Patient must have given informed consent
Consent,Patient or patient's legally authorized representative has provided written informed consent
Consent,Patient signs informed consent
Consent,Patients who sign and date a Patient Informed Consent form prior to the implant visit
Consent,Protocol requires prior Institutional Review Board (IRB) approval before any subject is entered into study.
Consent,Provide informed consent
Consent,provide Informed Consent.
Consent,Provide written informed consent signed by patient or legal guardian prior to entering the study or undergoing any study procedures.
Consent,provision of informed consent
Consent,Separate written informed consent obtained before screening and study start respectively
Consent,Separate written informed consent obtained before screening and study start  respectively
Consent,Signed consent form
Consent,Signed informed consent
Consent,Signed informed consent obtained from the subjects (if possible) and their parents
Consent,Signed informed consent.
Consent,Signed written informed consent
Consent,Subject or parent/legally authorized representative has provided written informed consent
Consent,Subjects should read  sign and date an Informed Consent Form prior to any study procedures
Consent,Will provide written informed consent prior to their participation in the study.
Consent,Written informed consent
Consent,Written informed consent obtained before inclusion and randomization.
Consent,Written informed consent obtained from the parent or guardian of the subjects.
Consent,Written informed consent prior to entry into the study.
Consent,Written informed consent signed
Consent,Written  voluntary informed consent.
Device,Exclusion Criteria: Implanted investigational drug eluting stents
Device,intrauterine device (IUD)
Device,Subject has a cardiac pacemaker or other implanted electro medical devices.
Device,Patients requiring specialized endotracheal tubes
Device,Have an active implantable device
Device,Any implanted device or prosthesis or intrauterine IUD type of device
Device,Condom or diaphragm
Device,double barrier  .  condom  diaphragm with spermicide)
Device,If patient uses a cane routinely in daily activities  then they can use it for their assessments
Device,Admitted to the NICU
Diagnostic or Lab Results,Have received intravascular contrast material within the preceding 14 days
Diagnostic or Lab Results,Any patient undergoing screening and/or surveillance colonoscopy and/or upper endoscopy with possible biopsy or removal of tissue by polypectomy
Diagnostic or Lab Results,A positive zidovudine (AZT) detection assay performed 7 days prior to drug dosing will exclude patients from study participation.
Diagnostic or Lab Results,Exclusion Criteria: Screening clinical laboratory values
Diagnostic or Lab Results,[Note: If one of the two values is < 400 the patient will be excluded
Diagnostic or Lab Results,Abnormal nasal epithelial TEPD total chloride conductance (a more electrically negative value than 5 mV for >= ???€chloride-free+isoproterenol).
Diagnostic or Lab Results,Must have a negative urine test for substances of abuse including marijuana  cocaine  cocaine derivatives  opiates and methadone
Diagnostic or Lab Results,2 positive Hepatitis B surface antigen results 6 months apart
Diagnostic or Lab Results,Exclude if B12 less than 100 pg/ml (normal range greater than 200)
Diagnostic or Lab Results,Expired breath CO level > 10 ppm and cotinine level > 210 ng/ml at the baseline measurement
Diagnostic or Lab Results,Positive results of urine drug screen testing (amphetamines  benzodiazepines  cannabis  barbiturates  cocaine  opiates  antidepressants).
Diagnostic or Lab Results,Positivity for HHV-8 antibodies and plasmaviremia (volunteers will be screened for anti-HHV-8 antibodies and positivity confirmed by PCR  only the individuals confirmed positive by PCR will be excluded)
Diagnostic or Lab Results,Subjects who have experienced elevations in liver function test parameters on other cholinesterase inhibitors are still eligible.
Diagnostic or Lab Results,triglyceride (TG) levels above 150 mg/dl 
Diagnostic or Lab Results,>= >= 5.0 ULN 
Diagnostic or Lab Results,1.5 x ULN
Diagnostic or Lab Results,(The lipid profiles at Visit 3 (baseline) and all subsequent visits were kept 'blinded' until data analysis)
Diagnostic or Lab Results,Abnormal age adjusted immunoglobulin levels (IgG or IgA)
Diagnostic or Lab Results,Note: creatinine clearance need not be determined if the baseline serum creatinine is within normal limits
Diagnostic or Lab Results,All available prior computed tomography (CT) or magnetic resonance imaging (MRI) scans should be reviewed and noted  and measurements showing progression of disease should be documented whenever possible
Diagnostic or Lab Results,> than 1mm ST segment elevation or depression in at least two contiguous leads  new T waves inversion in two leads).
Diagnostic or Lab Results,Concurrent Medication: Required for patients whose CD4 count falls below 200 cells/mm3:
Diagnostic or Lab Results,Calcium less than the ULN
Diagnostic or Lab Results,Exclude if folate less than 1.7 ng/ml (normal range greater than 1.9)
Diagnostic or Lab Results,Subject exhibits viral strains that are resistant to lopinavir.
Diagnostic or Lab Results,Patients with known positivity for human immunodeficiency virus (HIV) will be excluded due to possible pharmacokinetic interactions with bortezomib
Diagnostic or Lab Results,They must also have a negative serum beta-human chorionic gonadotropin (B-hCG) at Screening
Diagnostic or Lab Results,Documented to be HBsAg positive for > 6 months OR HBsAg positive and IgM anti-HBc negative and anti-HBs negative
Diagnostic or Lab Results,Referring Pap smear was ASCUS  + HPV or LGSIL
Diagnostic or Lab Results,Refraction with a spherical equivalent less than 5 Dp.
Diagnostic or Lab Results,Stable hemodynamic condition: systolic blood pressure on arrival higher than 80 mmHg in the absence of continuous vasopressive drugs administration.
Diagnostic or Lab Results,Wechsler Adult Intelligence Scale-Revised score < 70
Diagnostic or Lab Results,A score of greater than 4 on the Modified Hachinski Ischemic Scale.
Diagnostic or Lab Results,Any focal abnormality on neurologic exam.
Diagnostic or Lab Results,Any subject with a screening resting systolic blood pressure >180 mmHg and/or resting diastolic blood pressure of >100 mmHg unless  in the opinion of the principal investigator  the blood pressures would not endanger the subject while participating in thi
Diagnostic or Lab Results,AST and ALT >2.5 x ULN (AST and ALT >5 >=  ULN for subjects with liver metastasis)
Diagnostic or Lab Results,Be immunosuppressed defined as having: CD4+(T4) lymphocytes = or < 400 cells/mm3.
Diagnostic or Lab Results,Clinical laboratory tests (CBC  blood chemistries  urinalysis) taken at Visit 1 must have been within normal limits or clinically acceptable to the Investigator
Diagnostic or Lab Results,Clinical laboratory tests (CBC  blood chemistries  urinalysis)must be within normal limits or clinically acceptable to the Investigator/Sponsor.
Diagnostic or Lab Results,Clinically significant laboratory abnormalities.
Diagnostic or Lab Results,Diagnosis and Criteria for Inclusion: Diagnosis: This study was designed for untreated subjects with primary hypercholesterolemia with plasma LDL-C concentrations between >=3.3 mmol/L (130 mg/dL) to <=4.6 mmol/L (180 mg/dL) and triglyceride concentrations
Diagnostic or Lab Results,Do not have a positive test for HIV virus  hepatitis C virus  or hepatitis B surface antigen
Diagnostic or Lab Results,Exclude if T3 uptake is less than 19%
Diagnostic or Lab Results,free T4 index is less than 0.8
Diagnostic or Lab Results,HBeAg positive and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive with positive HBsAg for the previous 6 months
Diagnostic or Lab Results,If antibody-negative  patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.
Diagnostic or Lab Results,If antibody-negative  patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.
Diagnostic or Lab Results,If the patient fails this criterion  the Investigator may decide to conduct a 24-hour creatinine clearance test
Diagnostic or Lab Results,Inclusion Criteria: >=18 years and <= 75 years of age with LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to <= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit) and triglyceride concent
Diagnostic or Lab Results,Inclusion Criteria: >=18 years of age and treated with simvastatin 10 mg or 20 mg for at least 6 weeks and LDL-C levels of > 2.5 mmol/L to <=4.20 mmol/L (97 mg/dL to 160 mg/dL) at Visit 1.
Diagnostic or Lab Results,Inclusion Criteria: Age 18-80 years  protein concentration in ascitic fluid < 15 g/L and at least one of the following: serum creatinine >=  1.2 mg/dl or BUN >=  25 mg/dl  serum sodium >= 130 mEq/L or severe liver failure as defined by a Child-Pugh s
Diagnostic or Lab Results,Inclusion Criteria: Clinical diagnosis of ALS
Diagnostic or Lab Results,Inclusion Criteria: Eligible subjects included men or women   passage of 3 or more unformed stools in the preceding 24 hours accompanied by one or more
Diagnostic or Lab Results,Inclusion Criteria: Patients must meet all of the following conditions to be eligible for enrollment into the study: Diagnosis of CF based on conclusively abnormal sweat test (sweat chloride >35 mEq/liter.
Diagnostic or Lab Results,Laboratory tests within the normal range of the laboratory (hematology  biochemistry  urinalysis) or within the acceptable range per agreement between investigator and sponsor.
Diagnostic or Lab Results,Less than 5th percentile in birthweight and head circumference for gestational age
Diagnostic or Lab Results,LVEF normal
Diagnostic or Lab Results,Mini-Mental State Examination score at screening visit greater than 14
Diagnostic or Lab Results,Modified Hachinski Ischemic Index less than or equal to 4
Diagnostic or Lab Results,Must have coagulation parameters within the limits of normal for the testing facility
Diagnostic or Lab Results,Must have serum chemistry values and urinalysis values within the limits of normal for the testing facility
Diagnostic or Lab Results,OR more than 3 mutations from the other points of the LPV mutation score:10 20 24 46 53 54 63 71
Diagnostic or Lab Results,Oxygen saturation >= 92% on room air.
Diagnostic or Lab Results,Patient has any abnormal chemistry or hematology results that are deemed by the Investigator to be clinically significant.
Diagnostic or Lab Results,Patient has pain intensity score of at least 4 on the 11-point Likert numerical rating scale at screening
Diagnostic or Lab Results,Patients may be HBeAg positive  and anti-HBe negative OR HBeAg negative (pre-core mutant) and anti-HBe positive.
Diagnostic or Lab Results,Patients must have: Positive HIV antibody test results by ELISA.
Diagnostic or Lab Results,Patients with contra-indications for multiple biopsies
Diagnostic or Lab Results,Positive hepatitis B surface antigen  hepatitis C antibody test  or HIV test.
Diagnostic or Lab Results,Satisfactory medical assessment with no clinically significant or relevant
Diagnostic or Lab Results,Score of >= 11/14 on Section C (hand) of UE portion of Fugl Meyer Assessment (FMA)
Diagnostic or Lab Results,Subjects must have normal or clinically acceptable physical exam and ECG intervals (PR  QRS  QT and QTc) on 12-lead ECG (recorded at 25 mm/s).
Diagnostic or Lab Results,Subjects with controlled diabetes prior to entry must have a mean sitting after 5 minute of rest systolic/diastolic office blood pressure >= 128/78 mmHg from non-dominated arm
Diagnostic or Lab Results,T4 less than 2.9 ((g/dL)
Diagnostic or Lab Results,Weighing at least 60 kg  who are within 10% of their ideal weights 
Diagnostic or Lab Results,Weighing at least 60 kg  who are within 10% of their ideal weights 
Diagnostic or Lab Results,(If the patient awakens with a deficit  time of onset is considered the time the patient was last seen functioning normally.)
Diagnostic or Lab Results,[Note: If one of the two values is < 400 the patient will be excluded
Diagnostic or Lab Results,<12 months post-partum*>= 
Diagnostic or Lab Results,> than 1mm ST segment elevation or depression in at least two contiguous leads  new T waves inversion in two leads).
Diagnostic or Lab Results,>= 5.0 ULN 
Diagnostic or Lab Results,>=  21 days since completion of prior chemotherapy  >= 6 weeks since prior Mitomycin-C
Diagnostic or Lab Results,>=  50% stenosis for symptomatic subjects
Diagnostic or Lab Results,>=  80% stenosis for asymptomatic subjects or
Diagnostic or Lab Results,1.5 x ULN
Diagnostic or Lab Results,20 000/mL
Diagnostic or Lab Results,50 copies/ml for the last 6 months on HAART therapy.
Diagnostic or Lab Results,500 cells/mL
Diagnostic or Lab Results,500 mg/dL proteinuria on 2 consecutive spot urine protein/creat ratios
Diagnostic or Lab Results,50mL to 300mL of whole blood within 30 days  301 mL to 500 ml of whole blood within 45days or more than 500 mL of whole blood within 56 days prior to drug administration..
Diagnostic or Lab Results,50mL to 300mL of whole blood within 30 days  301 mL to 500 ml of whole blood within 45days or more than 500 mL of whole blood within 56 days prior to drug administration..
Diagnostic or Lab Results,5x Upper Limit of Normal (ULN)
Diagnostic or Lab Results,8.0 g/dL
Diagnostic or Lab Results,A CD4+ count between 200 and 500 cells/mm3.
Diagnostic or Lab Results,A minimum score of 20 on the YMRS (Youngs Mania Rating Scale).
Diagnostic or Lab Results,A minimum time period of 3 weeks should elapse between the completion of extensive radiation therapy for recurrent/metastatic disease and enrollment in the study.
Diagnostic or Lab Results,A Positive and Negative Syndrome Scale (PANSS) total score between 60 (included) and 120 (excluded)
Diagnostic or Lab Results,A Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure  unless the CK and CK-MB enzymes or Troponin levels are less than twice the Upper Normal Limit
Diagnostic or Lab Results,A significant (> 50%) stenosis proximal or distal to the target lesion
Diagnostic or Lab Results,Abnormal liver function (serum total bilirubin > the upper limit of normal  or serum ALT  AST  or GGT >2.0 times the upper limit of normal).
Diagnostic or Lab Results,Abnormal renal function (serum creatinine >1.5 times upper limit of normal).
Diagnostic or Lab Results,Abnormal thyroid function tests within the last 6 months
Diagnostic or Lab Results,Absolute granulocyte count >=  1 500/mm??
Diagnostic or Lab Results,Absolute neutrophil count (ANC) > 1 500/mm3  platelets > 100 000/mm3  and hemoglobin > 9 g/dl
Diagnostic or Lab Results,Absolute neutrophil count<750 cells/ul
Diagnostic or Lab Results,Acceptable hematologic status: Absolute neutrophil count (ANC) >=  1500 cells/mm(3) (1.5 >= 10(9)/L)
Diagnostic or Lab Results,Acceptable liver function: Bilirubin >= 1.5 times upper limit of normal (ULN)
Diagnostic or Lab Results,Acceptable renal function: For all patients serum creatinine within normal limits  OR calculated creatinine clearance >=  60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal.
Diagnostic or Lab Results,Activated partial thromboplastin time (aPTT) >1.5 >=  ULN
Diagnostic or Lab Results,Active malignancy of cervix  uterus  fallopian tube(s) or ovary > Stage I  or bladder of any Stage
Diagnostic or Lab Results,Adequate bone marrow reserve: (Haemoglobin >=  12g/l  Absolute Neutrophil Count (ANC) >=  2.0x 10^9  Platelets >= 100 000)
Diagnostic or Lab Results,Adequate organ function that has been determined within 7 days prior to enrollment  defined as:Leucocyte count > 3 000/uL
Diagnostic or Lab Results,All patients must be diagnosed as having hypertension: For this project  hypertension will be defined according to the widely accepted criteria of the 6th Joint National Committee (JNC VI) Guidelines on Prevention  Detection  Evaluation and Treatment of H
Diagnostic or Lab Results,All patients must be diagnosed as having hypertension: For this project  hypertension will be defined according to the widely accepted criteria of the 6th Joint National Committee (JNC VI) Guidelines on Prevention  Detection  Evaluation and Treatment of H
Diagnostic or Lab Results,Allowed: PCP prophylaxis (required for patients with CD4 count < 200 cells/mm3).
Diagnostic or Lab Results,ALT greater than 3xULN.
Diagnostic or Lab Results,ALT or AST > 5x Upper Limit of Normal (ULN)
Diagnostic or Lab Results,ALT/AST < 5 times x UNL  bilirubin < 1.5times x UNL  creatinine < 1.25 times x UNL  normal calcium level
Diagnostic or Lab Results,Ambulatory performance score of = or > 70 Karnofsky.
Diagnostic or Lab Results,An unintentional weight loss resulting in a weight 10% less than the lower limit of Ideal Body Weight for frame size  or a recent history of unintentional weight loss of 10% from the subjects baseline
Diagnostic or Lab Results,Anatomic criteria :length of aortic proximal neck >10 mm  diameter of aortic proximal neck < 32 mm  Absence of aortic neck angulation > 90>=  and patent iliac without important stenosis or tortuosity.
Diagnostic or Lab Results,ANC > 1 500/ul
Diagnostic or Lab Results,ANC > 500/mm^3
Diagnostic or Lab Results,ANC ?? 1500/ul  platelet count ?? 100 000/ul
Diagnostic or Lab Results,And modifications of ST-T (no persistent ST elevation) on 12-lead EKG 
Diagnostic or Lab Results,And presence of >= 1 de novo stenosis(es) >50% located on >= 1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
Diagnostic or Lab Results,And presence of >= 1 de novo stenosis(es) >50% located on >= 1 native coronary artery(ies) and successfully treated using percutaneous coronary intervention and stenting.
Diagnostic or Lab Results,and systolic blood pressure consistently < 90 mmHg
Diagnostic or Lab Results,Anemia (hemoglobin < 8.5 g/dl)
Diagnostic or Lab Results,Anemia defined as a hematocrit of < 30 and hemoglobin < 10g/dL.
Diagnostic or Lab Results,Angiographic exclusion criteria (as determined >= 30 days prior to procedure): The target carotid artery is completely occluded.
Diagnostic or Lab Results,Angiographic exclusion criteria: Unprotected left main coronary artery disease with >=  50% stenosis
Diagnostic or Lab Results,Angiographic inclusion criteria (as determined >= 30 days prior to procedure): Target lesion stenosis (% stenosis = (1-N/D) X 100)1  documented by selective angiography pre-intervention  is 1.1
Diagnostic or Lab Results,Any one of the following criteria: Diabetes  CRP >= 2 mg/L  or metabolic syndrome
Diagnostic or Lab Results,Any patient who has a platelet count < 100 000 cells/mm3 or > 700 000 cells/mm3 or a WBC of < 3 000 cells/mm3
Diagnostic or Lab Results,Are (1)NYHA Class IV or (2)NYHA Class III with highest calculated CrCl  60mL/min within the previous 30 days
Diagnostic or Lab Results,Are of 40 kg (88 pounds) of weight or more.
Diagnostic or Lab Results,AST (SGOT)  ALT (SGPT) and alkaline phosphatase >= 2.5 times ULN (if liver metastases are present  then >= 5 >=  ULN is allowed).
Diagnostic or Lab Results,AST and ALT levels which are less than or equal to 10 times the upper limit of normal.
Diagnostic or Lab Results,AST or ALT < 2 times ULN (unless related to primary disease)
Diagnostic or Lab Results,AST or ALT < 5 times upper limit of normal
Diagnostic or Lab Results,Asymptomatic patients with a stenosis greater than 80% by ultrasound or angiography performed in previous 30 days
Diagnostic or Lab Results,At least 1 measurable target lesion in accordance with RECIST criteria to assess clinical response (tumors within a previously irradiated field are designated as non-target).
Diagnostic or Lab Results,At least moderately concerned about gaining weight after quitting smoking
Diagnostic or Lab Results,At least one bidimensionally measurable lesion with clearly defined margins documented by: medical photograph for skin and oral lesions  plain X-ray with at least one diameter 0.5 cm or greater  CT  MRI  or palpation with both diameters 2 cm or greater
Diagnostic or Lab Results,At the time of inclusion (>=  1 day post PCI) patient does no longer require i.v
Diagnostic or Lab Results,Average of CD4+ cell count at 60 and at 21 days prior to study beginning = or < 400 cells/mm3.
Diagnostic or Lab Results,Axillary temperature >= 37.5oC but less than 40 oC or history of fever in preceding 24 hr.
Diagnostic or Lab Results,Baseline NIHSS score at least 2 points  not more than 21 points
Diagnostic or Lab Results,Baseline serum osmolarity of greater than 310 mOsm/L
Diagnostic or Lab Results,Be admitted to the hospital within 36 hours of the mandatory dose of IV furosemide 40 mg at between 2000 and 2200 hour on Day -1
Diagnostic or Lab Results,Be immunosuppressed defined as having CD4+(T4) lymphocytes = or < 400 cells/mm3  based on two measurements at least 1 week apart.
Diagnostic or Lab Results,Best Corrected Visual acuity >20 /25
Diagnostic or Lab Results,bifurcation lesions (side branch > 2 0 mm)
Diagnostic or Lab Results,Bilirubin < 2 mg/dL
Diagnostic or Lab Results,Bilirubin >= 1.5 times the upper limit of normal (ULN)
Diagnostic or Lab Results,Bilirubin less than or equal to 1.5 mg/dL
Diagnostic or Lab Results,Bladder capacity > 200cc (by any method)
Diagnostic or Lab Results,blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic 
Diagnostic or Lab Results,BNP levels equal to or greater than 300 pg/ml.
Diagnostic or Lab Results,Body weight >= 25 kg.
Diagnostic or Lab Results,Bone marrow involvement (< 25% neuroblasts) by morphologic exam within the past 2 weeks
Diagnostic or Lab Results,BPI 12 <= 4 (pain scale)
Diagnostic or Lab Results,Calculated creatinine clearance of less than 30 ml/min or serum creatinine > 3 mg/dL
Diagnostic or Lab Results,Calculated LDL-C concentration of at least 2.6 and 4.1mmol/l or less using the Friedewald equation  and triglyceride of less than 3.99 mmol/l
Diagnostic or Lab Results,Calgary Depression scale score >10 or Simpson-Angus Rating Scale score > 20
Diagnostic or Lab Results,CD4 cell count >100 cells/mL at screening
Diagnostic or Lab Results,CD4 count 300-600 cells/mm3.
Diagnostic or Lab Results,central venous pressure consistently < 6 mmHg
Diagnostic or Lab Results,Chronic oral daily requirement of 80-240 mg of furosemide for at least 7 days before the study start
Diagnostic or Lab Results,CKD stage 3 (GFR 30 - 59 ml/min) for CKD group
Diagnostic or Lab Results,Clinical laboratory values must meet the following: Granulocytes greater than or equal to 1 500/mm(3)
Diagnostic or Lab Results,Clinically significant anemia (HCT < 33%)
Diagnostic or Lab Results,clinically significant diameter of stenosis (50-99 % according to visual assessment of operator)
Diagnostic or Lab Results,combination of points 1 - 4
Diagnostic or Lab Results,Common carotid artery diameter where the Mo.Ma device will be positioned is 5-13 mm.
Diagnostic or Lab Results,Complete blood count and differential defined as: Hematocrit >= 30% for women  >= 38% for men
Diagnostic or Lab Results,Corrected QT interval < 0.47 seconds
Diagnostic or Lab Results,Creatinine > 1.5 x ULN
Diagnostic or Lab Results,Creatinine >= 1.5 times ULN
Diagnostic or Lab Results,Creatinine >= 2.0 mg/dL OR creatinine clearance >=  40 mL/min
Diagnostic or Lab Results,Creatinine clearance less than 50 ml/min
Diagnostic or Lab Results,Creatinine clearance or radioisotope GFR >=  60 mL/min
Diagnostic or Lab Results,Creatinine less than or equal to 1.6 mg/dL
Diagnostic or Lab Results,Creatinine within normal institutional limits or creatinine clearance (CrCl) greater than or equal to 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
Diagnostic or Lab Results,currently taking atorvastatin 10 mg daily and history has taken 80 % of daily doses for the preceding 6 weeks prior to Visit 3
Diagnostic or Lab Results,D in one eye (non-stud eye) and the presence of the following characteristics in the second eye (study eye  eye to be treated): At least 5 or more intermediate (> 63 ??m) or larger soft drusen AND/OR Confluent drusen within 3000 ??m of the fovea center
Diagnostic or Lab Results,Decreased helper/suppressor ratio < 1.0.
Diagnostic or Lab Results,Diagnosis of high-risk neuroblastoma  meeting one of the following criteria: Refractory disease  defined as no response  mixed response  or progressive disease after completion of induction therapy administered according to clinical trials COG-A3973 or CO
Diagnostic or Lab Results,Differential within institutional normal limits or approval of site physician
Diagnostic or Lab Results,Dilatation of the pupil < 5 mm
Diagnostic or Lab Results,Dilatation of the pupil < 5 mm
Diagnostic or Lab Results,Dilatation of the pupil < 5 mm.
Diagnostic or Lab Results,Discharge to a skilled nursing facility or long-term care facility (EXCEPTION: Subjects may be d/c'd to the 6A SNF unit at MetroHealth Medical Center)
Diagnostic or Lab Results,Documentation of left ventricular ejection fraction (LVEF) less than or equal to 40% measured by nuclear scan  echocardiogram (ECHO)  or ventriculogram  within 90 days prior to surgery.
Diagnostic or Lab Results,Donation of plasma (500 mL) within 7 days or donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
Diagnostic or Lab Results,Donation of plasma (500 mL) within 7 days prior to drug administration
Diagnostic or Lab Results,Donation of plasma (500 Ml) within 7 days to drug administration
Diagnostic or Lab Results,Donation of plasma (500 Ml) within 7 days to drug administration
Diagnostic or Lab Results,Donation or loss of hole blood (excluding the volume of blood drawn during the screening procedures of this study) prior to administration of the study medication as follows.
Diagnostic or Lab Results,Donation or loss of whole blood (excluding the volume of blood drawn during the screening procedures of this study) prior to administration of the study medication as follows.
Diagnostic or Lab Results,Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study)prior to the administration of the study medication (50 mL to 300 mL of whole blood within 30 days  301 mL to 500 mL of whole b
Diagnostic or Lab Results,Doppler index < 0 8
Diagnostic or Lab Results,Duration of insomnia complaint >1 month
Diagnostic or Lab Results,ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg  diastolic blood pressure lower than 60 or over 90 mmHg  or heart rate less than 60 or over 100 bpm) at screening.
Diagnostic or Lab Results,ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg  diastolic blood pressure lower than 60 or over 90 mmHg  or heart rate less than 60 or over 100 bpm) at screening.
Diagnostic or Lab Results,ECOG (Eastern Cooperative Oncology Group) status: 0-1-2
Diagnostic or Lab Results,ECOG 0-2
Diagnostic or Lab Results,ECOG performance status < 2 (Appendix 1).
Diagnostic or Lab Results,ECOG Performance Status >=1.
Diagnostic or Lab Results,ECOG Performance Status 0-1
Diagnostic or Lab Results,ECOG performance status 0-2
Diagnostic or Lab Results,ECOG performance status 0-2
Diagnostic or Lab Results,ECOG performance status 0-2 .
Diagnostic or Lab Results,ECOG score < 0 to 2
Diagnostic or Lab Results,ECOG score to be equal to or above 2
Diagnostic or Lab Results,Ejection fraction < 40%
Diagnostic or Lab Results,Ejection fraction >= 30%
Diagnostic or Lab Results,Ejection fraction >=  50%
Diagnostic or Lab Results,ET-743 at any time (Stage 1 only).
Diagnostic or Lab Results,either HIV-seropositive  CD4+ T-cell count of >=350/mm3
Diagnostic or Lab Results,Evidence of impaired renal function (eGFR <60 ml/min)
Diagnostic or Lab Results,EXCLUSION CRITERIA include: Impaired renal function  demonstrated by creatinine clearance < 30 ml/min
Diagnostic or Lab Results,Exclusion Criteria: Conditions associated with elevated TGF-Beta  
Diagnostic or Lab Results,Exclusion Criteria: Have systolic blood pressure consistently <90mm Hg
Diagnostic or Lab Results,Exclusion Criteria: Patients < 5 ans or > 65 ans
Diagnostic or Lab Results,Exclusion Criteria: Planned aortic valve replacement or repair
Diagnostic or Lab Results,Exclusion Criteria: Severe Hypertension defined by PAS > 180mmHg and/or PAD > 110 mmHg.
Diagnostic or Lab Results,Exclusion Criteria: Subjects who do not have a FEV1/forced vital capacity (FVC) ratio of >=70% at Visit 1.
Diagnostic or Lab Results,External carotid artery diameter where the Mo.Ma device will be positioned is 3-6 mm.
Diagnostic or Lab Results,Fagerstrom Test for Nicotine Dependence (FTND) score greater than 5
Diagnostic or Lab Results,falciparum of between 250 and 100 000 asexual parasites/mm3 as determined by microscopic exam of the thick or thin smear
Diagnostic or Lab Results,fasting blood sugar greater than 110 mg/dl
Diagnostic or Lab Results,Fasting triglyceride levels of >= 400 mg/dL (4.5 mmol/L)
Diagnostic or Lab Results,FEV_1 and DLCO >=  30% OR normal chest x-ray  pulse oximetry  and venous blood gas
Diagnostic or Lab Results,Forced vital capacity 50+%
Diagnostic or Lab Results,Functionality score ('Get-up-and-Go' test) must be > 10.0 sec but < 20.0 sec
Diagnostic or Lab Results,Granulocytes >= 1 500/ul  Platelets >= 100 000/ul  Creatinine >=ULN  Bilirubin >=1.5 mg/dl  AST >=2.5 x ULN
Diagnostic or Lab Results,has a history of renal failure and a serum creatinine value greater than 3.0 mg/dl
Diagnostic or Lab Results,has uncontrolled diabetes  defined as a documented plasma blood glucose value > 400 mg/dl (22.2 mmol/L) within three (3) days before surgery
Diagnostic or Lab Results,Have 2 measurements of viral load (amount of HIV in the blood) during the 6 months before entering the study that are below 400 copies/ml by RT-PCR test or below 500 copies/ml by branched DNA test  measured at least 8 weeks apart.
Diagnostic or Lab Results,Have a CD4 cell count of 200 copies/ml or higher within 60 days of study entry.
Diagnostic or Lab Results,Have a CD4+ count of 50 cells/mm3 or more.
Diagnostic or Lab Results,Have a Left Ventricular Ejection Fraction less than 40% (measured within 24 weeks before randomization)
Diagnostic or Lab Results,have a systolic/diastolic blood pressure <= 140/90 mm Hg
Diagnostic or Lab Results,Have a viral load below 50 copies/ml within 30 days prior to entry.
Diagnostic or Lab Results,Have an HIV count of 5 000 copies/ml or more within 30 days prior to study entry.
Diagnostic or Lab Results,Hb>10g/dl.
Diagnostic or Lab Results,HbA1c > 10%
Diagnostic or Lab Results,HbA1c > 7.5%
Diagnostic or Lab Results,heart rate < 55 beats per minute
Diagnostic or Lab Results,Hematocrit > 29%  ANC > 1 500  platelets > 125 000
Diagnostic or Lab Results,Hemoglobin <10 g/dL.
Diagnostic or Lab Results,Hemoglobin <8.5 g/dL (hemoglobin may be supported by transfusion  erythropoietin  or other approved hematopoietic growth factors
Diagnostic or Lab Results,Hemoglobin > 10 g/dL
Diagnostic or Lab Results,Hemoglobin >= 9.5 g/dL
Diagnostic or Lab Results,Hemoglobin  >= 9 g/dL
Diagnostic or Lab Results,Hemoglobin  >= 9 g/dL.
Diagnostic or Lab Results,Hemoglobin greater than or equal to 9 g/dL
Diagnostic or Lab Results,Hemoglobin should be >8 g/dL.
Diagnostic or Lab Results,HER2-positive  defined 3+ by IHC or HER2 gene amplification by FISH
Diagnostic or Lab Results,Hgb >=  10 g/dl  BUN < 25 mg and creatinine < 1.5 mg
Diagnostic or Lab Results,high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women 
Diagnostic or Lab Results,HIV RNA <100 000 copies/mL
Diagnostic or Lab Results,hospitalisation for less than 3 nights
Diagnostic or Lab Results,hospitalised in internal medicine
Diagnostic or Lab Results,Hypercalcemia (serum) > 2.75 mmol/l in three independent measurements during 10 days
Diagnostic or Lab Results,If abnormal laboratory results such as : Hb<8 g/dl
Diagnostic or Lab Results,If presence of the following mutations : in the protease : one among 32 47 48 50 82 84 90
Diagnostic or Lab Results,Impaired hepatic function (AST/SGOT or ALT/SGPT > 2 times the upper limit of the reference range)
Diagnostic or Lab Results,Impaired hepatic function (liver enzymes greater than the upper limit of normal or bilirubin outside the normal range).
Diagnostic or Lab Results,Impaired renal function (creatinine > 2 mg/dl) at the time of cell therapy
Diagnostic or Lab Results,Impaired renal function (creatinine > 3.0 mg/dl or 265 ??mol/l)
Diagnostic or Lab Results,in the reverse transcriptase : 215 or 184.
Diagnostic or Lab Results,Inclusion Criteria: BW below 1 500 gm
Diagnostic or Lab Results,Inclusion Criteria: HBV DNA positive with DNA levels at screening greater than or equal to 3 000 000 copies/mL.
Diagnostic or Lab Results,Inclusion Criteria: Patient with left ventricular systolic dysfunction  left ventricular ejection fraction >=35%  as documented at the moment of ICD implant
Diagnostic or Lab Results,Inclusion Criteria: Patient with mild or moderate hypertension defined with arterial diastolic pressure (PAD) at sit position between 90 mmHg and 110 mmHg and arterial systolic pressure (PAS) at sit position between 140 mmHg and 180 mmHg.
Diagnostic or Lab Results,Inclusion Criteria: Two mandibular third molars containing at least one mesially angular impaction with crown exposed to oral cavity
Diagnostic or Lab Results,Inclusion Criteria: visual acuity worse than 20/40  caused by central subepithelial fibrosis
Diagnostic or Lab Results,Individuals diagnosed with osteoporosis  .  bone density of hip greater than 2.5 standard deviations below the mean) will not be enrolled in the study
Diagnostic or Lab Results,International normalized ratio (INR) >1.5
Diagnostic or Lab Results,irradiation to 25% of bone marrow-containing areas  or
Diagnostic or Lab Results,Karnofsky/Lansky performance status 60-100%
Diagnostic or Lab Results,Kidney function: stadium 1-4.
Diagnostic or Lab Results,Laboratory evidence of hematologic disease (absolute leukocyte count <4000/mm3 or >14 500/mm3  absolute lymphocyte count <1500/mm3  platelet count <120 000/mm3  or hemoglobin <10.0 g/dL).
Diagnostic or Lab Results,Laboratory evidence of hematologic disease (absolute leukocyte count 3.5-11/ul  absolute lymphocyte count 560-5280/ul  platelet count 120 000-400 000/ul  or hemoglobin 10.0-16.5g/dL).
Diagnostic or Lab Results,Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).
Diagnostic or Lab Results,Laboratory evidence of liver disease (alanine aminotransferase [ALT] greater than 1.25 times the upper limit of normal of the testing laboratory).
Diagnostic or Lab Results,Laboratory values within the following limits: Hemoglobin > 10.0 g/dL Neutrophil count > 1.5 x l09/L Lymphocyte count > Lower limit of institutional normal Platelet count > 80 x l09/L Serum creatinine < 2.0 mg/dL Serum bilirubin < 2 x upper limit of insti
Diagnostic or Lab Results,Large (>=  3 cm) breast cancer
Diagnostic or Lab Results,LDL-C >200 mg/dL (5.2 mmol/L)
Diagnostic or Lab Results,LDL-C concentration greater than or equal to 2.5 mmol/L to less than or equal to 160 mg/dL (less than or equal to 4.1 mmol/L) based on blood specimens taken at Visit 1  using the Friedewald calculation as described in the Protocol Section 8.8
Diagnostic or Lab Results,Left ventricular ejection fraction (LVEF) <55%
Diagnostic or Lab Results,Left ventricular ejection fraction <50%
Diagnostic or Lab Results,Left ventricular systolic dysfunction as evidenced by left ventricular ejection fraction < 40%  measured using contrast or radionuclide ventriculography or by echocardiography  within 180 days of the study start
Diagnostic or Lab Results,lesion must be covered by stent length of no more than 24 mm and stent diameter of no more than 3 5 mm
Diagnostic or Lab Results,liver transaminases (ALT  AST) < 50 % above the upper limit of normal  with no active liver disease  and CK < 50 % above the upper limit of normal at Baseline Visit.
Diagnostic or Lab Results,Liver transaminases (ALT  AST) less than 50% above the upper limit of normal  with no active liver disease  and CPK less than 50% above the upper limit of normal as tested in blood specimens taken at Visit 1
Diagnostic or Lab Results,Lumbar spine or total hip BMD T-score 1ess than or equal to -2.0 and >/= 1 prevalent osteoporotic fracture  or lumbar spine or total hip BMD T-score less than or equal to -2.5 with or without and >/= 1 prevalent osteoporotic fracture
Diagnostic or Lab Results,Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight).
Diagnostic or Lab Results,Massive stroke (> 2/3 MCA territory) or any amount of midline shift due to cerebral edema on head CT.
Diagnostic or Lab Results,Maximal cardiac troponin elevation >=  4 (measured at 37>=  C)
Diagnostic or Lab Results,Medical disorder that would influence outcome of the study - e.g
Diagnostic or Lab Results,More than 12 weeks (was 24 weeks  AMENDED 3/31/96) of total prior AZT ( > 500 mg/day without serious adverse event)
Diagnostic or Lab Results,Morning FEV1 of 40-80% normal.
Diagnostic or Lab Results,Must have anatomic stenosis greater than 70% by ultrasound or angiography performed in previous 30 days
Diagnostic or Lab Results,Must have at least 1 of the following pancreatic manifestations of VHL documented by a non-invasive imaging study: Pancreatic cyst(s)
Diagnostic or Lab Results,Nephropathy (proteinuria >500 mg/day)
Diagnostic or Lab Results,NIHSS must be > 4 points.
Diagnostic or Lab Results,No more than 3 sites of skeletal disease as determined by an >= I-MIBG scan (for regional involvement of the skeleton [e.g.  pelvis  spine]  the tumor involvement should be < 25% of the site)
Diagnostic or Lab Results,Normal ALT (as defined by the range of the clinical site laboratories) and Creatinine (<= 1.6 mg/dL)
Diagnostic or Lab Results,Normal amplitude of accommodation
Diagnostic or Lab Results,Normal best-corrected visual acuity at 20/40 or better
Diagnostic or Lab Results,or if serum creatinine > upper limit of normal  a calculated creatinine clearance < 60 mL/min/1.73 m2).
Diagnostic or Lab Results,Patient has a Karnofsky Performance Status greater than or equal to 60%
Diagnostic or Lab Results,Patient has an estimated creatinine clearance of < 60 ml/min calculated using the Cockroft Gault method
Diagnostic or Lab Results,Patient in ability to undergone hepatic or pulmonary resection in case of recurrence during the follow-up (ECOG >= 2)
Diagnostic or Lab Results,Patient with elevated Prostate Specific Antigen (PSA)
Diagnostic or Lab Results,Patient with serum creatinine > 2 mg/dl or creatinine clearance < 60 ml/min
Diagnostic or Lab Results,Patients ever having had a value of CD4+ T cell number < 250 will be excluded]
Diagnostic or Lab Results,Patients must have an ECOG performance status of <2 (ECOG criteria published in [46])
Diagnostic or Lab Results,Patients must have an ECOG performance status of less than or equal to 1.
Diagnostic or Lab Results,Patients must have ECOG performance status 0-2.
Diagnostic or Lab Results,Patients must have had a colonoscopy within the past 5 years
Diagnostic or Lab Results,Patients must have normal organ and marrow function (as defined below) measured within one week prior to registration: Absolute neutrophil count >1 500/mm3.
Diagnostic or Lab Results,Patients should have adequate organ function related to the following: White count > 3000/ul  Platelet count > 70 000/ul  Hemoglobin > 8 g/l  Bilirubin WNL  AST and ALT < 2.5 x ULN  and Creatinine < 1.5 x ULN or 24 hour creatinine clearance > 60 ml/min
Diagnostic or Lab Results,Patients with clinically significant ECG abnormality  including prolonged QTc (defined as QTc >=450 msec using Fridericia's correction).
Diagnostic or Lab Results,Patients with X-ray findings of acute fractures  severe loss of bone density  avascular necrosis and/or severe bone or joint deformity.
Diagnostic or Lab Results,Performance Status
Diagnostic or Lab Results,Performance status 0-2
Diagnostic or Lab Results,Performance status contraindicating a hepatic or pulmonary surgery in case of recurrence.
Diagnostic or Lab Results,Performance status Not specified
Diagnostic or Lab Results,Performance status of 0-1
Diagnostic or Lab Results,Plasma HIV-1 viremia levels <= 50 000 copies/mL
Diagnostic or Lab Results,Platelet count < 100 000/ul
Diagnostic or Lab Results,Platelet count <75 000/ul
Diagnostic or Lab Results,Platelet count >
Diagnostic or Lab Results,Platelet count  >= 100 000 platelet/mm(3) (100 >= 10(9)/L)
Diagnostic or Lab Results,Platelet count  >= 100 000/mm??
Diagnostic or Lab Results,Platelet count  >= 100 000/ul
Diagnostic or Lab Results,Platelet count<50 000/ml
Diagnostic or Lab Results,Platelets >= 100 000/mm3
Diagnostic or Lab Results,Platelets greater than or equal to 100 000/mm(3)
Diagnostic or Lab Results,Platelets greater than or equal to 100 000/mm3.
Diagnostic or Lab Results,Poorly controlled hypertension  .  blood pressure: systolic >180 mm Hg or diastolic >100 mm Hg).
Diagnostic or Lab Results,Positive infectious disease markers from mother's blood or cord at time of -collection (See below for details).
Diagnostic or Lab Results,Presence of hypoalbuminaemia < 35 g/L
Diagnostic or Lab Results,Presence of serious acute infection requiring parenteral treatment at time of study entry.
Diagnostic or Lab Results,Presence of serious acute infection requiring parenteral treatment at time of study entry.
Diagnostic or Lab Results,Presenting for CABG with or without mitral valve repair or replacement procedure
Diagnostic or Lab Results,Previous enrollment in LABS-1
Diagnostic or Lab Results,Previously performed stem / mononuclear cell therapy
Diagnostic or Lab Results,PSA value equal to or above 2 ng/ml
Diagnostic or Lab Results,PT-INR/PTT < 1.5 x upper limit of normal.
Diagnostic or Lab Results,Radiation therapy to greater than or equal to 50% of the bone marrow
Diagnostic or Lab Results,range of reference diameter 2.5 to 4.0mm
Diagnostic or Lab Results,Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
Diagnostic or Lab Results,Recent donation of plasma (500 mL) within 7 days or recent donation or significant loss of whole blood (450 mL) within 56 days prior to the administration of the study medication
Diagnostic or Lab Results,Reference vessel diameter >=  2.5 and >= 3.75 mm by visual estimate
Diagnostic or Lab Results,remnant liver volume < 50%
Diagnostic or Lab Results,remnant liver volume >= 70%
Diagnostic or Lab Results,Renal anemia with hemoglobin (blood) < 10 mg/dl
Diagnostic or Lab Results,Renal failure (serum creatinine stably > 1.7 mg/dl
Diagnostic or Lab Results,Reported a stable weight history for at least 4 weeks prior to randomization at Visit 3 (baseline visit)
Diagnostic or Lab Results,Required Initial Laboratory Data: *ANC >=  1 500/mm3  *Platelet count >=  100 000/mm3  *SGPT < 1.5 times ULN  *Alkaline phosphatase < 2.0 times ULN  *Bilirubin < 1.5 mg/dl  *Serum creatinine < 1.5 times ULN
Diagnostic or Lab Results,Screening clinical laboratory values: Absolute neutrophil count <1500/ul
Diagnostic or Lab Results,Serum albumin <2.5 g/dL.
Diagnostic or Lab Results,Serum bilirubin < 1.5 times ULN
Diagnostic or Lab Results,Serum creatinine < 1.5 mg/dl  BUN < 25 mg/dl  serum SGOT and bilirubin < 1.5 times upper limit of normal
Diagnostic or Lab Results,Serum creatinine < 1.5 times ULN  or 24-hour creatinine clearance > 75 cc/min
Diagnostic or Lab Results,serum creatinine > 175 ??mol/L
Diagnostic or Lab Results,Serum creatinine >2.0 mg/dL
Diagnostic or Lab Results,Serum creatinine greater then 2 mg/dl.
Diagnostic or Lab Results,Serum Glutamate Pyruvate Transaminase (SGPT) >= 2.5 ULN  Serum Glutamate Oxaloacetate Transaminase (SGOT) >= 2.5 ULN 
Diagnostic or Lab Results,serum glutamyloxaloacetic transaminase (SGOT) < 2.5 ULN
Diagnostic or Lab Results,Serum potassium > 3.5 mEq/L.
Diagnostic or Lab Results,Serum potassium > 5.2 meq/L
Diagnostic or Lab Results,Seven of 10 patients in each treatment arm must have p24 antigen levels = or > 70 pg/ml (> 50 pg/ml at U
Diagnostic or Lab Results,Severe disorders of lipoprotein metabolism (Low-density lipoprotein cholesterol (LDL)> 5.0 mmol/L)
Diagnostic or Lab Results,Severe renal insufficiency /se creatinine greater than or equal to 150 umol/l/
Diagnostic or Lab Results,SGOT and SGPT >= 2.5 times upper limit of normal
Diagnostic or Lab Results,SGOT and/or SGPT > 1.5 upper limit normal  associated with Alk.phosph > 2.5 ULN
Diagnostic or Lab Results,SGOT less than 2.0 x ULN
Diagnostic or Lab Results,Shortening fraction >=  25% by ECHO OR ejection fraction > 30% by MUGA
Diagnostic or Lab Results,Show evidence of mild cognitive impairment (MCI) by meeting all of the following criteria: Global CDR score = 0.5  NYU Delayed Paragraph Recall less than 9  17-item HAM-D score less than 13  and HAM-D Item 1 (depressed mood) score =1.
Diagnostic or Lab Results,Show evidence of significant active hematological disease such as a white blood cell (WBC) count <= 2500/ul (2.50 1E+09/L)  an absolute neutrophil count <= 1000/ul (1.00 1E+09/L)  or a platelet count <100 000/mm^3.
Diagnostic or Lab Results,Significant hepatic insufficiency as defined by total bilirubin greater than 1.5 mg/dL or transaminase (ALT  AST) elevations greater than 2 times the upper limit of the laboratory reference range.
Diagnostic or Lab Results,Significant regional wall motion abnormality on echocardiography at the time of acute PCI (ejection fraction >= 50% on visual estimation).
Diagnostic or Lab Results,Significant renal impairment  .  creatinine clearance < 45 mL/min by the Cockcroft-Gault formula)  or changing renal function during the 7 days before study start  or intrinsic renal disease
Diagnostic or Lab Results,Stable elevations of liver enzymes  alanine aminotransferase (ALT)  and aspartate aminotransferase (AST) due to concomitant medications will be allowed if they are less than 2 times the ULN.
Diagnostic or Lab Results,Stimulated C-peptide > 0.2pmol/L on MMTT
Diagnostic or Lab Results,study participants had to have a normal Pap smear within the previous 12 months
Diagnostic or Lab Results,Subject had abnormal pre-intervention blood counts with platelets < 50 000/cubic mm or > 700 000/cubic mm or white blood cell count < 3 000/cubic mm.
Diagnostic or Lab Results,Subject has a Karnofsky Score &#8805
Diagnostic or Lab Results,Subject has any of the following abnormal laboratory test results at screening: Hemoglobin &lt
Diagnostic or Lab Results,Subject has severe chronic renal failure (creatinine > 2.5 mg/dl).
Diagnostic or Lab Results,Subject is &#8805
Diagnostic or Lab Results,Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule.
Diagnostic or Lab Results,Subject must have an undetectable viral load (VL) &lt
Diagnostic or Lab Results,Subjects must have a baseline FEV1 of >=65% of predicted normal value at Visit 1.
Diagnostic or Lab Results,Subjects must have a FEV1 >=  0.70L at Visit 1.
Diagnostic or Lab Results,Subjects must have an LDL-C concentration >= 2.6 mmol/L (100 mg/dL) to <= 4.1 mmol/L (160 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Subjects must have an LDL-C concentration >=3.3 mmol/L (130 mg/dL) to <=4.6 mmol/L (180 mg/dL) using the Friedewald calculation available at the time of randomization Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Subjects must have liver transaminases (ALT  AST) < 50% above the upper limit of normal  with no active liver disease  and CK < 50% above the upper limit of normal at Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Subjects must have liver transaminases (ALT  AST) <50% above the upper limit of normal  with no active liver disease  and CK <50% above the upper limit of normal at Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Subjects must have triglyceride concentrations of < 3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Subjects must have triglyceride concentrations of <3.99 mmol/L (350 mg/dL) at Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline visit).
Diagnostic or Lab Results,Subjects must report a stable weight history for at least 4 weeks prior to entry into study at Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Subject's serum AST and ALT levels must be &lt
Diagnostic or Lab Results,Subjects who do not have a ??15 pack-year smoking history and a baseline breathlessness severity grade of ??2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visit 1.
Diagnostic or Lab Results,Subjects who  through completion of the study  would have donated in excess of 500 mL blood in 14 days  or 500-750 mL blood in 14 days (unless approved by the Principal Investigator  1000 mL blood in 90 days  1250 mL blood in 120 days  1500 mL blood in 18
Diagnostic or Lab Results,Subjects who  through completion of the study  would have donated in excess of 500 mL blood in 14 days  or 500-750 mL of blood in 14 days (unless approved by Principal Investigator  1000 mL blood in 90 days  1250 mL blood in 120 days  1500 mL blood in 180
Diagnostic or Lab Results,Subjects with no stenosis or stenosis <50% on angiography
Diagnostic or Lab Results,Subjects with serum creatinine greater than 3.
Diagnostic or Lab Results,Subjects with serum total bilirubin greater than 4.
Diagnostic or Lab Results,Systolic blood pressure (SBP) consistently < 90 mm Hg
Diagnostic or Lab Results,systolic blood pressure < 105 mm Hg
Diagnostic or Lab Results,Systolic blood pressure greater > 200 mm Hg or MAP > 120 mm HG when patient is initially monitored.
Diagnostic or Lab Results,Target lesion involves bifurcation class D & type G including a side branch >=  2.5mm in diameter (either stenosis of both main vessel and major side branch or stenosis of just major side branch) that would require stenting of diseased side branch
Diagnostic or Lab Results,Target lesion stenosis is >= 50% and <100% (minimum TIMI flow I at the time of the PCI procedure) (visual estimate)
Diagnostic or Lab Results,Target lesion(s) is(are) located in a native coronary artery  which can be covered by one single stent of maximum 33 mm
Diagnostic or Lab Results,The coronary artery lesion should be >=27 mm in length (a margin of 3mm proximal and 3mm distal is recommended) and should be entirely covered by one single Genous Bio-engineered R stentTM
Diagnostic or Lab Results,The inability to position a stiff .035' guidewire in the external carotid artery (ECA).
Diagnostic or Lab Results,The investigators will also exclude subjects with hematocrit < 30%.
Diagnostic or Lab Results,The laboratory values used for exclusion of subjects will be fasting glucose > 110 mg/dl  glycosylated hemoglobin (HgBA1) > 6.5%  serum creatinine > 1.5 mg/dl  ALT or AST > 2x the upper limit of normal  cholesterol > 250 mg/dl
Diagnostic or Lab Results,the need for urgent intervention  defined according to the American College of Cardiology/ American Heart Association (ACC/AHA) guidelines as being patients who are required to stay in the hospital  but may be scheduled and operated on within a normal sch
Diagnostic or Lab Results,The patient would be allowed to enroll in the study if the 24-hour test result is < 60 ml/min.
Diagnostic or Lab Results,The presence of severe renal impairment (CrCl <30 mL/min or creatinine >3 x ULN)  nephrotic syndrome  or patients undergoing dialysis
Diagnostic or Lab Results,Thrombocytopenia (plt < 100 k)  PTT > 100 sec  INR > 3.0 at time of treatment.
Diagnostic or Lab Results,Thrombopenia < 100 000/ml
Diagnostic or Lab Results,Total bilirubin < 3.0 mg/dL
Diagnostic or Lab Results,Total bilirubin within normal institutional limits.
Diagnostic or Lab Results,Total bilirubin within normal limits and AST/ALT less than 3 times the upper limit of normal (less than 5 times the upper limit of normal in the presence of liver metastases).
Diagnostic or Lab Results,Total lymphocyte count >= 1000 cells/mm3
Diagnostic or Lab Results,Transaminases (AST and ALT) <3 X ULN.
Diagnostic or Lab Results,Treatment exclusion criteria (obtained after anesthesia induction and before chest incision prior to the start of study drug) include: mean pulmonary artery pressure consistently < or equal to 15mmHg
Diagnostic or Lab Results,Treatment with thrombolysis followed by PCI with stent implantation.
Diagnostic or Lab Results,Triglyceride concentration of less than 350 mg/dL (less than 3.99 mmol/L) based on blood specimens taken at Visit 1
Diagnostic or Lab Results,triglycerides <= 4.00 mmol/L drawn  and liver transaminases (ALT  AST) <=50% above the upper limit of normal at Visit 2  with no active liver disease  and/or creatine kinase (CK) <=50% above the upper limit of normal
Diagnostic or Lab Results,Uncontrolled diabetes mellitus (HbA1c >11% within the last 1 month prior to Screening)
Diagnostic or Lab Results,Uncontrolled hypertension (diastolic BP > 100 mm Hg or systolic BP > 200 mm Hg)
Diagnostic or Lab Results,Untreated  current  and severe Major Depressive Disorder as determined by the Structured Clinical Interview for DSM-IV and a score > 30 on the Beck Depression Inventory
Diagnostic or Lab Results,WBC > 15 000/mm3 within 72 hours of surgery
Diagnostic or Lab Results,WBC > 4 000/ml  ANC > 1 500/ml  platelets>100 000/ml
Diagnostic or Lab Results,Weight greater than 100kg.
Diagnostic or Lab Results,White cell counts >= 4 000 cells/mm3
Diagnostic or Lab Results,WHO diagnostic criteria for diabetes mellitus is fasting plasma glucose > 7.0 mmol/l (126 mg/dl) or 2-h plasma glucose > 11.1 mmol/l (200mg/dl).
Diagnostic or Lab Results,with Karnofsky Score > 70
Diagnostic or Lab Results,You must have stable glycemic control.
Diagnostic or Lab Results,Zubrod performance status of 0 - 2
Diagnostic or Lab Results,Zubrod performance status of 0-1.
Diagnostic or Lab Results,Good physical health on the basis of medical history  physical examination  and laboratory screening.
Diagnostic or Lab Results,Inclusion Criteria: Presence on a tissue biopsy of large non septated hyphae compatible with zygomycete
Diagnostic or Lab Results,Laboratory results: Bilirubin >= Upper Limit Normal (ULN)
Diagnostic or Lab Results,Low HDL cholesterol
Diagnostic or Lab Results,Non echogenicity
Diagnostic or Lab Results,Patient must have a modified SLEDAI score > 3 at both screening and qualifying visits (Appendix A-2)
Diagnostic or Lab Results,Patients diagnosed with DME
Diagnostic or Lab Results,Patients having any arthrogram of the signal joint within the past 3 months prior to Screening.
Diagnostic or Lab Results,Physical examination and laboratory tests of hematologic  hepatic and renal functions
Diagnostic or Lab Results,Physical examination and laboratory tests of hematologic  hepatic and renal functions.
Diagnostic or Lab Results,Physically acceptable for this study as confirmed by medical history  physical exam  neurological exam  and clinical tests
Diagnostic or Lab Results,Serum bilirubin >2.0 x upper limit of normal (ULN)
Diagnostic or Lab Results,Stimulator parameters may not be changed for at least 1 month prior to Visit 1 or during the study
Diagnostic or Lab Results,Malnourishment (body weight < -2.5 SDS for height and gender) or severe deterioration of fat metabolism
Diagnostic or Lab Results,>= 4/5 on manual muscle testing for the deltoid on the affected side if isolated movement is present
Diagnostic or Lab Results,Any clinically significant abnormality found during medical screening
Diagnostic or Lab Results,Any clinically significant abnormality found during medical screening.
Diagnostic or Lab Results,Certified as healthy by a comprehensive clinical assessment (detailed medical history and a complete physical examination).
Diagnostic or Lab Results,Clinical diagnosis of exudative AM
Diagnostic or Lab Results,Clinical laboratory tests (CBC  blood chemistries  urinalysis) must be within normal limits or clinically acceptable to the investigator at Visit 3 (Baseline Visit).
Diagnostic or Lab Results,Clinical laboratory values had to be within normal limits or out-of-range limits must be designated as not clinically significant (some exceptions per protocol)
Diagnostic or Lab Results,Cord blood meets all selection and testing criteria (see below).
Diagnostic or Lab Results,Corneal  lens  or vitreous opacification precluding funduscopic exam.
Diagnostic or Lab Results,Corneal  lens  or vitreous opacification that precludes funduscopic exam.
Diagnostic or Lab Results,Exclusion Criteria: Abnormal marrow function as defined by leucocyte  neutrophil  or platelet counts outside of normal limits.
Diagnostic or Lab Results,Full passive ROM at the wrist and the thumb  index and long finger MCP joints on the affected side
Diagnostic or Lab Results,Preserved hematologic  hepatic  and renal function as defined by required lab values.
Diagnostic or Lab Results,Patients with acute Intracerebral hemorrhage diagnosed by neuroimaging
Diagnostic or Lab Results,Exclusion Criteria: Abnormal EKG
Diagnostic or Lab Results,Between 15th and 95th BMI percentile for their age
Diagnostic or Lab Results,weigh > 70 kg or have a bmi > 26 kg / m2 at time of screening. 
Diagnostic or Lab Results,bmi must be > 27 and < 40 
Diagnostic or Lab Results,exclusion criteria - for ra patients: bmi > or = 30. 
Diagnostic or Lab Results,bmi (body mass index) 19-30 kg / m2 (42-66 lb / m2) 
Diagnostic or Lab Results,normal body mass index (18-30 kg / m2). 
Diagnostic or Lab Results,body mass index (bmi  kg / m(2)) > or = 30 and < or = 19. 
Diagnostic or Lab Results,have a body mass index (bmi) >= 18 kg / m2 
Diagnostic or Lab Results,body mass index (bmi) >= 85 th percentile for age and gender 
Diagnostic or Lab Results,normal weight-for-height weight 50-80 kg 
Diagnostic or Lab Results,patient is >= 60' in height. 
Diagnostic or Lab Results,have height or weight < the 5 th percentile. 
Diagnostic or Lab Results,normal high blood pressure of 80-89 mm hg. 
Diagnostic or Lab Results,diastolic blood pressure between 78 and 89 mm hg 
Diagnostic or Lab Results,blood pressure > 140 / 90 mm hg must be treated and maintained < 170 / 100 mm hg on antihypertensives 
Diagnostic or Lab Results,systolic blood pressure < 120 mm hg 
Diet,Any food allergy  intolerance  restriction or special diet that  in the opinion of the Medical Sub- Investigator  could contraindicate the subject's participation in this study.
Diet,Exclusion Criteria: Habitual dietary intake of less than 30% fat
Diet,Had been previously prescribed a cholesterol lowering diet and exercise program at least 4 weeks prior to Visit 1 and had been advised to continue the same diet and exercise program during the study
Diet,Ingestion of grapefruit or grapefruit juice within 1 week of the study and a willingness to abstain from the consumption of grapefruit or grapefruit juice for the duration of the study.
Diet,Lack of access to regular meals
Diet,Subjects must have maintained a cholesterol lowering diet program for at least 4 weeks prior to the study and be willing to continue the same diet program during the study.
Diet,This patient must has been under proper but insufficient hygieno dietetic diet
Diet,Use of grapefruit juice products
Diet,Any use of dietary  herbal  and/or fitness/body-building supplements (with the exception of vitamins)
Diet,cholesterol lowering diet and exercise program for at least 4 weeks prior to and during the study  and stable weight history.
Diet,Subjects must have failed a cholesterol-lowering diet and exercise program of at least 4 weeks duration prior to Visit 3 (Baseline Visit).
Diet,Subject is willing to follow the AHA diet and exercise program throughout the study
Diet,Subjects who have been on an abnormal diet (for whatever reason) during the 28 days preceding the study
Disease Stage,Abnormal cardiac or cardiovascular function  or serious cardiac illness or medical condition in the previous 6 months including  but not confined to: New York Heart Association (NYHA) grade 2 or higher congestive heart failure (CHF) or who has had angiopl
Disease Stage,Inclusion Criteria: Clinical diagnosis of type I diabetes and using daily insulin therapy for at least twelve months
Disease Stage,2 before criteria have been replaced by : Patients with colorectal adenocarcinoma which is histologically proved and classified stage II perforated  III or IV  totally removed  in total remission 
Disease Stage,5 times normal (grade 2 or less) at the start of the study.
Disease Stage,Absence of ischemic changes on EKG  
Disease Stage,Accepts Healthy Volunteers: Grade II to IV GVHD
Disease Stage,Patients who develop Grade II  III  or IV acute GVHD following allogeneic hematopoietic cell transplantation
Disease Stage,Adequately treated stage I or II cancer for which patient is currently in complete remission
Disease Stage,Advanced (Stage III or IV)  histologically-documented epithelial ovarian cancer or primary peritoneal cancer (excluding small  round-cell histologies).
Disease Stage,All groups : Heart failure (NYHA class >= II)
Disease Stage,American Society of Anesthesiology (ASA) physical classification I to III
Disease Stage,Based upon a knee X-ray performed within 6 months prior to Screening  the radiograms must be classified as a Grade II or III for osteoarthritis of the knee according to the Kellgren & Lawrence grading system based upon a radiologist's written report or in
Disease Stage,Baseline score >= 14 on the HAM-D17.
Disease Stage,Cancer stage I or II (except T4 operated in emergency) or IV without possibility to remove metastasis or R2 after surgery.
Disease Stage,CHF patients in Class III and class IV NYHA symptoms who have had a minimum of one acute decompensated episode in the previous six months
Disease Stage,Clinical stage T 1-4  N 0-3  M0
Disease Stage,Clinically significant valvular abnormality or pericardial effusion (associated with NYHA class II-IV symptoms)
Disease Stage,Current treatment with an ACE-I or ARB (Note: can participate if on ACE-I after 6 week washout period)
Disease Stage,Diagnosis: borderline personality disorder by DSM-IV criteria
Disease Stage,Documented bacterial/fungal/viral infection requiring administration of IV antibiotics within 7 days before surgery
Disease Stage,Early stage disease (any T  any N  M0)
Disease Stage,Exclusion Criteria: Congestive heart failure (defined as New York Heart Association class III or IV heart failure)
Disease Stage,Exclusion Criteria: HAM-D17 item 3 score>= 3.
Disease Stage,Exclusion Criteria: Known significant CVD (history of MI  recurrent stroke  or NYHA class III or greater).
Disease Stage,Exclusion Criteria: No DSM-IV diagnosis other than schizophrenia
Disease Stage,Exclusion Criteria: Other current or past DSM-IV Axis I diagnosis
Disease Stage,For panels B and C  subject may be treated with combination oral anti-hyperglycemic medications
Disease Stage,Grade 1 or higher peripheral neuropathy.
Disease Stage,Grade 2 or 3 AIN is interchangeable with high grade SIL.
Disease Stage,Have at least one of the Class P-2 symptoms (by CDC criteria).
Disease Stage,Have documentation indicating that the patient was consistently New York Heart Association (NYHA) Class III or IV during the 60 days before randomization
Disease Stage,History of ACE-I induced angioedema
Disease Stage,history of congestive heart failure (New York Heart Association [NYHA]Class III or IV)
Disease Stage,History of diabetes (Type I or Type II)
Disease Stage,History of grade 2 or higher peripheral neuropathy.
Disease Stage,HLA-matched unrelated donor (10/10 match on high-resolution [HR] typing of HLA-A  B  C  DRB1  and DQB1)
Disease Stage,IBS-C patients diagnosed on the basis of Rome II criteria
Disease Stage,IIb-IIIa stage
Disease Stage,Inclusion Criteria: CD20+ B-cell non-Hodgkin's lymphoma (NHL) with measurable disease
Disease Stage,Inclusion Criteria: Chronic symptomatic NYHA Class II or III CHF for at least 90 days before the study
Disease Stage,Inclusion Criteria: confirmed diagnosis of schizophrenia according to DSM-IV-IV from patient's medical files
Disease Stage,Inclusion Criteria: Diagnosis of idiopathic Parkinson's Disease  Modified Hoehn & Yahr up to stage III  UPDRS motor score (part III) must have a total of at least 10 at baseline.
Disease Stage,Inclusion Criteria: DSM-IV diagnosis of schizophrenia or schizoaffective disorder and nicotine dependence
Disease Stage,Inclusion Criteria: Histologic or cytologic diagnosis of stage IIIB/IV NSCLC
Disease Stage,Inclusion Criteria: Japanese patients with a DSM-IV diagnosis of schizophrenia
Disease Stage,Inclusion Criteria: NYHA class II-IV CHF
Disease Stage,Inclusion Criteria: Proven  peripheral arterial disease  Fontain II-III stage  patient submitted to secondary prophylactic thrombocyte aggregation inhibiting treatment
Disease Stage,Inclusion Criteria: Soft tissue sarcoma chemosensible  stage IV
Disease Stage,Inclusion Criteria: Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%)
Disease Stage,Insulin dependent diabetes (Type I)
Disease Stage,Karnofsky performance status (KPS) >=  70% (see Appendix III).
Disease Stage,May have history of substance use and other Axis II disorders
Disease Stage,Meets DSM-IV>=  criteria for a primary diagnosis of schizophrenia.
Disease Stage,Met the DSM-IV and NINCDS-ADRDA criteria for AD.
Disease Stage,New York Heart Association heart failure stage III or IV
Disease Stage,Not classified as morbidly obese (body fat greater than 30% for men and 35% for women)
Disease Stage,NOTE: The terms condyloma  grade 1 AIN  and low grade SIL are interchangeable
Disease Stage,NYHA Class III or IV heart failure
Disease Stage,One allele- or antigen-mismatched unrelated donor (9/10 match on HR typing)  mismatched at HLA-A  B  DRB1  or DQB1 (only when HLA-C mismatch is not available)
Disease Stage,Patients entering the Phase 2 portion of the study must have a histologically or cytologically documented diagnosis of advanced (Stage IIIb/IV) NSCLC.
Disease Stage,Patients must not have any pre-existing neuropathy of grade > 1.
Disease Stage,Patients must not have history of congestive heart failure of any grade according to Heart Association (NYHA) (see Appendix 2).
Disease Stage,Patients will be eligible for enrollment if they fulfill the following criteria: Histological diagnosis of surgically resected Stage IIB  IIC  Stage III or Stage IV (AJCC criteria) melanoma independent of NY-ESO-1 expression in a tumor biopsy
Disease Stage,Patients with a removed colorectal tumour which is histologically proved and classified N+ and/or M+ (stage III or IV)
Disease Stage,Patients with Kellgren-Lawrence Grade IV OA  .  large osteophytes  marked narrowing  severe sclerosis  and definite deformity) and Grade I OA of the knee.
Disease Stage,Patients with moderate or severe cardiac failure (New York Heart Association class III and IV)
Disease Stage,Peripheral neuropathy grade >=  2
Disease Stage,Permission of the subject's primary physician to participate in the aquatic class
Disease Stage,Phase I - Current grade 1 AIN  .  low grade SIL) OR treated or untreated grade 2 or 3 AIN  .  high grade SIL).
Disease Stage,Phase II - Prior histologically confirmed grade 2 or 3 AIN / high grade SIL  with ablative therapy within the past 30-90 days.
Disease Stage,Positivity for HBV antigens (HBs Ag  HBe Ag)  and HCV  HTLV-I and HTLV-II antibodies
Disease Stage,Preexisting peripheral neuropathy must be equal to or less than grade 1
Disease Stage,Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method)
Disease Stage,Subjects with NYHA Class III or IV heart failure  or LVEF <30
Disease Stage,Inclusion Criteria: Diabetes type II according to 1985 WHO criteria.
Disease  Symptom and Sign,bifurcation lesion requiring stenting of main and side branch
Disease  Symptom and Sign,Gastroenteritis within 7 days preceding the first study vaccine administration.
Disease  Symptom and Sign,Pneumocystis carinii pneumonia prophylaxis.
Disease  Symptom and Sign,Pulmonary disease (COPD  asthma or other condition) that required inpatient medical or surgical treatment within 60 days before surgery
Disease  Symptom and Sign,Target lesion has excessive tortuosity unsuitable for stent delivery and deployment
Disease  Symptom and Sign,Patient must be a candidate for resection of the recurrent tumor
Disease  Symptom and Sign,(2) muscle weakness in a characteristic distribution (distal predominant)
Disease  Symptom and Sign,(Was written as - No current retinal detachment (although old retinal detachments unrelated to HIV infection which have been repaired are permitted).
Disease  Symptom and Sign,Within these three months of treatment  the subject's cognitive condition must be clinically unchanged or worse for the subject to be acceptable
Disease  Symptom and Sign,Ventricular arrhythmias requiring chronic drug treatment or ICD
Disease  Symptom and Sign,The patient has earlier /within 6 months/ obtained treatment because of BPH
Disease  Symptom and Sign,Weakness of sufficient severity to justify treatment and provide a reasonable opportunity to observe a therapeutic effect
Disease  Symptom and Sign,Allowed: Prophylaxis treatment for Pneumocystis carinii pneumonia (PCP).
Disease  Symptom and Sign,Angina pectoris requiring anti-anginal treatment
Disease  Symptom and Sign,CAD with indication for bypass surgery
Disease  Symptom and Sign,CMV prophylaxis.
Disease  Symptom and Sign,Currently undergoing or recommended to undergo treatment of pelvic organ prolapse
Disease  Symptom and Sign,Radiologically-documented evidence of progressive disease.
Disease  Symptom and Sign,>=  50% stenosis for symptomatic subjects
Disease  Symptom and Sign,>=  80% stenosis for asymptomatic subjects or
Disease  Symptom and Sign,Exclusion Criteria: Signs or symptoms of severe malaria
Disease  Symptom and Sign,Not balanced diabetes
Disease  Symptom and Sign,hallucinations) and /or sleep attacks.
Disease  Symptom and Sign,Have uncontrolled partial seizures despite having been treated with at least three different AEDs (given concurrently or sequentially) for at least 2 years.
Disease  Symptom and Sign,Exclusion Criteria: Congenital DM-1
Disease  Symptom and Sign,Inclusion Criteria: Diagnosis of Juvenile or Adolescent Idiopathic Scoliosis
Disease  Symptom and Sign,no CKD for control group
Disease  Symptom and Sign,Inclusion Criteria: moderate to severe fatigue >6 months after last chemotherapy or radiation treatment >5 years from diagnosis
Disease  Symptom and Sign,Relapsed following high-dose chemoradiotherapy including autologous stem cell transplantation
Disease  Symptom and Sign,Achieved a complete remission (CR)  very good partial remission (VGPR)  or partial remission (PR) after >= >= 2 different salvage regimens  as defined by the following: In CR after treatment with some form of salvage therapy  .  >= I-MIBG  antibody-bas
Disease  Symptom and Sign,sensation of incomplete evacuation
Disease  Symptom and Sign,Be refractory to medication
Disease  Symptom and Sign,Patients with chronic non-cancer pain that necessitates the use of non-injectable opioid analgesics
Disease  Symptom and Sign,history of a neurologic event (cerebrovascular accident  transient ischemic attack or carotid endarterectomy)
Disease  Symptom and Sign,Exclusion: Have onset of migraine after age 50
Disease  Symptom and Sign,Exclusion Criteria: excluded medical conditions like: pre-existing neuropathy  active heart diseases or ischemia  serious infections  HIV infection  chronic hepatitis B or C  brain metastasis  seizures  hypersensitivity to taxanes  organ transplants  some
Disease  Symptom and Sign,Presence of a progressive central nervous system (CNS) disease  including degenerative CNS diseases and progressive tumors.
Disease  Symptom and Sign,There is no diffuse leptomeningeal disease
Disease  Symptom and Sign,Any clinically significant history of ongoing problems or problems known to interfere with the absorption  distribution  metabolism or excretion of drugs of drugs
Disease  Symptom and Sign,Any clinically significant gastrointestinal pathology or unresolved gastrointestinal symptoms susceptible of interfering with the absorption of drugs
Disease  Symptom and Sign,de-novo stenosis
Disease  Symptom and Sign,Diagnosed as having Plasmodium falciparum uncomplicated malaria.
Disease  Symptom and Sign,Evidence of cathartic colon or a history of laxative use  that in the investigator's opinion is consistent with severe laxative dependence such that the patient is likely to require or use laxatives during the study
Disease  Symptom and Sign,Evidence of hand pain as defined by current metacarpophalangeal (MCP) joint pain upon palpation and/or wrist or MCP pain upon extension
Disease  Symptom and Sign,History of schizoaffective disorder and not stabilized on a mood stabilizer  .  lithium  valproate  carbamazepine)
Disease  Symptom and Sign,Immune compromise due to HIV infection  organ transplantation  or treatment of malignancy
Disease  Symptom and Sign,Inclusion Criteria: History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years
Disease  Symptom and Sign,Subjects who are positive for hepatitis B surface antigen or hepatitis C antibody.
Disease  Symptom and Sign,Uncontrolled diarrhea or nausea preventing ingestion of medicine.
Disease  Symptom and Sign,Exclusion Criteria: Systemic illnesses that have an adverse effect on balance
Disease  Symptom and Sign,straining while having a bowel movement
Disease  Symptom and Sign,Demonstrated reversible airflow restriction.
Disease  Symptom and Sign,2nd or 3rd degree heart block without pacemaker treatment
Disease  Symptom and Sign,Inclusion Criteria: Patients with acute myocardial infarction (ST elevation in at least 2 leads >=  0.2 mV in V1 V2 or V3 or >=  0.1 mV in other leads)  treated by one of the following procedures:
Disease  Symptom and Sign,Untreated or under-treated major depressive disorder
Disease  Symptom and Sign,(Note: Prior history of deep vein thrombosis will not exclude subjects from participating in this study.)
Disease  Symptom and Sign,Significant prenatal diagnosed focal brain lesions
Disease  Symptom and Sign,Marfan syndrome with recognized aortic root dilation
Disease  Symptom and Sign,History of evidence of a medical or neurological condition that would expose the subject to an undue risk of a significant adverse event or interfere with assessments of safety or efficacy during the trial
Disease  Symptom and Sign,Patients with a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use.
Disease  Symptom and Sign,Patients with the following are excluded: Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
Disease  Symptom and Sign,Patients with the following conditions or symptoms are excluded: Symptomatic of any class P-2 symptoms (except lymphadenopathy at time of study entry.
Disease  Symptom and Sign,Inclusion Criteria: Severe obstructive sleep apnea 
Disease  Symptom and Sign,Chronic Hypertension
Disease  Symptom and Sign,History of Stage III hypertension (diastolic BP > 110 mmHg or systolic BP > 180 mmHg) or a history of hypertensive urgency or emergency.
Disease  Symptom and Sign,Again  if bilateral knee pain is present  the investigator will select the more painful knee and the contralateral knee must have a VAS pain score of < 30 mm.
Disease  Symptom and Sign,Any condition or situation that  in the opinion of the investigator  might pose a risk to the subject or interfere with participation in the study.
Disease  Symptom and Sign,Clinically significant medical history
Disease  Symptom and Sign,Opioid-induced constipation (OIC) is defined as follows: less than 3 spontaneous bowel movements per week and at least one of the following on at least 25% of occasions:
Disease  Symptom and Sign,Patients who require the use of manual maneuvers to have a bowel movement
Disease  Symptom and Sign,Unstable medical condition
Disease  Symptom and Sign,Patients must have had knee pain in the signal knee on at least 50% of the days in the month preceding Screening.
Disease  Symptom and Sign,(2) muscle weakness in a characteristic distribution (distal predominant)
Disease  Symptom and Sign,Serious  non-healing wound  or bone fracture.
Disease  Symptom and Sign,(Was written as - No current retinal detachment (although old retinal detachments unrelated to HIV infection which have been repaired are permitted).
Disease  Symptom and Sign,A clinical diagnosis of AD.
Disease  Symptom and Sign,Acute disease at time of enrollment.
Disease  Symptom and Sign,Any cervical condition that would make ROM & strength testing painful.
Disease  Symptom and Sign,Any disorder initiating or maintaining sleep such as Obstructive Sleep Apnea  Insomnia  Restless Leg Syndrome  Periodic Limb Movement Disorder  Circadian Rhythm Disorder and Parasomnia
Disease  Symptom and Sign,Any other clinical relevant serious disease  including uncontrolled Diabetes  severe liver disease  or severe renal disease at the time of randomization
Disease  Symptom and Sign,Any significant medical condition which in the Investigator's opinion may interfere with the patient's optimal participation in the study
Disease  Symptom and Sign,Any unstable cardio-vascular disease   unstable hypertensive disease needing modification or introduction of an anti-hypertensive treatment)
Disease  Symptom and Sign,Axillary temperature >=  37.5??C and/or history of fever in the previous 48 hours without any other evident cause
Disease  Symptom and Sign,Babies born to mother with either clinical chorioamnionitis  preterm and prelabor rupture of the membranes (PPROM)  or preterm labor
Disease  Symptom and Sign,chronic diarrhea  inflammatory bowel diseases)  unresolved gastrointestinal symptoms  
Disease  Symptom and Sign,chronic diarrhea  inflammatory bowel diseases)  unresolved gastrointestinal symptoms  
Disease  Symptom and Sign,Chronic renal failure on hemodialysis
Disease  Symptom and Sign,Clinically significant history or presence of any clinically significant gastrointestinal pathology  
Disease  Symptom and Sign,Clinically significant history or presence of any clinically significant gastrointestinal pathology  
Disease  Symptom and Sign,Clinically significant history or presence of any clinically significant gastrointestinal pathology  unresolved gastrointestinal symptoms  liver or kidney disease  or other conditions known to interfere with the absorption  distribution  metabolism  or ex
Disease  Symptom and Sign,Clinically significant oral lesions or dental conditions that would have interfered with eating a regular diet
Disease  Symptom and Sign,Co-existing Condition: Patients with any of the following conditions or symptoms are excluded:
Disease  Symptom and Sign,Co-existing Condition: Patients with the following conditions or symptoms are excluded:
Disease  Symptom and Sign,Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Disease  Symptom and Sign,Conditions listed in Exclusion Co-Existing Conditions and symptoms.
Disease  Symptom and Sign,Congestive heart failure at time of enrollment
Disease  Symptom and Sign,coughing up or vomiting blood
Disease  Symptom and Sign,Current clinically significant suicidal ideation
Disease  Symptom and Sign,Current history of panic disorder  obsessive-compulsive disorder  alcohol or substance abuse.
Disease  Symptom and Sign,cystic fibrosis and coeliac disease) special educational needs  
Disease  Symptom and Sign,Development of any of the medical conditions listed as exclusion criteria for the CHTF919N2201 study.
Disease  Symptom and Sign,diarrhea  vomiting)  liver or kidney disease  or other conditions known as interface with the absorption  distribution  metabolism  or excretion of the drug.
Disease  Symptom and Sign,diarrhea  vomiting)  liver or kidney disease  or other conditions known as interface with the absorption  distribution  metabolism  or excretion of the drug.
Disease  Symptom and Sign,dry eye ocular signs
Disease  Symptom and Sign,Excluded: Prophylaxis for oral candidiasis or otitis media or other infections.
Disease  Symptom and Sign,Exclusion Criteria: Anti-GBM disease  Dialysis-dependency or pulmonary hemorrhage
Disease  Symptom and Sign,Exclusion Criteria: chronic illnesses with dietary management implications  
Disease  Symptom and Sign,Exclusion Criteria: Clinically significant abnormalities found during medical screening
Disease  Symptom and Sign,Exclusion Criteria: Clinically significant illnesses within 4 weeks of the administration of study medication
Disease  Symptom and Sign,Exclusion Criteria: Cognitively impaired
Disease  Symptom and Sign,Exclusion Criteria: Diabetes diagnosed <6 months of age
Disease  Symptom and Sign,Exclusion Criteria: Diabetics are excluded.
Disease  Symptom and Sign,Exclusion Criteria: diagnosis of anxiety disorder or chronic pain syndrome chronic disabilities or developmental delays are currently on psychotherapeutic or sedating medication are on chronic pain medication or opiate any known adverse effect to the stud
Disease  Symptom and Sign,Exclusion Criteria: History of ventricular arrythmias or any other arrythmias  
Disease  Symptom and Sign,Exclusion Criteria: Known diabetics
Disease  Symptom and Sign,Exclusion Criteria: Subjects must not have any significant medical condition which  in the judgment of the Investigator  is a contraindication to the use of phenylephrine HCl  might interfere with the study or requires treatment expected to affect the blo
Disease  Symptom and Sign,Existing Mental Health issues
Disease  Symptom and Sign,fever >38.5 C  vomiting  diarrhea  wheezing  or crackles).
Disease  Symptom and Sign,fractures of the extremities combined with blunt/penetrating visceral trauma
Disease  Symptom and Sign,Frequent vomiting or medical condition that could interfere with oral medication intake  
Disease  Symptom and Sign,Have a history of psychogenic seizures in the past 2 years.
Disease  Symptom and Sign,Have diarrhea an average of 3 times a day for at least 3 weeks.
Disease  Symptom and Sign,Have nausea and/or vomiting an average of 2 times per day for at least 1 week.
Disease  Symptom and Sign,History of acute MI within the last 6 months
Disease  Symptom and Sign,history of bleeding diathesis (ie
Disease  Symptom and Sign,History of previous closed head trauma or brain injury
Disease  Symptom and Sign,history of coronary heart disease (type II diabetic patients > 30 years old with no CHD)
Disease  Symptom and Sign,History of previous closed head trauma or brain injury
Disease  Symptom and Sign,History of uncontrolled psychiatric condition within 6 months prior to Day 1.
Disease  Symptom and Sign,If they have musculoskeletal or neurological deficits that preclude increased physical activity
Disease  Symptom and Sign,immunocompromised
Disease  Symptom and Sign,Inclusion Criteria: documented dry eye history
Disease  Symptom and Sign,Inclusion Criteria  for health facilities were: 1) public and licensed private health facilities providing outpatient services  and 2) the level of care was appropriate for use of Integrated Management of Childhood Illness (IMCI) guidelines.
Disease  Symptom and Sign,Inclusion Criteria: Patients with end stage renal disease on hemodialysis
Disease  Symptom and Sign,Inclusion Criteria: Sexually active male patient with lower urinary tract symptoms indicative of severe BPH  at whom disturbances of urinary retention and urination are present
Disease  Symptom and Sign,Inclusion Criteria: TID diagnosis confirmed by presence of at least 1 diabetes autoantibody Children >=  1 years
Disease  Symptom and Sign,Intractable or frequent vomiting that regularly interfered with eating
Disease  Symptom and Sign,Life-time history of bipolar disorders  schizophrenia or schizoaffective disorder.
Disease  Symptom and Sign,Major deterioration of the abdominal cavity  
Disease  Symptom and Sign,Major deterioration of the abdominal wall  
Disease  Symptom and Sign,Measurable neurologic deficit other than isolated facial weakness  sensory loss or ataxia
Disease  Symptom and Sign,Mixed UI as evidenced by stress and urge symptoms reported on MESA (either percent of urge-type symptoms >=  the percent of stress-type symptoms or urge symptom score >= 7 if stress predominant) followed by report of 'moderately' or 'greatly'/'quite a b
Disease  Symptom and Sign,More than mild diarrhea (defined as more than transient or > 4 loose stools per day).
Disease  Symptom and Sign,ocular symptoms
Disease  Symptom and Sign,Orthostatic hypotension in the history
Disease  Symptom and Sign,Patient has severe pain from causes other than PHN.
Disease  Symptom and Sign,Patient must meet at least four of the eleven ACR criteria for systemic lupus
Disease  Symptom and Sign,Patient with end stage renal disease or receiving hemodialysis treatment
Disease  Symptom and Sign,Patients must also have measurable disease outside of the irradiated field
Disease  Symptom and Sign,Patients must meet one of the following criteria: Have at least one of the class P-2 symptoms (by CDC criteria).
Disease  Symptom and Sign,Patients of either sex  any race  aged over 50 years and over  diagnosed with exudative (wet) AMD in one eye (non-study eye) and non-exudative (dry) AMD (intermediate or large/confluent drusen  with hyperpigmentation  and no CNV or geographic atrophy) in 
Disease  Symptom and Sign,Patients with a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators.
Disease  Symptom and Sign,Patients with any inter-current chronic disease(s) or condition(s) that may predispose them to a high probability of interfering with the completion of the 6 month follow-up of the study such as peptic ulcer  liver disease  severe coronary disease  renal 
Disease  Symptom and Sign,Patients with known history of inflammatory skin disorders  . psoriasis  lupus) that may be exacerbated by Resiquimod.
Disease  Symptom and Sign,Patients with soft tissue disease are eligible provided they exhibit either a VGPR or PR in the primary soft tissue mass and in any sites of metastatic soft tissue disease
Disease  Symptom and Sign,Patients with stroke will be selected based on the following criteria: 85 years old or less with a history of ischemic stroke within 3 months resulting in mild to moderate neurological impairment (Rankin scale < 3)
Disease  Symptom and Sign,Patients with the following are excluded: History of seizures
Disease  Symptom and Sign,Patients with the following symptoms or conditions are excluded: Active medical problems for which the patient is undergoing evaluations or for which prohibited therapy is required.
Disease  Symptom and Sign,Platinum-resistant disease defined as having a best response of SD or disease progression during or within 6 months of discontinuing a platinum-based chemotherapy (carboplatinum  cisplatinum  or another organoplatinum compound).
Disease  Symptom and Sign,post-stroke duration >=  1-mo  but < 24-mo
Disease  Symptom and Sign,Post-traumatic aneurysm
Disease  Symptom and Sign,shoulder pain sustained for >=  1-mo
Disease  Symptom and Sign,Significant diarrhea
Disease  Symptom and Sign,Stable disease
Disease  Symptom and Sign,Subject has active hepatitis B (HbsAg +).
Disease  Symptom and Sign,Subject has chronic or paroxysmal atrial fibrillation that is not treated by Coumadin.
Disease  Symptom and Sign,Subject is a candidate for single lesion carotid artery stenting using a femoral arterial approach.
Disease  Symptom and Sign,Subjects who have a history of any clinically significant local or systemic infectious disease within four weeks prior to initial treatment administration.
Disease  Symptom and Sign,Subjects with clinically apparent cardiovascular disease including prior history of cardiac angina  MI  interventional percutaneous procedures  coronary artery bypass graft  congestive heart disease  cerebral vascular accident  peripheral vascular disease
Disease  Symptom and Sign,Subjects with moderate or severe COPD or on home oxygen.
Disease  Symptom and Sign,tear use
Disease  Symptom and Sign,Unevaluated hematuria
Disease  Symptom and Sign,With a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use.
Disease  Symptom and Sign,Women in an immunocompromised state (diabetes  HIV  on chronic immunosuppressants or steroids  etc)
Disease  Symptom and Sign,Exclusion Criteria: Untreated hypothyroidism (TSH > 4.25 UIU/ML)
Disease  Symptom and Sign,Exclusion Criteria: Patients with colorectal cancer  previous colonic surgery  active colitis and musculoskeletal problems Patients may also be excluded after the first insertion  if painful  routine care will proceed
Disease  Symptom and Sign,(G-CSF and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the investigator
Disease  Symptom and Sign,(Note: Prior history of deep vein thrombosis will not exclude subjects from participating in this study.)
Disease  Symptom and Sign,(Patients with a CNS mass or history of seizure disorder may enroll.)
Disease  Symptom and Sign,(Sharpening of the tibial spine is not considered to be an osteophyte).
Disease  Symptom and Sign,(The lipid profiles at Visit 3 (baseline) and all subsequent visits were kept 'blinded' until data analysis)
Disease  Symptom and Sign,(Was written - Ganciclovir or foscarnet for non-CMV herpes infections within 6 months prior to study entry.)
Disease  Symptom and Sign,A 30-day washout period must be achieved for any patient involved in a previous clinical study.
Disease  Symptom and Sign,A current diagnosis of active peptic ulceration.
Disease  Symptom and Sign,A current diagnosis of acute  severe  or unstable asthmatic conditions.
Disease  Symptom and Sign,A current diagnosis of any primary neurodegenerative disorder  e.g.  Parkinson's disease.
Disease  Symptom and Sign,A current diagnosis of severe and unstable cardiovascular disease.
Disease  Symptom and Sign,A current diagnosis of sick-sinus syndrome or conduction deficits (sino-atrial block  second or third degree atrio-ventricular block).
Disease  Symptom and Sign,A current diagnosis of uncontrolled seizure disorder.
Disease  Symptom and Sign,A diagnosis of unstable angina  NSTEMI  or STEMI
Disease  Symptom and Sign,A disability that may prevent the subject from completing all study requirements  .  blindness  deafness  severe language difficulty).
Disease  Symptom and Sign,A documented history of transient ischemic attacks.
Disease  Symptom and Sign,A history of chronic obstructive lung disease 
Disease  Symptom and Sign,A history of current or recurrent disease that could have an effect on the study
Disease  Symptom and Sign,A patient will be ineligible for study entry if he/she meets any of the following exclusion criteria: has planned aortic dissection repair and/or requires aortic root reconstruction
Disease  Symptom and Sign,A radiated bony lesion may not be considered an evaluable lesion  unless there is evidence of disease progression at that site prior to administration of study drug.
Disease  Symptom and Sign,Ability to tolerate NMES to the ECR and EDC for full wrist and finger extension
Disease  Symptom and Sign,Abnormalities on screening chest x-ray suggesting clinically significant active pulmonary disease other than CF  or new  significant abnormalities such as atelectasis or pleural effusion which may be indicative of clinically significant active pulmonary i
Disease  Symptom and Sign,Absence of histologic or mycologic zygomycosis documentation 
Disease  Symptom and Sign,Accepts Healthy Volunteers: Diagnosis of von Hippel-Lindau syndrome (VHL) by the Urologic Oncology Branch using germ line analysis OR clinical criteria and family history
Disease  Symptom and Sign,Active AIDS-defining illness or other clinically significant or uncontrolled medical problems
Disease  Symptom and Sign,Active asthma or bronchospasm
Disease  Symptom and Sign,Active asthma or bronchospasm
Disease  Symptom and Sign,active autoimmune disease.
Disease  Symptom and Sign,Active bleeding diathesis or coagulopathy  or will refuse blood transfusions
Disease  Symptom and Sign,Active cholecystitis  gall bladder symptoms  or potential hepato-biliary abnormalities
Disease  Symptom and Sign,Active congestive heart failure  angina and/or arrhythmia requiring therapy or previous myocardial infarction
Disease  Symptom and Sign,Active infection
Disease  Symptom and Sign,active infection
Disease  Symptom and Sign,Active infection
Disease  Symptom and Sign,Active infection or fever or diarrhea within last 4 weeks.
Disease  Symptom and Sign,Active infection requiring systemic antibiotics  antivirals  or antifungals including HIV/AIDS  hepatitis B  or hepatitis C infection.
Disease  Symptom and Sign,Active infection.
Disease  Symptom and Sign,Active opportunistic infections
Disease  Symptom and Sign,active symptoms of coronary artery disease  uncontrolled seizure disorder
Disease  Symptom and Sign,Active ulcus pepticum
Disease  Symptom and Sign,Active  unstable severe cardiovascular disease  including poorly controlled angina  congestive heart failure (CHF)  arrhythmias  myocardial infarction (MI)  cardiomyopathy  atrioventricular (AV) block  electrocardiogram (ECG) evidence of acute ischemia  o
Disease  Symptom and Sign,Acute and chronic heart failure
Disease  Symptom and Sign,Acute bacterial  fungal or viral infection
Disease  Symptom and Sign,Acute decompensated heart failure cohort defined as: Objective evidence of heart failure (of any cause/etiology) demonstrated by typical symptoms/signs combined with an imaging modality (see appendix for criteria)
Disease  Symptom and Sign,Acute disc herniation  discopathy or spondylolysis
Disease  Symptom and Sign,Acute gastric ulcer
Disease  Symptom and Sign,Acute or chronic pulmonary  cardiovascular  hepatic  renal or neurological condition  malnutrition  or any other clinical findings that in the opinion of the clinical investigator may increase the risk of participating in the study
Disease  Symptom and Sign,Acute or chronic pulmonary  cardiovascular  hepatic  renal or neurological condition  malnutrition  or any other clinical findings that in the opinion of the PI may increase the risk of participating in the study
Disease  Symptom and Sign,Acute thrombosis
Disease  Symptom and Sign,ADPKD  diagnosed by the following findings on ultra scan: for patients without ADPKD family history: > 5 bilateral cysts
Disease  Symptom and Sign,Allowed: Prophylactic pentamidine for Pneumocystis carinii pneumonia (PCP).
Disease  Symptom and Sign,An acute illness with fever (rectal temperature >=  100.4>= F [38.0>= C]) in the 72 hours preceding enrollment in the trial (defer enrollment).
Disease  Symptom and Sign,Anamnestic or clinical signs of acute myocardial infarction  atrial fibrillation  heart valve disease or chronic heart failure
Disease  Symptom and Sign,Anamnestic or clinical signs of disease in lungs  liver endocrine organs or brain or neoplastic disease
Disease  Symptom and Sign,And absence of significant functional or anatomic abnormalities suggestive of atherosclerosis on non-invasive arterial studies (measurements of intima-media thickness  pulse wave velocity  ankle-brachial index  >= ).
Disease  Symptom and Sign,And normal coronary angiography performed because of suspected coronary artery disease
Disease  Symptom and Sign,and/or documented history of unstable angina or non-Q wave myocardial infarction.
Disease  Symptom and Sign,and/or documented history of unstable angina or non-Q wave myocardial infarction.
Disease  Symptom and Sign,Aneurysm developed on native infra-renal aorta or iliac.
Disease  Symptom and Sign,Angina pectoris that requires antianginal medication
Disease  Symptom and Sign,Antiretroviral therapy for human immunodeficiency virus (HIV)
Disease  Symptom and Sign,Antiretrovirals.
Disease  Symptom and Sign,Any active uncontrolled infection including AIDS  hepatitis B or C.
Disease  Symptom and Sign,Any chronic organic disease of the CNS (other than schizophrenia)
Disease  Symptom and Sign,Any clinically significant history of chronic gastrointestinal disease.
Disease  Symptom and Sign,Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  immunologic  psychiatric  or metabolic disease
Disease  Symptom and Sign,Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  psychiatric  or metabolic disease.
Disease  Symptom and Sign,Any clinically significant history or presence of clinically significant neurological  endocrinal  cardiovascular  pulmonary  hematologic  psychiatric  or metabolic disease.
Disease  Symptom and Sign,Any condition or disease that may interfere with the evaluation of at least 2 lumbar vertebrae (not necessarily contiguous)  determined in a screening radiograph by a radiologist at the central facility (eg  confluent aortic calcifications  severe osteoar
Disease  Symptom and Sign,Any confirmed or suspected immunosuppressive or immunodeficient condition  based on medical history and physical examination (no laboratory testing required).
Disease  Symptom and Sign,Any evidence of renal dysfunction (proteinuria
Disease  Symptom and Sign,Any heart attack  stroke or TIAs within the last 6 months or serious arrhythmias needing medication
Disease  Symptom and Sign,Any history of bleeding disorder.
Disease  Symptom and Sign,Any known congenital heart disease
Disease  Symptom and Sign,Any medical condition that may be exacerbated by bleeding  including a known bleeding disorder such as a coagulation defect  thrombocytopenia  active gastric or duodenal ulcer  or history of GI bleeding.
Disease  Symptom and Sign,Any other solid lesion(s) of the pancreas
Disease  Symptom and Sign,Appropriate studies will be undertaken in HIV-positive patients who are receiving or not receiving combination anti-retroviral therapy when indicated.
Disease  Symptom and Sign,Are known to be infected with human immunodeficiency virus (HIV)  hepatitis B or hepatitis C
Disease  Symptom and Sign,Arterial stenosis on unique kidney - arterial bilateral kidney stenosis
Disease  Symptom and Sign,Asymptomatic aneurysm
Disease  Symptom and Sign,Asymptomatic aneurysm
Disease  Symptom and Sign,At least 6 years of education  or sufficient work history to exclude mental retardation.
Disease  Symptom and Sign,Atrial fibrillation/flutter
Disease  Symptom and Sign,Average use of over 2 puffs of albuterol per day in the previous 7 days OR Having symptoms of asthma on 5 of the last 7 days OR Awakening at night due to asthma at least once in the previous 7 days OR Having been treated with a course of oral or intraveno
Disease  Symptom and Sign,Bi-dimensionally measurable lesions
Disease  Symptom and Sign,bleeding disorder
Disease  Symptom and Sign,both history of liver disease & abnormal liver enzyme lab results
Disease  Symptom and Sign,Cardiac arrhythmia
Disease  Symptom and Sign,Cardiac disease
Disease  Symptom and Sign,Cardiovascular DiSease
Disease  Symptom and Sign,caregivers having severe illnesses
Disease  Symptom and Sign,Chest radiography showing evidence of active or acute cardiac or pulmonary disease
Disease  Symptom and Sign,Chronic Heart Failure cohort defined as: Echocardiographic evidence of systolic or diastolic heart failure (see appendix for criteria)
Disease  Symptom and Sign,Chronic inflammatory disease
Disease  Symptom and Sign,Chronic liver  heart  kidney  or ( untreated) thyroid disease
Disease  Symptom and Sign,Chronic medical  congenital  or developmental disorder that  in the opinion of the investigator  could interfere with trial conduct or completion.
Disease  Symptom and Sign,Chronic or acute renal  hepatic or metabolic disorder.
Disease  Symptom and Sign,Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.
Disease  Symptom and Sign,Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.
Disease  Symptom and Sign,chronic total occlusion
Disease  Symptom and Sign,Clinical findings: skin thickening  joint contraction  oral ulceration  diarrhea.
Disease  Symptom and Sign,Clinical findings: skin thickening  joint contraction  oral ulceration  diarrhea.
Disease  Symptom and Sign,Clinical signs of myopic retinopathy  or refraction higher than -8 diopter power.
Disease  Symptom and Sign,Clinically asymptomatic HIV-1 infected individuals (CDC Clinical category A)  as determined by two positive Enzyme-linked immunosorbent assay (ELISA) and a confirmatory Western Blot
Disease  Symptom and Sign,Clinically significant disease  as determined by the investigator  that would compromise the ability of the participant to complete the study requirements
Disease  Symptom and Sign,Clinically significant fatigue (4.5+ on Fatigue Severity Scale with duration 3+ months plus impairment in 1+ categories of role function)
Disease  Symptom and Sign,Clinically significant history of diabetes.
Disease  Symptom and Sign,Clinically significant history of diabetes.
Disease  Symptom and Sign,Clinically significant history of hyperthyroidism.
Disease  Symptom and Sign,Clinically significant history of hyperthyroidism.
Disease  Symptom and Sign,Clinically significant illness within 4 weeks prior to the administration of the study medication
Disease  Symptom and Sign,Clinically significant illness within 4 weeks prior to the administration of the study medication
Disease  Symptom and Sign,Clinically significant illnesses within 4 weeks of the administration of study medication
Disease  Symptom and Sign,Clinically significant illnesses within 4 weeks of the administration of study medication
Disease  Symptom and Sign,Clinically significant illnesses within 4 weeks of the administration of study medication
Disease  Symptom and Sign,Clinically significant peripheral vascular disease.
Disease  Symptom and Sign,Clinically significant pulmonary or neurologic impairment other than seizure disorder or CNS mass lesion.
Disease  Symptom and Sign,Clinically significant pulmonary or neurologic impairment  such as intubation or coma
Disease  Symptom and Sign,Coenrolled in AIEDRP CORE01 trial
Disease  Symptom and Sign,cognitive deficits
Disease  Symptom and Sign,Cognitive impairment
Disease  Symptom and Sign,Cognitive impairment sufficient to warrant a diagnosis of dementia.
Disease  Symptom and Sign,Co-infection with HCV or HIV
Disease  Symptom and Sign,Coma.
Disease  Symptom and Sign,Comatose at screening
Disease  Symptom and Sign,Co-morbid illness expected to cause death within 6 months
Disease  Symptom and Sign,complete occlusion of target vessel
Disease  Symptom and Sign,Complete remission from positive symptoms of psychosis as judged by a psychiatric evaluation
Disease  Symptom and Sign,Concomitant conditions listed in Exclusion Co-existing Conditions.
Disease  Symptom and Sign,Concomitant conditions  diseases  medications and/or clinical history
Disease  Symptom and Sign,Concurrent uncontrolled cardiovascular  hematologic  respiratory  CNS  gastrointestinal disease or chronic alcoholism.
Disease  Symptom and Sign,Confirmed or suspected autoimmune disease
Disease  Symptom and Sign,Confirmed or suspected autoimmune disease
Disease  Symptom and Sign,Confirmed or suspected immunosuppressive or immunodeficient condition  including human immunodeficiency virus (HIV) infection
Disease  Symptom and Sign,Confirmed or suspected immunosuppressive or immunodeficient condition  including human immunodeficiency virus (HIV) infection
Disease  Symptom and Sign,Congenital disease constitutes ~10% of all cases of DM-1
Disease  Symptom and Sign,Constipation  according to the investigator's clinical judgment  that is resulting from opioid use for non-cancer chronic pain
Disease  Symptom and Sign,Constipation  according to the investigator's clinical judgment  that is resulting from opioid use for non-cancer chronic pain
Disease  Symptom and Sign,Contraindication to ARBs  such as history of angioedema to ARBs  renovascular hypertension
Disease  Symptom and Sign,Contralateral occlusion of internal carotid artery and vertebral arteries.
Disease  Symptom and Sign,CT or MRI since onset of memory impairment demonstrating the absence of a clinically significant focal lesion
Disease  Symptom and Sign,Current diagnosis of a serious documented medical disorder that would make bupropion treatment risky OR results of psychiatric/medical screening that suggest a reason for concern  .  a history of severe heart  liver  or kidney disease or diabetes mellitus
Disease  Symptom and Sign,Current enrollment in any other clinical study
Disease  Symptom and Sign,Current evidence of or history of diabetes mellitus or hypoadrenalism
Disease  Symptom and Sign,Current history of uncontrolled hypertension  insulin dependent or uncontrolled diabetes  cardiovascular disease unless controlled and stable for 6 months or more  bleeding disorders  or autoimmune disorders such as fibromyalgia  chronic fatigue syndrome 
Disease  Symptom and Sign,Current presence of dyskinesias 
Disease  Symptom and Sign,Current sleep disorders such as nightmare disorder  restless legs syndrome  or suspected sleep disorder requiring polysomnographic assessment  such as obstructive sleep apnea or periodic leg movements.
Disease  Symptom and Sign,Currently receiving antiretroviral therapy (other than the intrapartum NVP or other peripartum regimens)
Disease  Symptom and Sign,Cystic fibrosis (Celiac disease and adequately treated thyroid disease do not exclude subjects from enrollment)
Disease  Symptom and Sign,death due to the sickness within four weeks
Disease  Symptom and Sign,dermal infections or burns  hernia)
Disease  Symptom and Sign,Developmental delay  neurologic disorder  or seizure disorder.
Disease  Symptom and Sign,diabetes and currently taking an oral hypoglycemic agent or insulin
Disease  Symptom and Sign,diabetes mellitus
Disease  Symptom and Sign,Diabetes mellitus
Disease  Symptom and Sign,Diabetes mellitus or liver and renal dysfunction or asthma
Disease  Symptom and Sign,diabetes  autoimmune diseases  corneal thickness less tha 400 micron.
Disease  Symptom and Sign,Diabetic patients of over 10 years duration with impaired glucose control  after at least 6 months of accepted treatment in a Diabetes Clinic by the study staff before inclusion in the study  who exhibit symptoms which could signify the possibility of dia
Disease  Symptom and Sign,Diagnosis of asthma for at least 6 months.
Disease  Symptom and Sign,Diagnosis of congestive heart failure for at least 3 months
Disease  Symptom and Sign,diagnosis of dementia at admission
Disease  Symptom and Sign,Diagnosis of probable Alzheimer's disease
Disease  Symptom and Sign,Documented atherosclerotic disease  CHD  or diabetes mellitus
Disease  Symptom and Sign,Documented CHF
Disease  Symptom and Sign,documented coronary heart disease
Disease  Symptom and Sign,documented history of atherothrombotic cerebrovascular disease
Disease  Symptom and Sign,documented history of atherothrombotic cerebrovascular disease
Disease  Symptom and Sign,documented history of cardiovascular disease including coronary artery disease  uncontrolled hypertension  aortic stenosis  congestive heart failure  cardiac arrhythmias or conduction defects greater that first degree atrioventricular (AV) block  sinoatri
Disease  Symptom and Sign,Documented HIV-positive subject.
Disease  Symptom and Sign,Documented or suspected liver disease (including laboratory evidence of hepatitis)
Disease  Symptom and Sign,Does not have a chronic disease that affects calcium or bone metabolism  .  asthma with chronic use of high dose steroids  inflammatory bowel disease  Crohn's disease  primary hyperparathyroidism  seizure disorder with use of phenobarbital  etc.).
Disease  Symptom and Sign,Drugs that have or will cause prolonged neutropenia  significant pancreatitis  significant nephrotoxicity  or peripheral neuropathy within 1 week of entry.
Disease  Symptom and Sign,Early in life  the weakness in individuals with congenital DM-1 derives from maldevelopment of skeletal muscle rather than muscle degeneration
Disease  Symptom and Sign,Encephalopathy
Disease  Symptom and Sign,epilepsy  thyroid disease  HIV  etc.
Disease  Symptom and Sign,ESRD
Disease  Symptom and Sign,Evaluable CMV retinitis with photographable lesions.
Disease  Symptom and Sign,Ever received any influenza vaccine  other than at Visits 1 and 2 of study GRC28  or known to have ever been diagnosed with laboratory-confirmed influenza.
Disease  Symptom and Sign,Evidence of autoimmune disease including  but not limited to  ulcerative colitis  Crohn's disease  rheumatoid arthritis (RA)  systemic lupus erythematosus (SLE) sceloderma  or another diseases in which immune function or immune competence is known to be i
Disease  Symptom and Sign,Evidence of clinical symptoms from a hemorrhagic or nonhemorrhagic stroke with all symptoms from previous stroke(s) completely resolved
Disease  Symptom and Sign,Evidence of nasal or pharyngeal obstruction on physical examination.
Disease  Symptom and Sign,Evidence of past or present CNV in the study eye
Disease  Symptom and Sign,Excluded: (within 30 days prior to study entry)
Disease  Symptom and Sign,Exclusion Criteria: absence of polycystic ovarian syndrome  hydrosalpinx or endometriosis.
Disease  Symptom and Sign,Exclusion Criteria: Advanced  severe  and unstable disease of any type that may interfere with primary and secondary variable evaluations including any medical condition that could be expected to progress  recur  or change to such an extent that it may bi
Disease  Symptom and Sign,Exclusion Criteria: Any severe medical illness that  in the opinion of the investigator  will interfere with the ability to adhere to therapy or will result in making therapy too risky for the patient
Disease  Symptom and Sign,Exclusion Criteria: atrial fibrillation  abnormal hearth rhythms
Disease  Symptom and Sign,Exclusion Criteria: Axis I diagnosis of schizophrenia  schizoaffective disorder  or bipolar I disorder during the subject's lifetime
Disease  Symptom and Sign,Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations
Disease  Symptom and Sign,Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations
Disease  Symptom and Sign,Exclusion Criteria: Cataract or other eye disease that may interfere with fundus examinations
Disease  Symptom and Sign,Exclusion Criteria: Complicating medical issues that would interfere with blood drawing or monitoring.
Disease  Symptom and Sign,Exclusion Criteria: Considered by the investigator to be at imminent risk of suicide or injury to self  others  or property.
Disease  Symptom and Sign,Exclusion Criteria: Current evidence of other causes of dementia
Disease  Symptom and Sign,Exclusion Criteria: depression: score > 12 on the Geriatric Depression Scale
Disease  Symptom and Sign,Exclusion Criteria: Diabetes mellitus
Disease  Symptom and Sign,Exclusion Criteria: Diagnosis is unclear or a suspicion of other parkinsonian syndromes 
Disease  Symptom and Sign,Exclusion Criteria: Diagnosis of COPD.
Disease  Symptom and Sign,Exclusion Criteria: Do not suffer from a serious mental illness
Disease  Symptom and Sign,Exclusion Criteria: evidence of joint or overlying skin infection
Disease  Symptom and Sign,Exclusion Criteria: Evidence of structural abnormality of the gastrointestinal tract or disease/conditions.
Disease  Symptom and Sign,Exclusion Criteria: Existence of congenital anomalies and genetic disease
Disease  Symptom and Sign,Exclusion Criteria: Have a diagnosis of learning disability or organic brain syndrome.
Disease  Symptom and Sign,Exclusion Criteria: Have had a myocardial infarction within 30 days prior to Day -1
Disease  Symptom and Sign,Exclusion Criteria: Health facilities in which the level of care was not appropriate for use of Integrated Management of Childhood Illness (IMCI) guidelines .  one referral hospital and one sub-specialty hospital).
Disease  Symptom and Sign,Exclusion Criteria: Hemorrhagic stroke 
Disease  Symptom and Sign,Exclusion Criteria: History of AIDS-related opportunistic or neoplastic disease
Disease  Symptom and Sign,Exclusion Criteria: History of medical condition that would preclude scheduled study visits
Disease  Symptom and Sign,Exclusion Criteria: History of mental illness
Disease  Symptom and Sign,Exclusion Criteria: History of Type 1 diabetes
Disease  Symptom and Sign,Exclusion Criteria: History of unstable angina  any recent angina (defined as chest pain) in the past 3 months  recent myocardial infarction (less then 3 months)  any history of ventricular arrhythmia  presence of left ventricular bundle branch block on E
Disease  Symptom and Sign,Exclusion Criteria: History or presence of disorders commonly accepted as contraindications to steroid hormonal therapy  e.g.  deep vein thrombophlebitis  thromboembolic disorders  cerebral vascular or coronary artery disease  etc.
Disease  Symptom and Sign,Exclusion Criteria: History or presence of significant cardiovascular  pulmonary  hepatic  renal  hematologic  gastrointestinal  endocrine  immunologic  dermatologic  neurologic or psychiatric disease
Disease  Symptom and Sign,Exclusion Criteria: History or presence of significant cardiovascular  pulmonary  hepatic  renal  hematologic  gastrointestinal  endocrine  immunologic  dermatologic  neurologic or psychiatric disease.
Disease  Symptom and Sign,Exclusion Criteria: Hyperparathyroidism
Disease  Symptom and Sign,Exclusion Criteria: lesion in saphenous vein graft
Disease  Symptom and Sign,Exclusion Criteria: Not cases of Kawasaki disease
Disease  Symptom and Sign,Exclusion Criteria: Other kidney disease
Disease  Symptom and Sign,Exclusion Criteria: Patient has evolving stroke or intracranial hemorrhage
Disease  Symptom and Sign,Exclusion Criteria: Patients who are in third degree heart block
Disease  Symptom and Sign,Exclusion Criteria: Patients who are receiving opioids for abdominal pain or connective tissue disorders.
Disease  Symptom and Sign,Exclusion Criteria: Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study
Disease  Symptom and Sign,Exclusion Criteria: patients with significant cardiovascular illness (recent acute myocardial infarction  uncompensated heart failure  cardiac arrhythmia)
Disease  Symptom and Sign,EXCLUSION CRITERIA: Presence or history of clinically relevant cardiovascular  hepatic  pulmonary  gastrointestinal  renal  metabolic  hematological  neurologic or psychiatric disease  any acute infectious disease or signs of acute illness  and myasthenia
Disease  Symptom and Sign,Exclusion Criteria: Prior myocardial infarction
Disease  Symptom and Sign,Exclusion Criteria: Psychiatric conditions other than depression
Disease  Symptom and Sign,Exclusion Criteria: psychiatric disorders
Disease  Symptom and Sign,Exclusion Criteria: Regional wall motion abnormality outside the area involved in the index acute myocardial infarction.
Disease  Symptom and Sign,Exclusion Criteria: Respiratory disease other tha asthma
Disease  Symptom and Sign,Exclusion Criteria: Sickness  psychopathology or developmental disabilities
Disease  Symptom and Sign,Exclusion Criteria: Significant medical disease including: uncontrolled congestive heart failure
Disease  Symptom and Sign,Exclusion Criteria: Significant neurologic disease such as Parkinson's disease  stroke  brain tumor  multiple sclerosis  or seizure disorder
Disease  Symptom and Sign,Exclusion Criteria: Subject has a history of stroke  seizures  or other neurological disorders
Disease  Symptom and Sign,Exclusion Criteria: Subject is mentally or legally incapacitated  has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of a clinically significant psychiatric disorder ov
Disease  Symptom and Sign,Exclusion Criteria: Subject may not have Class IV congestive heart failure.
Disease  Symptom and Sign,Exclusion Criteria: Subject with an HIV primo-infection status
Disease  Symptom and Sign,Exclusion Criteria: Subjects to whom any of the following applies will be excluded from the study.
Disease  Symptom and Sign,Exclusion Criteria: Subjects to whom any of the following applies will be excluded from the study.
Disease  Symptom and Sign,Exclusion Criteria: Subjects with recent (within 30 days of randomization) or current opportunistic infection or neoplasm characteristic of AIDS (Category C of the CDC Classification System for HIV-1 infection  1993 Revised Version).
Disease  Symptom and Sign,Exclusion criteria: Subjects with uncontrolled intercurrent illness including  but not limited to  ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements  significant history of uncontrolle
Disease  Symptom and Sign,Exclusion Criteria: uncontrolled systemic disease
Disease  Symptom and Sign,Exclusion Criteria: Uncontrolled systemic disease
Disease  Symptom and Sign,Exclusion Criteria: Uncontrolled systemic disease
Disease  Symptom and Sign,Exclusion Criteria: Uncontrolled systemic disease
Disease  Symptom and Sign,Exclusion Criteria: Unstable angina oder MI within 3 months prior to inclusion
Disease  Symptom and Sign,Exclusion Criteria: Weight loss due to factors other than AIDS-related wasting
Disease  Symptom and Sign,Exclusion Criteria: Who are receiving opioids for abdominal pain or connective tissue disorders.
Disease  Symptom and Sign,Exclusion Criteria: You are in the acute recovery phase following myocardial infarction.
Disease  Symptom and Sign,Exclusion Criteria: You cannot be in this study if you any of the following:
Disease  Symptom and Sign,Extensive diffuse atherosclerotic disease involving the arch or common carotid that would preclude safe introduction of catheters and sheaths for endovascular therapy
Disease  Symptom and Sign,Family history of rupture of intracerebral aneurisms
Disease  Symptom and Sign,fast atrial fibrillation  ventricular tachycardia  or supraventricular tachycardia) with hemodynamic instability
Disease  Symptom and Sign,First episode of CMV retinitis.
Disease  Symptom and Sign,Fit one of the zidovudine use groups listed in Disease Status
Disease  Symptom and Sign,For patients who progress while receiving hormonal therapy alone  the patient may be enrolled on study as soon as they have recovered from all side effects of the hormonal therapy
Disease  Symptom and Sign,for patients with ADPKD family history: < 30 years: 2 cysts (unilateral or bilateral) 30-60 years: 2 or more bilateral cysts > 60 years: 4 or more bilateral cysts
Disease  Symptom and Sign,For the purposes of this study  CHD will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing)
Disease  Symptom and Sign,For the purposes of this study  CHD will include one or more of the following features: documented stable angina (with evidence of ischemia on exercise testing)
Disease  Symptom and Sign,fractures of the extremities combined with blunt/penetrating thoracic trauma
Disease  Symptom and Sign,Free of any clinically significant diseases other than hyperlipidemia  CHD  or diabetes mellitus that would interfere with study evaluations
Disease  Symptom and Sign,Free of liver and kidney diseases  and with no evidence of uncontrolled hypertension and/or diabetes
Disease  Symptom and Sign,Frequent headaches and/or migraine  recurrent nausea and/or vomiting (more than twice a month).
Disease  Symptom and Sign,Fulfilled DSM->=  criteria for major depressive disorder.
Disease  Symptom and Sign,Full functional independence prior to the present stroke indicated by an estimated premorbid mRS score of 0 or 1
Disease  Symptom and Sign,gastric ulcer  intracranial bleeding
Disease  Symptom and Sign,Gastrointestinal bleeding within 3 months
Disease  Symptom and Sign,GI symptoms for at least 2 months before entering study
Disease  Symptom and Sign,Glaucoma
Disease  Symptom and Sign,Glaucoma
Disease  Symptom and Sign,Group 1 (Non-ST-elevation acute myocardial infarction) : Chest pain less than 48 hours before admission 
Disease  Symptom and Sign,Group 1 : Preexisting EKG abnormalities (including left bundle branch block) precluding accurate assessment of ST-T changes
Disease  Symptom and Sign,Group 1: Co-morbid conditions such as severe heart  lung  kidney or liver disease.
Disease  Symptom and Sign,Group 2 (Stable coronary artery disease) : Documented myocardial ischemia (stable angina or positive stress test)
Disease  Symptom and Sign,Group 2 : History of acute coronary syndrome
Disease  Symptom and Sign,Group 3 (Normal coronary arteries) : No history of coronary artery disease  neurovascular disease or peripheral artery disease 
Disease  Symptom and Sign,Groups 1 and 2: Culprit coronary artery stenosis is a restenosis or a stent thrombosis or is located in a bypass graft.
Disease  Symptom and Sign,Had a biventricular pacemaker placed within the 45 days before randomization or a single or dual chamber pacemaker or an automatic implantable cardiac defibrillator placed within the 15 days before randomization
Disease  Symptom and Sign,Had an uncontrolled thyroid disorder
Disease  Symptom and Sign,Had severe obstructive pulmonary disease or active neurological events
Disease  Symptom and Sign,had skin conditions resulting in oily  irritated or damaged skin at all potential application sites
Disease  Symptom and Sign,has a history of chronic hepatic failure and/or hepatic cirrhosis
Disease  Symptom and Sign,has a known or suspected hereditary complement deficiency
Disease  Symptom and Sign,Has clinically significant valvular heart disease
Disease  Symptom and Sign,has current cardiogenic shock  acute left ventricular rupture  acute septal rupture or acute papillary muscle rupture
Disease  Symptom and Sign,Have a fungal infection of the affected fingernails
Disease  Symptom and Sign,Have a history of central nervous system disease  such as seizures
Disease  Symptom and Sign,Have a history of pancreatitis or gallstones.
Disease  Symptom and Sign,Have a history of psoriasis or lichen planus involving any nail  or active contact dermatitis involving the affected fingernails
Disease  Symptom and Sign,Have a known or suspected history of a genetic condition affecting the nails  .  Darier's disease  nail-patella syndrome  tuberculosis sclerosis)
Disease  Symptom and Sign,Have a serious illness that required systemic treatment or a hospital stay unless treatment was completed at least 14 days prior to entering the study  or are on stable treatment  in the doctor's opinion  for at least 14 days prior to entering the study.
Disease  Symptom and Sign,Have a significant psychiatric disorder
Disease  Symptom and Sign,Have a substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse.
Disease  Symptom and Sign,Have an active  ongoing gastrointestinal disease or infection such as colitis  diverticulitis  Crohn's disease  peptic ulcer disease  giardiasis  or cryptosporidiosis.
Disease  Symptom and Sign,Have an acute febrile illness or upper respiratory tract illness within 72 hours prior to administration of study medication
Disease  Symptom and Sign,Have any acute or chronic disease  .  history of hepatitis or HIV-1)
Disease  Symptom and Sign,Have any other concomitant life-threatening disease 
Disease  Symptom and Sign,Have at least three of the five characteristics listed below  indicating presence of metabolic syndrome  as defined by NCEP-III: waist measuring more than 40 inches (for men) or more than 35 inches (for women) 
Disease  Symptom and Sign,Have averaged at least three partial seizures per month  with no 21-day seizure-free period during the 2 months preceding randomization
Disease  Symptom and Sign,Have been previously vaccinated within the last 10 years (vaccinia-experienced cohort only)
Disease  Symptom and Sign,Have cardiac disease including congestive heart failure or arrhythmia
Disease  Symptom and Sign,Have certain serious medical conditions  including an AIDS-defining clinical condition.
Disease  Symptom and Sign,Have current signs or symptoms of severe  progressive  or uncontrolled renal  hepatic  hematologic  gastrointestinal  endocrine  pulmonary  cardiac  neurologic  or cerebral disease
Disease  Symptom and Sign,Have had a diagnosis of probable Alzheimer's disease.
Disease  Symptom and Sign,Have had systemic treatment with certain other drugs that may interfere with the study within 14 days of entering the study.
Disease  Symptom and Sign,Have not engaged in an HIV risk behavior during the three-month period prior to the baseline evaluation.
Disease  Symptom and Sign,have one or more of the following risk factors: diabetes mellitus
Disease  Symptom and Sign,Have onycholysis (lifting of the nail plate off the nailbed) of the affected fingernails
Disease  Symptom and Sign,Have or suspect they have acute hepatitis within 30 days of entering the study.
Disease  Symptom and Sign,Have peripheral neuropathy (a condition affecting the nervous system) or other condition or prior therapy that  in the opinion of the investigator  would affect the study.
Disease  Symptom and Sign,Have signs of bacterial  fungal or viral skin lesions that may interfere with measurement of the target lesions.
Disease  Symptom and Sign,Have symptomatic ventricular tachycardia
Disease  Symptom and Sign,Have the diagnosis of epilepsy with partial seizures with or without secondarily generalized seizures according with the International League Against Epilepsy's Classification of Epileptic Seizures (1981)
Disease  Symptom and Sign,Have uncontrolled hypertension
Disease  Symptom and Sign,Head CT showing no evidence of intracranial hemorrhage or mass lesion which might increase the risk of bleeding.
Disease  Symptom and Sign,Healthy subjects are defined as individuals who are free from clinically significant illness or disease (such as coronary arterial disease  chronic heart failure  bleeding disorder  hypertension  chronic renal failure etc.) as determined by their medical 
Disease  Symptom and Sign,Healthy subjects as established by medical history and clinical examination before entering into the study.
Disease  Symptom and Sign,hemodynamic instability
Disease  Symptom and Sign,Hemorrhage on initial MRI or CT or other structural lesion that might raise the risk of intracranial bleeding.
Disease  Symptom and Sign,Hepatic insufficiency /AST  ALT 3 fold of the upper limit of the normal value/
Disease  Symptom and Sign,Hepatitis B or C infection AND liver enzymes of Grade 2 or greater OR evidence or history of severe hepatitis or cirrhosis
Disease  Symptom and Sign,Higher degree heart valve disease
Disease  Symptom and Sign,Higher degree ventricular arrhythmias
Disease  Symptom and Sign,High-risk uncontrolled arrhythmias
Disease  Symptom and Sign,History and/or presence of any clinically significant cardiovascular disease  clinically significant hepatic  renal  or endocrine dysfunction  stroke  uncontrolled diabetes  hyperthyroidism  convulsive disorders  neoplastic disease other than basal cell c
Disease  Symptom and Sign,History and/or presence of any non-asthmatic acute or chronic lung disease  including but not limited to bronchitis  emphysema  active tuberculosis  bronchiectasis or cystic fibrosis
Disease  Symptom and Sign,History bronchial asthma and bronchospastic diseases.
Disease  Symptom and Sign,History bronchial asthma and bronchospastic diseases.
Disease  Symptom and Sign,history of 2 myocardial infarctions  or a myocardial infarction that occurred greater than 48 hours but less than four (4) weeks prior to CABG
Disease  Symptom and Sign,History of abdominal fistula  gastrointestinal (GI) perforation  or intra-abdominal abscess within 6 months prior to Day 1.
Disease  Symptom and Sign,History of acute or chronic pancreatitis.
Disease  Symptom and Sign,History of angioedema  hereditary or idiopathic
Disease  Symptom and Sign,History of ascites  variceal hemorrhage or hepatic encephalopathy
Disease  Symptom and Sign,history of asthma  bronchospastic lung disease  or hyper-reactive airway disease
Disease  Symptom and Sign,History of bleeding disorder
Disease  Symptom and Sign,history of congestive heart failure
Disease  Symptom and Sign,History of encephalopathy  neuropathy  or unstable CNS pathology (HIV or non-HIV related)
Disease  Symptom and Sign,history of gout
Disease  Symptom and Sign,History of hepatitis or active liver disease.
Disease  Symptom and Sign,History of HIV infection
Disease  Symptom and Sign,History of hypertrophic or alcoholic cardiomyopathy
Disease  Symptom and Sign,History of immunodeficiency disease (such as HIV) or autoimmune disease except vitiligo.
Disease  Symptom and Sign,History of known presence of cardiogenic shock  sinus bradycardia  Wolff-Parkinson White Syndrome  congestive heart failure or angina.
Disease  Symptom and Sign,History of known presence of cardiogenic shock  sinus bradycardia  Wolff-Parkinson White Syndrome  congestive heart failure or angina.
Disease  Symptom and Sign,History of major complications of lung disease (including recent massive hemoptysis or pneumothorax) within 2 months prior to start of study treatment.
Disease  Symptom and Sign,History of major ipsilateral stroke with sufficient atrophy to increase risk of procedure associated bleed
Disease  Symptom and Sign,History of more than one seizure per month during the last year (or  since the stroke if no seizures prior to stroke)
Disease  Symptom and Sign,history of myocardial infarction
Disease  Symptom and Sign,history of myocardial infarction
Disease  Symptom and Sign,History of non-HIV related neoplastic diseases  autoimmune diseases  angina or cardiac arthymias  or any other clinically significant medical problems
Disease  Symptom and Sign,History of obstructive valvular disease
Disease  Symptom and Sign,history of ocular fundus diseases
Disease  Symptom and Sign,History of ophthalmic disease in the study eye other than AMD
Disease  Symptom and Sign,History of other upper motor neuron lesion
Disease  Symptom and Sign,History of pain syndrome
Disease  Symptom and Sign,history of pre-stroke shoulder pain
Disease  Symptom and Sign,History of psychiatric illness
Disease  Symptom and Sign,History of pulmonary hypertension within the last 3 months
Disease  Symptom and Sign,History of recent myocardial infarction  stroke  or uncontrolled CHF  epilepsy  or hypertension
Disease  Symptom and Sign,History of restrictive cardiomyopathy
Disease  Symptom and Sign,History of reversible cardiomyopathy
Disease  Symptom and Sign,History of serious opportunistic infection.
Disease  Symptom and Sign,History of severe and symptomatic cardiac valvular disease.
Disease  Symptom and Sign,History of severe asthma  anaphylactic reactions  angioedema  angioneurotic oedema or Quincke's Oedema
Disease  Symptom and Sign,History of severe hypoglycemia
Disease  Symptom and Sign,History of significant maternal deprivation  abuse  or malnutrition
Disease  Symptom and Sign,History of status epilepticus in the past year or seizure clusters where individual seizures cannot be counted.
Disease  Symptom and Sign,History of stroke
Disease  Symptom and Sign,History of symptomatic peripheral vascular disease or Raynaud's syndrome.
Disease  Symptom and Sign,history of thromboembolic diseases
Disease  Symptom and Sign,History of thromboembolic or cerebrovascular events  such as stroke  or transient ischemic attack (TIA)
Disease  Symptom and Sign,History of use of diuretic therapy for CHF (including this admission) 
Disease  Symptom and Sign,History or current psychosis or bipolar disorder
Disease  Symptom and Sign,History or evidence of thromboembolic events or any first degree relative with a history of thromboembolic events
Disease  Symptom and Sign,History or presence of central nervous system disease.
Disease  Symptom and Sign,History or presence of clinically significant gastro-oesophageal reflux  stomach ulcers  or indigestions
Disease  Symptom and Sign,History or presence of clinically significant myasthenia gravis
Disease  Symptom and Sign,History or presence of clinically significant severe renal or hepatic dysfunction
Disease  Symptom and Sign,HIV exposure
Disease  Symptom and Sign,HIV Infected
Disease  Symptom and Sign,HIV infection or active hepatitis
Disease  Symptom and Sign,HIV negative
Disease  Symptom and Sign,HIV positive
Disease  Symptom and Sign,HIV seropositive.
Disease  Symptom and Sign,HIV status or other severe illnesses will be assessed using medical records.
Disease  Symptom and Sign,HIV/AIDS
Disease  Symptom and Sign,HIV-HBV co-infected individuals from the Alfred Hospital  the Royal Melbourne Hospital and high case load GP clinics who are referred to the Alfred Hospital
Disease  Symptom and Sign,HIV-positive
Disease  Symptom and Sign,HIV-positive subjects are excluded from the study.
Disease  Symptom and Sign,However  documentation of disease progression is not mandatory for enrollment.
Disease  Symptom and Sign,Hypercalcemia
Disease  Symptom and Sign,Hyperpigmentation
Disease  Symptom and Sign,Hypersplenism
Disease  Symptom and Sign,hypertension
Disease  Symptom and Sign,i.e.  uncontrolled hypertension  unstable angina  recent myocardial infarction (within prior 3 months)  uncontrolled congestive heart failure  and cardiomyopathy with decreased ejection fraction.
Disease  Symptom and Sign,ICP greater than 20mmHg  not related to a transient noxious stimulus and not responding to standard measures for controlling ICP (ventricular drainage  elevation of head of the bed and optimizing PaCO2)
Disease  Symptom and Sign,ICP monitor in place
Disease  Symptom and Sign,Identification of new parqueurs circulated in coronary artheriosclerosis and complications of the new differentiel technicology
Disease  Symptom and Sign,If at any time prior to enrollment in the study  the patient's cardiologist determines that the patient should not participate in this study  the patient will not be enrolled in the trial.
Disease  Symptom and Sign,If at any time prior to enrollment in the study  the patient's cardiologist determines that the patient should not participate in this study  the patient will not be enrolled in the trial.
Disease  Symptom and Sign,If predilation of the lesion is visually deemed necessary it should be performed prior to measuring the length of the lesion.
Disease  Symptom and Sign,If screen values do not meet the absolutely exclusionary values given below but are still outside the normal reference range  treatment for folic acid/B12 deficiency or thyroid disorder  as appropriate  may be initiated or adjusted with re-evaluation of t
Disease  Symptom and Sign,If the only site of measurable disease is a previously irradiated area  the patient must have documented progression of disease in this area.
Disease  Symptom and Sign,If the serology is documented to be a false positive or due to an adequately treated infection  the volunteer is eligible]
Disease  Symptom and Sign,If they have cardiac disease or other severe comorbidity
Disease  Symptom and Sign,If they have other pulmonary diseases
Disease  Symptom and Sign,If you do not qualify for the trial  study personnel will explain the reasons.
Disease  Symptom and Sign,Impaired glucose tolerance
Disease  Symptom and Sign,In men  evidence of a mass lesion on clinical examination by their primary care physician within twelve months prior to entry into the study (specifically prostate or testicular mass on clinical exam or other signs of mass lesion) or evidence of mass lesi
Disease  Symptom and Sign,In- or out-patients (change of institutionalization status during the trial period is allowed).
Disease  Symptom and Sign,Inclusion Criteria: A clinical diagnosis of DM-1 according to accepted clinical research criteria.23 The clinical research criteria require each of the following: (1) clinically evident myotonia
Disease  Symptom and Sign,Inclusion Criteria: Acute or early HIV infection  as determined by the NIH Acute Infection and Early Disease Research Program (AIEDRP) definition
Disease  Symptom and Sign,Inclusion Criteria: ADHD diagnosis
Disease  Symptom and Sign,Inclusion Criteria: Are HIV-positive.
Disease  Symptom and Sign,Inclusion Criteria: Be diagnosed with multiple migraines per month of moderate to severe intensity
Disease  Symptom and Sign,Inclusion Criteria: Be receiving care for HIV at one of the participating immunology clinics
Disease  Symptom and Sign,Inclusion Criteria: biopsied-proved crescentic glomerulonephritis  with rapidly progressive renal failure
Disease  Symptom and Sign,Inclusion Criteria: biopsied-proved primary glomerular diseases  and nephrotic syndrome
Disease  Symptom and Sign,Inclusion Criteria: Clinical diagnosis of polycystic ovary syndrome
Disease  Symptom and Sign,Inclusion Criteria: Clinically confirmed diagnosis of osteoarthritis from a physician
Disease  Symptom and Sign,Inclusion Criteria: Coronary disease
Disease  Symptom and Sign,Inclusion Criteria: Critically ill  postoperative/posttraumatic patients with severe systemic inflammatory response syndrome (SIRS) or severe sepsis
Disease  Symptom and Sign,Inclusion Criteria: Critically ill  postoperative/posttraumatic patients with threatening acute renal failure
Disease  Symptom and Sign,Inclusion Criteria: Diagnosis of depression
Disease  Symptom and Sign,Inclusion Criteria: Diagnosis of DR.
Disease  Symptom and Sign,Inclusion Criteria: Diagnosis of ocular hypertension or glaucoma
Disease  Symptom and Sign,Inclusion Criteria: Diagnosis of ocular hypertension or glaucoma
Disease  Symptom and Sign,Inclusion Criteria: Diagnosis of schizophrenia or schizoaffective disorder
Disease  Symptom and Sign,Inclusion Criteria: Ethnically Japanese patients with glaucoma or ocular hypertension in each eye who require IOP-lowering therapy in both eyes
Disease  Symptom and Sign,Inclusion Criteria: First myocardial infarction
Disease  Symptom and Sign,Inclusion Criteria: Free of active ocular or systemic disease
Disease  Symptom and Sign,Inclusion Criteria: Group 1 (Non-ST-elevation acute myocardial infarction) :
Disease  Symptom and Sign,Inclusion Criteria: Have a primary diagnosis of Bipolar I Disorder  current episode manic (DSM-IV 296.4x) or mixed (DSM-IV296.6x) as determined by a structured clinical interview (Mini International Neuropsychiatric Interview (MINI)) at screening.
Disease  Symptom and Sign,Inclusion Criteria: Have had a diagnosis of probable Alzheimer's disease
Disease  Symptom and Sign,Inclusion Criteria: Have HIV infection or AIDS.
Disease  Symptom and Sign,Inclusion Criteria: Logan student  staff  or faculty or general public with a minimal of 2 year history of diagnosed Multiple Sclerosis (MS)
Disease  Symptom and Sign,Inclusion Criteria: measurable disease as defined by the presence of at least one measurable lesion
Disease  Symptom and Sign,Inclusion Criteria: multiple trauma injury  injury severity score (ISS) > 18 with
Disease  Symptom and Sign,Inclusion Criteria: ocular hypertension or glaucoma in both eyes
Disease  Symptom and Sign,Inclusion Criteria: Ocular hypertension or glaucoma in both eyes
Disease  Symptom and Sign,Inclusion Criteria: Ocular hypertension or glaucoma in both eyes
Disease  Symptom and Sign,Inclusion Criteria: Patients diagnosed with AMD  or
Disease  Symptom and Sign,Inclusion Criteria: Patients who fulfill the criteria of Kawasaki disease or atypical Kawasaki disease and their household family members
Disease  Symptom and Sign,Inclusion Criteria: Patients who meet current indications for an ICD
Disease  Symptom and Sign,Inclusion Criteria: Patients with acute ischemic stroke in whom treatment can be initiated within 12 hours of a clearly defined symptom onset
Disease  Symptom and Sign,Inclusion Criteria: Patients with atrial fibrillation undergoing radiofrequency ablation
Disease  Symptom and Sign,Inclusion Criteria: Poorly controlled asthma
Disease  Symptom and Sign,Inclusion Criteria: Subject must have symptomatic AF
Disease  Symptom and Sign,Inclusion Criteria: Subjects have participated in primary study HBV-280
Disease  Symptom and Sign,Inclusion Criteria: Subjects who had completed the double-blind phase or discontinued due to lack of efficacy after at least 21 days of treatment  who signed the informed consent for the open-label phase  and who the investigator agreed that open-label tr
Disease  Symptom and Sign,Inclusion Criteria: Type 2 diabetes
Disease  Symptom and Sign,Inclusion: Mild to moderate Osteoarthritis of the target knee.
Disease  Symptom and Sign,Incontinence symptoms present for at least (3) months*
Disease  Symptom and Sign,indication for revascularization (angina status  myocardial ischemia  positive stress test  pathologic FFR)
Disease  Symptom and Sign,Individuals who are obese.
Disease  Symptom and Sign,Individuals with scoliosis carrying additional diagnoses of illness.
Disease  Symptom and Sign,Intestinal obstruction /because of the castor oil content of the drug/
Disease  Symptom and Sign,is receiving  or is planning to receive  any other investigational drug or device  or will participate in any other research study during the trial
Disease  Symptom and Sign,isolated head injury with morphological changes in CCT
Disease  Symptom and Sign,Isolated systolic Hypertension
Disease  Symptom and Sign,ISS < 18
Disease  Symptom and Sign,Key Exclusion Criteria: Obesity of known endocrine origin
Disease  Symptom and Sign,Known bleeding disorder.
Disease  Symptom and Sign,Known hepatic disease
Disease  Symptom and Sign,Known history of carotid disease
Disease  Symptom and Sign,Known history of corneal disease
Disease  Symptom and Sign,Known HIV  Hepatitis B or C virus  or tuberculosis infection
Disease  Symptom and Sign,Known HIV  Hepatitis B  or Hepatitis C infection.
Disease  Symptom and Sign,Known HIV-infection (HIV testing is not required for participation).
Disease  Symptom and Sign,Known immunodeficiency
Disease  Symptom and Sign,Known positive HIV status.
Disease  Symptom and Sign,Lack of ICP monitoring
Disease  Symptom and Sign,Lacunae infarcts present in areas affecting cognition (entorhinal cortex  hippocampus  medial temporal lobe) will also exclude the subject from the study.
Disease  Symptom and Sign,Later in life  these individuals are also subject to the added effects of a wasting process similar to classical DM-1
Disease  Symptom and Sign,left main stenosis
Disease  Symptom and Sign,lesion in native coronary artery
Disease  Symptom and Sign,Less than 6 months post-stroke
Disease  Symptom and Sign,leukopenia and/or thrombocytopenia
Disease  Symptom and Sign,Low doses are allowed if received for 60 or more days before entering the study with no plans to change the dose during the first 24 weeks of the study.
Disease  Symptom and Sign,Major congenital infections
Disease  Symptom and Sign,Major fetal anomaly or congenital malformation
Disease  Symptom and Sign,Major psychiatric illness (major depression  bipolar disorder  or schizophrenia) within twelve months of entry.
Disease  Symptom and Sign,Measurable disease
Disease  Symptom and Sign,Measurable disease
Disease  Symptom and Sign,Measurable disease
Disease  Symptom and Sign,Measurable disease defined as at least one malignant lesion that can be accurately and serially measured in at least one dimension (longest diameter to be recorded)  using a caliper (diameter > 10 mm) for superficial cutaneous disease  or using contrast-e
Disease  Symptom and Sign,Measurable disease  defined as >=  1 lesion that can be accurately measured in >=  1 dimension
Disease  Symptom and Sign,Measurable or evaluable disease determined as per RECIST criteria
Disease  Symptom and Sign,Measurable or evaluable disease.
Disease  Symptom and Sign,Medical disorder that would not allow use of olanzapine
Disease  Symptom and Sign,Medical illness which would prevent assessment of muscle strength or function
Disease  Symptom and Sign,Medically healthy subjects with clinically normal laboratory profiles will be enrolled in the study
Disease  Symptom and Sign,Medically healthy subjects with clinically normal laboratory profiles will be enrolled in the study
Disease  Symptom and Sign,Mental retardation
Disease  Symptom and Sign,Mesenteric or peripheral vascular thrombosis.
Disease  Symptom and Sign,Mild non-prolipherative retinopathy (based on ETDRS criteria)
Disease  Symptom and Sign,Moderate to severe baseline disability (pre-stroke Rankin score of > 3)  severe or terminal concurrent medical illness with expected survival of < 3 months  or other concurrent medical or psychiatric condition which may limit neurologic assessment or pati
Disease  Symptom and Sign,Mood disorder due to general medical condition.
Disease  Symptom and Sign,Multiple carotid stenoses exist in the internal carotid artery (ICA) that cannot be covered by one stent.
Disease  Symptom and Sign,Mycotic aneurysm  infectious false aneurysms
Disease  Symptom and Sign,Myocardial infarction within 6 months prior to enrollment  uncontrolled angina  severe uncontrolled ventricular arrhythmias  or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Disease  Symptom and Sign,Myocardial infarction within 90 days of study start  unstable angina within 14 days of study start  or any clinical evidence of active myocardial ischemia
Disease  Symptom and Sign,Myocardial infarction within the last 6 months prior study entry
Disease  Symptom and Sign,Myocardial infarction within the past 6 months
Disease  Symptom and Sign,Need to acutely revascularize additional vessels  outside the infarct artery.
Disease  Symptom and Sign,Neoplastic disease without documented remission within the past 5 years.
Disease  Symptom and Sign,No active infection
Disease  Symptom and Sign,No active opportunistic infection.
Disease  Symptom and Sign,No active or recent (within the past 30 days) fungal infection
Disease  Symptom and Sign,No AIDS opportunistic infection within 30 days of screening
Disease  Symptom and Sign,No alarm indicators on clinical assessment (weight loss of more than 7kg  bleeding  recent recurrent vomiting  progressive dysphagia).
Disease  Symptom and Sign,no bleeding diathesis or coagulopathy.
Disease  Symptom and Sign,No concurrent combination antiretroviral therapy for HIV-positive patients
Disease  Symptom and Sign,No convulsive disorders such as epilepsy
Disease  Symptom and Sign,No current major depression or PTSD.
Disease  Symptom and Sign,No hemorrhagic diathesis.
Disease  Symptom and Sign,No history of CHF or cardiomyopathy
Disease  Symptom and Sign,No history suggestive of small bowel obstruction
Disease  Symptom and Sign,No neuroleptic malignant syndrome or physical fatigue associated with dehydration  malnutrition
Disease  Symptom and Sign,No present illness or history of diabetes or risks of diabetes such as hyperglycemia and obesity
Disease  Symptom and Sign,No previous heart attack or a stroke  or other forms of these diseases.
Disease  Symptom and Sign,No prior end-organ CMV disease - PER AMENDMENT 4/25/96: No prior end organ CMV disease within the past 6 months
Disease  Symptom and Sign,No prior or current history of AIDS.
Disease  Symptom and Sign,No proven or suspected sepsis  pneumonia  or meningitis unless appropriate therapeutic measures have been initiated to control the infection and systemic signs are no longer life-threatening
Disease  Symptom and Sign,No psychiatric illness or social situation that would preclude study compliance
Disease  Symptom and Sign,No rapidly progressive disease
Disease  Symptom and Sign,No uncontrolled intercurrent illness including  but not limited to  any of the following: Ongoing or active infection
Disease  Symptom and Sign,Non infectious false aneurysms developed on prosthesis (Deleted by amendment n>= 1 at the request of AFSSAPS)
Disease  Symptom and Sign,Non-healing wounds  ulcer  or long bone fracture
Disease  Symptom and Sign,Non-ruptured symptomatic aneurysm or aneurysm complicated with emboli.
Disease  Symptom and Sign,Non-stable diabetes mellitus
Disease  Symptom and Sign,Not meeting entry criteria for ADAF (as above)
Disease  Symptom and Sign,On moderate doses of ICS with inadequate asthma control.
Disease  Symptom and Sign,one or more de novo lesions in 1  2 or 3 native coronary arteries
Disease  Symptom and Sign,Ongoing acute illness including acute upper or lower respiratory infections within 2 weeks before start of study treatment.
Disease  Symptom and Sign,or have acute contrast nephropathy
Disease  Symptom and Sign,or infectious disease in the month before admission
Disease  Symptom and Sign,Ostial target lesion
Disease  Symptom and Sign,Other diseases that may make study completion difficult or unlikely
Disease  Symptom and Sign,Other laboratory abnormalities that judged by the investigator would interfere with the patients participation in the trial or the evaluation of the trial results
Disease  Symptom and Sign,Other retinal vascular disease
Disease  Symptom and Sign,Other severe chronic diseases  .  cardiologic  renal  or hepatic diseases
Disease  Symptom and Sign,Other system illnesses such as renal  hepatic  gastrointestinal  severe hyperlipidemia and hypertension that require medication
Disease  Symptom and Sign,partial bowel obstruction).
Disease  Symptom and Sign,Participant has a cold or upper respiratory distress
Disease  Symptom and Sign,Patient diagnosed with liver disease  defined as AST or ALT > 3x the upper limit of normal
Disease  Symptom and Sign,Patient has a history of chronic hepatitis B or C  hepatitis within the past 3 months  or HIV infection.
Disease  Symptom and Sign,Patient has a history of seizure (except for infantile febrile seizure) or is at risk of seizure due to head trauma.
Disease  Symptom and Sign,patient has active peptic ulcer disease
Disease  Symptom and Sign,Patient has presence of non-contiguous satellite lesions
Disease  Symptom and Sign,Patient has severe chronic diarrhea  chronic constipation [unless attributed to drugs that will be washed out]  uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.
Disease  Symptom and Sign,Patient has skin conditions in the area affected by the neuropathy that could alter sensation.
Disease  Symptom and Sign,Patient must be treated for SLE with doses of prednisone < 30 mg/day (including those on NO glucocorticoid therapy) unchanged for > 6 weeks prior to study entry (including both screening and qualifying visits)
Disease  Symptom and Sign,Patient must have a diagnosis of SLE > 6 months according to the 1989 revised ACR criteria
Disease  Symptom and Sign,Patient must have glioma progression or recurrence following radiotherapy that was no less than 50 Gy (+/- chemotherapy
Disease  Symptom and Sign,Patient with any condition which in the Investigator's or sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation  
Disease  Symptom and Sign,Patient with disease worsening and in incapacity to move about to CHJM
Disease  Symptom and Sign,Patient with left ventricular systolic dysfunction implanted wih ICD
Disease  Symptom and Sign,Patients admitted within 24 hours and can be enrolled within 48 hours after qualifying ischemic stroke onset
Disease  Symptom and Sign,Patients entering the Phase 1 portion of the study can have either measurable or evaluable disease.
Disease  Symptom and Sign,Patients entering the Phase 2 portion of the study must have measurable disease meeting RECIST criteria.
Disease  Symptom and Sign,Patients having significant bleeding diathesis.
Disease  Symptom and Sign,Patients may be eligible for this study if they: Are HIV infected.
Disease  Symptom and Sign,Patients may be eligible for this study if they: Are HIV-positive.
Disease  Symptom and Sign,Patients must be: HIV positive by ELISA and Western blot.
Disease  Symptom and Sign,Patients must have unidimensionally measurable disease (RECIST criteria)
Disease  Symptom and Sign,Patients must have: A working diagnosis of HIV infection.
Disease  Symptom and Sign,Patients must have: HIV infection.
Disease  Symptom and Sign,Patients must have: HIV infection.
Disease  Symptom and Sign,Patients must have: HIV infection.
Disease  Symptom and Sign,Patients must have: HIV seropositivity.
Disease  Symptom and Sign,Patients must meet the criteria for chronic idiopathic constipation for at least 12 weeks
Disease  Symptom and Sign,Patients must not have had prior radiotherapy to areas of measurable disease unless they have clearly progressive disease in this site or there is measurable disease outside the area of prior radiation.
Disease  Symptom and Sign,Patients must not have uncontrolled intercurrent illness including  but not limited to  ongoing or active infection  unstable angina pectoris  cardiac arrhythmia  or psychiatric illness/social situations that would limit compliance with study requirements
Disease  Symptom and Sign,Patients must: Be HIV positive
Disease  Symptom and Sign,Patients taking any agent reported to have symptom relief for arthritis or be a disease/structure modifying drug  
Disease  Symptom and Sign,Patients who are not clinically stable such as those who had cardiac arrest  who are intubated  who have active psychosis  or who are cognitively impaired.
Disease  Symptom and Sign,Patients who are on regular automated peritoneal dialysis due to end stage renal failure for at least 3 months.
Disease  Symptom and Sign,Patients will be excluded from the study if they fulfill any of the following criteria: Serious illnesses  e.g.  serious infections requiring antibiotics.
Disease  Symptom and Sign,Patients with a hemiparesis of the lower limbs
Disease  Symptom and Sign,Patients with a history of viral infections such as HIV or hepatitis B  C.
Disease  Symptom and Sign,Patients with active infection of the skin near the potential injection site.
Disease  Symptom and Sign,Patients with acute myocardial infarction (ST elevation in at least 2 leads >=  0.2 mV in V1 V2 or V3 or >=  0.1 mV in other leads)  treated by one of the following procedures: Acute PCI with stent implantation for acute ST elevation MI for either denov
Disease  Symptom and Sign,Patients with an onset date of acute GVHD that is less than or equal to 100 days posttransplant.
Disease  Symptom and Sign,Patients with an undeterminate colitis
Disease  Symptom and Sign,Patients with any abnormal laboratory value or physical finding that  in the view of the responsible clinician  may interfere with interpretation of the study results  be indicative of an underlying disease state  or compromise the safety.
Disease  Symptom and Sign,Patients with any abnormal laboratory value or physical finding that  in the view of the responsible clinician  may interfere with interpretation of the trial results  be indicative of an underlying disease state  or compromise the safety.
Disease  Symptom and Sign,Patients with any coagulation  bleeding or blood disorders.
Disease  Symptom and Sign,Patients with any coagulation  bleeding or blood disorders.
Disease  Symptom and Sign,Patients with any evidence of cancer or history of significant cardiovascular disease (including heart attack  stroke or drop attacks termed transient ischemic attacks (TIAs)  or blockages of the arteries in the legs termed peripheral arterial disease (PA
Disease  Symptom and Sign,Patients with any inter-current disease(s) or condition(s) that may interfere with the free use and evaluation of the affected knee for the 6 month course of the trial (cancer  other rheumatic diseases  gout  severe congenital defects  etc.).
Disease  Symptom and Sign,Patients with any of the following conditions or symptoms are excluded: Febrile illness with temperature > 38.5 degrees C (101.3 degrees F) within 3 days prior to study entry.
Disease  Symptom and Sign,Patients with asthma  rhinitis  or nasal polyps.
Disease  Symptom and Sign,Patients with asthma  rhinitis  or nasal polyps.
Disease  Symptom and Sign,Patients with chronic candidiasis (yeast infection) or bacterial infection will be allowed.
Disease  Symptom and Sign,Patients with Class IV heart failure.
Disease  Symptom and Sign,Patients with Class IV heart failure.
Disease  Symptom and Sign,Patients with clinically significant medio-lateral and/or anterior-posterior instability.
Disease  Symptom and Sign,Patients with corneal disease associated with endothelial dysfunction  including pseudophakic corneal edema  Fuchs' dystrophy  posterior polymorphous dystrophy  endothelial failure from another cause  interstitial keratitis (non-herpetic)  or perforating 
Disease  Symptom and Sign,Patients with disease accessible for biopsy will be preferentially selected for participation in the study
Disease  Symptom and Sign,Patients with documented history of any gastrointestinal disorders  including bleeding ulcers.
Disease  Symptom and Sign,Patients with documented history of any gastrointestinal disorders  including bleeding ulcers.
Disease  Symptom and Sign,Patients with gout or calcium pyrophosphate (pseudogout) diseases that had flared within the previous 6 months prior to Screening.
Disease  Symptom and Sign,Patients with inflammatory arthropathies such as rheumatoid arthritis  lupus  or psoriatic arthritis
Disease  Symptom and Sign,Patients with measurable disease
Disease  Symptom and Sign,Patients with medical condition which need urgent or special antihypertentive therapy  such as hypertensive encephalopathy  aortic dissection  acute renal failure  acute pulmonary edema  or acute myocardial infarction
Disease  Symptom and Sign,Patients with OA that is dominantly in the lateral compartment or any significant valgus deformity
Disease  Symptom and Sign,Patients with osteonecrosis of either knee.
Disease  Symptom and Sign,Patients with peripheral neuropathy that would be severe enough to interfere with the evaluation of the patient.
Disease  Symptom and Sign,Patients with severe aortic insufficiency  or aortic regurgitation.
Disease  Symptom and Sign,Patients with severe aortic insufficiency  or aortic regurgitation.
Disease  Symptom and Sign,Patients with significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia.
Disease  Symptom and Sign,Patients with signs and symptoms of osteoarthritis of at least one knee: Diagnosed according to ACR criteria.
Disease  Symptom and Sign,Patients with symptoms consistent with osteoarthritis of the knee for at least 6 months prior to Screening
Disease  Symptom and Sign,Patients with the following are excluded: History of clinically important disease other than HIV infection defined by the investigator as possibly putting the patient at risk during study participation.
Disease  Symptom and Sign,Patients with the following prior conditions are excluded: History of ventricular arrhythmias or myocardial infarction.
Disease  Symptom and Sign,Patients with the following prior conditions are excluded: Unexplained temperature >= 38.5 C for 7 days or chronic diarrhea (>= three stools daily) for 15 days  if occurring within 30 days prior to study entry.
Disease  Symptom and Sign,Patients with the following symptoms or conditions are excluded: Active cytomegalovirus disease.
Disease  Symptom and Sign,Patients with the following symptoms or conditions are excluded: Evidence of retinal vascular or related infectious disease or other retinal lesions that would interfere with the ability to detect responses to therapy or progression.
Disease  Symptom and Sign,Patients with the following symptoms or conditions are excluded: PER AMENDMENT 4/25/96: Retinal detachment not scheduled for surgical repair  in all eyes meeting other eligibility criteria
Disease  Symptom and Sign,Patients with vascular insufficiency of lower limbs that is severe enough to interfere with the evaluation of the patient.
Disease  Symptom and Sign,PER AMENDMENT 4/25/96: Presence of CMV retinal lesions that are only in areas of the retina which cannot be photographed.
Disease  Symptom and Sign,Percutaneous revascularization  if required or planned  must occur prior to randomization
Disease  Symptom and Sign,peripheral vascular disease
Disease  Symptom and Sign,Peritonitis episode less than 6 weeks before enrolment
Disease  Symptom and Sign,Pleural effusion or ascites that causes respiratory compromise.
Disease  Symptom and Sign,Polytraumatized patients with an ISS > 18 Controls: healthy volunteers
Disease  Symptom and Sign,poorly controlled diabetes (HbA1c > 7.0)
Disease  Symptom and Sign,Positive Helicobacter pylori serology.
Disease  Symptom and Sign,positive serology to AgHbS  HCV or HIV
Disease  Symptom and Sign,Positive testing for hepatitis B  hepatitis C or HIV at screening
Disease  Symptom and Sign,Positive testing for hepatitis B  hepatitis C or HIV at screening
Disease  Symptom and Sign,Positive testing for hepatitis B  hepatitis C or HIV at screening
Disease  Symptom and Sign,Positive testing for hepatitis B  hepatitis C or HIV at screening
Disease  Symptom and Sign,Positive testing for hepatitis B  hepatitis C  or HIV at screening.
Disease  Symptom and Sign,Positive testing for hepatitis B  hepatitis C  or HIV at screening.
Disease  Symptom and Sign,Post Acute Coronary Syndrome
Disease  Symptom and Sign,Postoperative/posttraumatic critically ill patients admitted to the intensive care unit
Disease  Symptom and Sign,Postoperative/posttraumatic critically ill patients admitted to the intensive care unit
Disease  Symptom and Sign,PPROM before 22 weeks
Disease  Symptom and Sign,Preeclampsia or eclampsia
Disease  Symptom and Sign,Pre-operative signs and symptoms of hypofunction of the HPA axis
Disease  Symptom and Sign,Presence of a detectable  volitionally-activated EMG signal from the paretic wrist or finger extensors (ECR or EDC)
Disease  Symptom and Sign,Presence of a zygomycete in culture associated with clinical or radiological abnormalities compatible with fungal invasive infection.
Disease  Symptom and Sign,Presence of major active psychiatric disease
Disease  Symptom and Sign,Presence of multiple co-morbidities such as poorly controlled diabetes  dialysis-dependant renal failure  hepatic failure
Disease  Symptom and Sign,Presence of nonmotor simple partial seizures only.
Disease  Symptom and Sign,Presence of primary generalized epilepsies or seizures  such as absences  myoclonic epilepsies  Lennox-Gastaut syndrome.
Disease  Symptom and Sign,Previous intracranial hemorrhage or brain surgery within the past twelve months
Disease  Symptom and Sign,Prior personal history of Guillain-Barr?? syndrome.
Disease  Symptom and Sign,Profound hypoxia or hypercarbia as defined as a PaO2 level less than 50 or a PaCO2 level of greater than 60.
Disease  Symptom and Sign,Psychiatric illness on meds
Disease  Symptom and Sign,Psychotic or bipolar disorder
Disease  Symptom and Sign,Refractive error between six diopters of myopia and five diopters of hyperopia with regular astigmatism of any amount
Disease  Symptom and Sign,refusal of the patient or close relative for participating in the study
Disease  Symptom and Sign,Registered and followed for RAS at the same site at which they are being followed for SELECT
Disease  Symptom and Sign,renal insufficiency (Creat > 2.0)
Disease  Symptom and Sign,Restrictive or obstructive cardiomyopathy  constrictive pericarditis  pericardial tamponade  or other conditions in which cardiac output is dependent on venous return
Disease  Symptom and Sign,Restrictive or obstructive cardiomyopathy  constrictive pericarditis  pericardial tamponade  other conditions in which cardiac output was dependent on venous return  or for subjects expected to have low filling pressures
Disease  Symptom and Sign,Ruptured aneurysm after endoprosthesis (Deleted by amendment n>= 1 at the request of AFSSAPS)
Disease  Symptom and Sign,Score of > 0.5 on the ACTG AIDS dementia complex staging test
Disease  Symptom and Sign,second or third degree heart block without a pacemaker
Disease  Symptom and Sign,Secondary Hypertension
Disease  Symptom and Sign,Seizure disorder or traumatic brain injury.
Disease  Symptom and Sign,Serious cardiovascular disease  wearing a pacemaker
Disease  Symptom and Sign,serious infection)
Disease  Symptom and Sign,Serious medical condition including but not limited to: Uncontrolled hypertension
Disease  Symptom and Sign,Serious mental illness which makes them unsuitable for interviewing (accommodation will be made for HIV-related cognitive deficits & related illnesses)
Disease  Symptom and Sign,Severe arrhythmia
Disease  Symptom and Sign,severe behavioral or psychological symptoms in dementia (BPSD) judged by a geriatrician
Disease  Symptom and Sign,Severe dementia
Disease  Symptom and Sign,severe illnesses  judged by a geriatrician
Disease  Symptom and Sign,Severe liver disease
Disease  Symptom and Sign,severe malnutrition)
Disease  Symptom and Sign,Severe migraine  epilepsy
Disease  Symptom and Sign,Severe respiratory insufficiency
Disease  Symptom and Sign,severe somatic disorders
Disease  Symptom and Sign,Severe  known hepatic insufficiency
Disease  Symptom and Sign,Severe  known renal insufficiency
Disease  Symptom and Sign,Show evidence of clinically significant disease (cardiac  respiratory  gastrointestinal  renal disease  etc) that  in the opinion of the investigator  could affect either the patient's safety or the conduct of the study.
Disease  Symptom and Sign,Show evidence of significant  active  hepatic disease
Disease  Symptom and Sign,Sickle cell disease( SS SC  SBETA O  SDpunjab) and control without sickle cell disease
Disease  Symptom and Sign,Significant cardiac disease or central nervous system lesions.
Disease  Symptom and Sign,Significant hemoptysis within one year prior to Study Day 1.
Disease  Symptom and Sign,Significant liver disease (GOT > 2x upper limit) or spontaneous INR > 1.5)
Disease  Symptom and Sign,Significant neurologic/psychiatric disorders
Disease  Symptom and Sign,Significant recent (within past 3 months) risk of committing suicide
Disease  Symptom and Sign,Significant symptomatic cardiac disease.
Disease  Symptom and Sign,Significant underlying medical condition that could impair continuous participation in study.
Disease  Symptom and Sign,Significant underlying medical condition that could impair continuous participation in study.
Disease  Symptom and Sign,Signs of liver impairment shown as elevated serum ALT or serum bilirubin
Disease  Symptom and Sign,Soft tissue disease that has been irradiated in the past 2 months is not assessable as measurable disease
Disease  Symptom and Sign,Soft tissue disease within a prior irradiated field must have progressed to be considered assessable
Disease  Symptom and Sign,Spastic cerebral palsy
Disease  Symptom and Sign,stenoses of bypass grafts
Disease  Symptom and Sign,Steven-Johnson syndrome  bronchospasm  or hypotension)
Disease  Symptom and Sign,stroke
Disease  Symptom and Sign,Stroke or Transient Ischemic Attack (TIA) within 3 months prior to inclusion
Disease  Symptom and Sign,Study partner or caregiver to assure compliance
Disease  Symptom and Sign,Subject has a concurrent chronic or acute illness or other condition that might confound the results of safety assessments or that might increase risk to the subject
Disease  Symptom and Sign,Subject has a history of clinically significant endocrine (except for Type 2 diabetes mellitus)  gastrointestinal  cardiovascular  hematological  hepatic  immunological  renal  respiratory  or genitourinary abnormalities or diseases
Disease  Symptom and Sign,Subject has a history of seizures  any tic disorder  or a current diagnosis and/or a known family history of Tourette's Disorder
Disease  Symptom and Sign,Subject has a history of stroke  chronic seizures  or major neurological disorder
Disease  Symptom and Sign,Subject has a known family history of sudden cardiac death or ventricular arrhythmia
Disease  Symptom and Sign,Subject has a major residual neurological deficit (stroke scales: Barthel >= 60  NIH >=  15 or Rankin > 3) at pre-procedure neurological exam.
Disease  Symptom and Sign,Subject has a recent history of eye infection or other inflammatory eye conditions
Disease  Symptom and Sign,Subject has any condition  which precludes compliance with study and/or device instructions.
Disease  Symptom and Sign,Subject has congestive heart failure
Disease  Symptom and Sign,Subject has glaucoma or is blind
Disease  Symptom and Sign,Subject has had a stroke or retinal artery occlusion within one (1) month prior to index procedure.
Disease  Symptom and Sign,Subject has had a transient ischemic attack (TIA) or amaurosis fugax within 48 hours prior to index procedure.
Disease  Symptom and Sign,Subject has had active bleeding diathesis requiring blood transfusion within one (1) month prior to index procedure.
Disease  Symptom and Sign,Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator.
Disease  Symptom and Sign,Subject has history of a blood or platelet related disorder including prior deep venous thrombosis
Disease  Symptom and Sign,Subject has peripheral vascular disease  which precludes safe femoral artery sheath insertion.
Disease  Symptom and Sign,Subject has renal insufficiency
Disease  Symptom and Sign,Subject has type 1 diabetes
Disease  Symptom and Sign,Subject is both HIV positive and HCV positive (must be viremic for HCV  not just antibody positive).
Disease  Symptom and Sign,Subject is known or is suspected to suffer from intestinal obstruction.
Disease  Symptom and Sign,Subject is suffering from dementia.
Disease  Symptom and Sign,Subject may not have uncorrected electrolyte imbalance.
Disease  Symptom and Sign,Subjects in this group experience increased premature mortality and increased risk of microvascular and cardiovascular complications (25).
Disease  Symptom and Sign,Subjects is currently considered a suicide risk  has previously made a suicide attempt or has a prior history of  or is currently demonstrating suicidal ideation
Disease  Symptom and Sign,Subjects must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations  procedures or participation.
Disease  Symptom and Sign,Subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
Disease  Symptom and Sign,Subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
Disease  Symptom and Sign,subjects must be free of any clinically significant diseases other than hyperlipidemia or coronary heart disease that would interfere with study evaluations.
Disease  Symptom and Sign,Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.
Disease  Symptom and Sign,Subjects must have a pre-established primary clinical diagnosis of COPD.
Disease  Symptom and Sign,Subjects must have documented coronary heart disease (CHD)
Disease  Symptom and Sign,Subjects must have documented coronary heart disease (CHD)
Disease  Symptom and Sign,Subjects must meet all the following criteria in order to be included in the study.
Disease  Symptom and Sign,Subjects must meet all the following criteria in order to be included in the study.
Disease  Symptom and Sign,Subjects who are poor medical risks because of active nonmalignant systemic disease.
Disease  Symptom and Sign,Subjects who are positive for HIV antibodies.
Disease  Symptom and Sign,Subjects who have acute or unstable medical illness or organic failure.
Disease  Symptom and Sign,Subjects with a pacemaker or persistent LBBB
Disease  Symptom and Sign,Subjects with a prior history of depression (but not currently depressed) are allowed in the study.
Disease  Symptom and Sign,Subjects with concurrent infectious disease.
Disease  Symptom and Sign,Subjects with moderate or severe aortic stenosis  aortic regurgitation  mitral stenosis or mitral regurgitation
Disease  Symptom and Sign,Subjects with recurrent head and neck cancer with no clinically measurable distant disease as well as those subjects in whom distant disease was of low volume and local and regional palliation is clinically warranted will be eligible.
Disease  Symptom and Sign,Suffer from a serious and persistent mental illness (SMI)
Disease  Symptom and Sign,Supra-renal thoracic-abdominal aneurysm
Disease  Symptom and Sign,Suspected or known ulcerative colitis
Disease  Symptom and Sign,Suspected seizure at the onset of stroke.
Disease  Symptom and Sign,Symptomatic as evidenced by transient ischemic attack or non-disabling stroke in the hemisphere supplied by the target vessel within 180 days of procedure
Disease  Symptom and Sign,Symptomatic cardiomyopathy.
Disease  Symptom and Sign,Symptomatic congestive heart failure
Disease  Symptom and Sign,Symptomatic is defined as carotid stenosis associated with ipsilateral transient or visual TIA evidenced by amaurosis fugax  ipsilateral hemispheric TIAs or ipsilateral ischemic stroke within 6 months prior to enrollment.
Disease  Symptom and Sign,Symptomatic ischemic heart disease (CCS class 1-4  Braunwald class IB  IC  and/or objective evidence of myocardial ischemia)
Disease  Symptom and Sign,Symptomatic liver or kidney disease  insulin requiring diabetes or type 2 diabetes requiring oral anti-diabetic agents.
Disease  Symptom and Sign,Symptomatic pancreatitis.
Disease  Symptom and Sign,symptomatic peripheral vascular disease (claudication)
Disease  Symptom and Sign,symptomatic peripheral vascular disease (claudication)
Disease  Symptom and Sign,symptoms (stable or unstable angina pectoris) or objective evidence of myocardial ischemia
Disease  Symptom and Sign,Target lesion is within the internal carotid artery and/or involves the bifurcation of the CCA.
Disease  Symptom and Sign,Technical constraints (validation of experience form) : Trained operator (at least 15 endoprosthesis in asymptomatic patients)  Endovascular materials at disposal
Disease  Symptom and Sign,The common carotid artery ostium has stenosis that requires treatment.
Disease  Symptom and Sign,The last chemotherapy must have been at least 4 weeks prior to study drug administration.
Disease  Symptom and Sign,The presence of any of the following diseases or another disease that the investigator believes to be a contraindication to participation in the protocol: Asthma if treated with systemic or daily inhaled corticosteroids in the last 6 months (Intermittent 
Disease  Symptom and Sign,The presence of any of the following will exclude a subject from study enrollment: Subject has dysphagia
Disease  Symptom and Sign,The presence of ipsilateral intracranial stenosis that requires treatment.
Disease  Symptom and Sign,The presence of severe liver disease with cirrhosis  recent active hepatitis  active chronic hepatitis  ALT or AST >3 x ULN  biliary obstruction with hyperbilirubinemia (total bilirubin >2 x ULN)
Disease  Symptom and Sign,The study center will determine if you meet all of the criteria
Disease  Symptom and Sign,The study center will determine if you meet all of the criteria
Disease  Symptom and Sign,The subject should be excluded if peripheral neuropathy  macrocytic anemia  or myxedema is present.
Disease  Symptom and Sign,These may include hyperthyroidism  hypothyroidism  uncontrolled diabetes mellitus  coronary heart disease  ischemic heart disease  elevated intraocular pressure  prostatic hypertrophy.
Disease  Symptom and Sign,These symptoms must include knee joint pain  and may include crepitus  swelling and/or effusion of the knee.
Disease  Symptom and Sign,This exclusion would include individuals with orthopedic  cardiac  or pulmonary disorders which preclude proper positioning on the myometry testing table  or restrict their ability to tolerate repeated maximum muscle contractions.
Disease  Symptom and Sign,thrombus in target lesion as visualized by angiography
Disease  Symptom and Sign,throughout the study and for 3 months after the study.
Disease  Symptom and Sign,Thyroid disease
Disease  Symptom and Sign,transient ischemic attack
Disease  Symptom and Sign,Tuberculous  diabetic  or hypertensive retinopathy  or other retinal lesions that would interfere with measurements of response or progression.
Disease  Symptom and Sign,Tumorous disease
Disease  Symptom and Sign,Type 1 Diabetes
Disease  Symptom and Sign,Type 2 diabetic patients with Mild non-prolipherative retinopathy fulfilling the inclusion criterion.
Disease  Symptom and Sign,Ulcers
Disease  Symptom and Sign,Unable to communicate with local study staff
Disease  Symptom and Sign,Uncontrolled cardiac arrhythmias
Disease  Symptom and Sign,Uncontrolled cardiac conditions or severe unstable medical illnesses
Disease  Symptom and Sign,uncontrolled diabetes mellitus
Disease  Symptom and Sign,Uncontrolled high blood pressure  uncontrolled diabetes mellitus  unstable angina  symptomatic congestive heart failure (CHF)  myocardial infarction (MI) within 6 months  or uncontrolled arrhythmia.
Disease  Symptom and Sign,Uncontrolled hypertension
Disease  Symptom and Sign,Uncontrolled hypertension
Disease  Symptom and Sign,Uncontrolled hypertension
Disease  Symptom and Sign,Uncontrolled maternal illness
Disease  Symptom and Sign,Uncontrolled or secondary hypertension
Disease  Symptom and Sign,Uncontrolled severe arterial hypertension
Disease  Symptom and Sign,Uncontrolled systemic illness.
Disease  Symptom and Sign,Underlying liver disease
Disease  Symptom and Sign,Unmixed infection with P
Disease  Symptom and Sign,Unstable angina
Disease  Symptom and Sign,Unstable angina pectoris
Disease  Symptom and Sign,Untreated and uncontrolled hypertension
Disease  Symptom and Sign,Untreated endocrine disorders such as hypothyroidism  hypopituitarism  hypogonadism detected by pre-operative measurement of TSH  FT4  LH  FSH and free testosterone
Disease  Symptom and Sign,Untreated thyroid disease (hypo or hyperthyroidism)
Disease  Symptom and Sign,upper extremity hemiplegia due to hemorrhagic or nonhemorrhagic stroke
Disease  Symptom and Sign,Urodynamic Stress Incontinence
Disease  Symptom and Sign,Ventricular arrythmias requiring medical or defibrillatory intervention
Disease  Symptom and Sign,Vitreous syneresis or posterior vitreous detachment
Disease  Symptom and Sign,Vitreous syneresis or posterior vitreous detachment
Disease  Symptom and Sign,Weight losses was clinically associated with AIDS-related wasting and not related to any other disease process
Disease  Symptom and Sign,With a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators.
Disease  Symptom and Sign,with contradiction of cardiac and pulmonary diseases
Disease  Symptom and Sign,without contradiction of cardiac and pulmonary diseases
Disease  Symptom and Sign,You cannot be in this study if you any of the following: History of cardiac disease  with New York Heart Association Class II or greater with congestive heart failure
Disease  Symptom and Sign,You have Major Depressive Disorder  an Anxiety Disorder  or some other psychiatric illnesses that the doctor will ask you about.
Disease  Symptom and Sign,You have uncontrolled narrow angle glaucoma.
Disease  Symptom and Sign,You may be eligible for this study if you: Are HIV-positive.
Disease  Symptom and Sign,Confirmed sodic depletion.
Disease  Symptom and Sign,Inclusion Criteria: Symptomatic Chiari malformation
Disease  Symptom and Sign,similar findings in a first degree relative.
Disease  Symptom and Sign,Co-existing Condition: Patients with the following conditions or symptoms are excluded.
Disease  Symptom and Sign,Co-existing Condition: Patients with the following conditions or symptoms are excluded:
Disease  Symptom and Sign,Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Disease  Symptom and Sign,Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Disease  Symptom and Sign,Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Disease  Symptom and Sign,Co-existing Condition: Patients with the following symptoms or conditions are excluded:
Enrollment in other studies,Inclusion Criteria: Patient has completed the 12 week double blind treatment of study CHTF919N2201
Enrollment in other studies,Another member of the same household is participating in this study.
Enrollment in other studies,Participation in any HIV vaccine trials
Enrollment in other studies,Patients in Phase IV studies may be eligible.
Enrollment in other studies,Subjects participating in the protocol entitled 'IRB: 0701014
Enrollment in other studies,Patients included in others clinical trials of imagery.
Enrollment in other studies,Inclusion Criteria: Post-angioplasty patients who had previously participated in an RCT designed to motivate multi-behavior change.
Enrollment in other studies,Coenrolled in any other HIV treatment or investigational drug trial
Enrollment in other studies,Have participated in a clinical trial of an investigational drug or device within 30 days before randomization
Enrollment in other studies,Participated in a previous clinical trial of Exelon.
Enrollment in other studies,Inclusion Criteria: Participation in a previous MPC-7869 randomized protocol
Enrollment in other studies,Have participated in a study involving administration of an investigational compound within 3 months of Visit 1 (Screening)  or within 5 half-lives of the previous investigational compound  whichever is longer  or who have been previously treated with E20
Enrollment in other studies,Participation in any previous clinical trial conducted by Orexigen Therapeutics
Enrollment in other studies,Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.
Enrollment in other studies,Ongoing participation in any other therapeutic clinical trial.
Enrollment in other studies,participation on another clinical trial at the same time
Enrollment in other studies,Not currently enrolled in another medical study
Enrollment in other studies,Previous participation in an MPC-7869 clinical study.
Enrollment in other studies,Are enrolled in another anti-HIV drug study while participating in this study.
Enrollment in other studies,Participation in an intervention study (including psychological studies) in past 6 weeks.
Enrollment in other studies,Participation in another clinical study
Enrollment in other studies,Participation in another clinical trial within the last 30 days
Enrollment in other studies,Participation in other clinical trial
Enrollment in other studies,participation in other trials
Enrollment in other studies,Participation in other trials
Enrollment in other studies,Prior enrolment in the POISE-2 pilot trial
Enrollment in other studies,- Subjects must NOT meet any of the following exclusion criteria: Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to Screening.
Enrollment in other studies,Concurrently participating in another clinical study  at any time during the study period  in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
Enrollment in other studies,Enrolled in other studies at the same time
Enrollment in other studies,Enrollment in any other clinical trial
Enrollment in other studies,Exclusion Criteria: Will not be eligible if not a part of the previous study
Enrollment in other studies,Must have been in the previous study.
Enrollment in other studies,Participation in another trial that may influence the results of this study
Enrollment in other studies,Participation in any other clinical trial or use of an investigational product within 30 days of entry into the study.
Enrollment in other studies,Participation in any other interventional clinical trial within 30 days prior to enrollment  or planned participation in another interventional clinical trial prior to termination of the subject's participation in the study.
Enrollment in other studies,Participation in other clinical trial within 30 days prior to inclusion
Enrollment in other studies,Participation in other investigational trial within 30 days.
Enrollment in other studies,Participation in other trials
Enrollment in other studies,Participation with 30 days in investigational study.
Enrollment in other studies,Patient has been excluded from other multi-institutional trials
Enrollment in other studies,Patient is currently enrolled in another investigational drug or device study
Enrollment in other studies,Patient is participating in another clinical study that may have an impact on the study endpoints.
Enrollment in other studies,Patients currently enrolled in ACTG 051 who have not reached the study end points but who meet the entry criteria for ACTG 144 may be co-enrolled in ACTG 144.
Enrollment in other studies,Patients participating in an experimental drug/device study or any clinical trial within the previous 30 days prior to Screening.
Enrollment in other studies,Patients who are participating in another study that requires Ethics Committee approval
Enrollment in other studies,Previous participation in this trial
Enrollment in other studies,Simultaneous participation in any other interventional clinical trial
Enrollment in other studies,Simultaneous participation in any other interventional clinical trial
Enrollment in other studies,Subject has participated in  is participating in  or plans to participate in another clinical study that may affect either the pre-procedure or follow-up results.
Enrollment in other studies,Subject is currently participating in another clinical trial with an investigation product/device (or within 30 days of screening).
Enrollment in other studies,Subjects who have participated in another clinical trial with 28 days of study start.
Enrollment in other studies,Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other study.
Enrollment in other studies,Have participated in any investigational drug or device trial in the last 4 weeks or plan to participate in any other study during the year.
Enrollment in other studies,participation in another trial
Enrollment in other studies,Patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study
Enrollment in other studies,Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
Enrollment in other studies,Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
Enrollment in other studies,Use of an investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication.
Enrollment in other studies,Have not participated in any clinical trial using investigational product within past month
Enrollment in other studies,Having received an investigational product within the last 12 weeks preceding the trial
Enrollment in other studies,Inclusion Criteria : Previously enrolled in study GRC28 and received 2 vaccinations of the assigned lot.
Enrollment in other studies,This study will include thirty males and females who took part in a previous study of a single oral dose of vitamin D.
Enrollment in other studies,Enrollment in another clinical trial in which AZT is a treatment.
Enrollment in other studies,Exposure to another investigational drug within 14 days prior to start of study treatment.
Enrollment in other studies,Have received another investigational agent within the 4 weeks before administration of test drug
Enrollment in other studies,Participation in another drug trials or planned use of vascular interventions within the previous 30 days
Enrollment in other studies,Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent.
Enrollment in other studies,Subjects who have participated in another clinical trial within 28 days of study start
Enrollment in other studies,Use of investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication
Enrollment in other studies,Use of investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication
Enrollment in other studies,Use of any experimental HIV therapy or participation in another experimental protocol within three (3) months of pre-study screening
Enrollment in other studies,Enrollment in other trials designed to modify post-procedure behaviors.
Enrollment in other studies,Enrollment in other trials designed to modify post-procedure behaviors.
Enrollment in other studies,Use of investigational drug or participation in an investigational study  within 30 days prior to administration of the study medication
Enrollment in other studies,Enrollment in a conflicting trial
Enrollment in other studies,Currently participating in an investigational drug or another device study that has not completed the primary endpoint  or subject to inclusion in another investigational drug or another device study during follow-up of this study
Enrollment in other studies,has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization
Enrollment in other studies,Patient who participated in any prior DHEA study or administration of DHEA within the past 3 months
Enrollment in other studies,Subject has participated in any investigational clinical or vaccine trial within 30 days prior to the first dose of study drug
Enrollment in other studies,participated in another investigational study within 4 weeks prior to the prestudy (screening) visit
Enrollment in other studies,Enrollment in another treatment protocol that expressly prohibits concomitant treatment with zidovudine (AZT).
Ethnicity,Patients must identify their ethnicity as Latino or Hispanic
Ethnicity,Self-identified African Americans  English speaking African-born individuals and Latinos.
Ethnicity,Inclusion Criteria: Caucasian men and women
Ethnicity,Inclusion Criteria: Patients must be self-identified as African-Americans.
Ethnicity,Self-identify as being Latino/Hispanic.
Ethnicity,Inclusion Criteria: Patients must be self-identified as African-Americans.
Ethnicity,Inclusion Criteria: Healthy male non-asian subjects
Ethnicity,Inclusion Criteria: Caucasian
Ethnicity,African-Americans.
Ethnicity,Latino or Hispanic
Exercise,Not currently exercising  defined as engaging in an average of less than 60 minutes of exercise/week during the last month
Exercise,Physician has placed no restrictions on physical exercise
Exercise,exercise < 20 min / day two days a week 
Exercise,amount of physical activity exceeds 120 minutes of moderate exercise per week 
Exercise,moderate exercise examples: brisk walking  golfing  gardening  housework  house painting 
Exercise,no concurrent regular exercise of 3 or more hours a week 
Exercise,subjects who exercise vigorously 
Exercise,ability to walk for exercise 
Exercise,performs insufficient exercise 
Exercise,performance of exercise training at regular intervals (> once per week) at a moderate to vigorous intensity at any time in the 6 weeks prior to study entry
Exercise,current participation in a regular exercise program 
Exercise,inability to perform bicycle exercise test 
Exercise,heavy exercise within 24 hours before study entry evaluations are done
Exercise,able to exercise > 6 minutes on the treadmill 
Exercise,initiation of an exercise program within 4 weeks of screening or initiation of an exercise program during the study
Gender,female
Gender,Females or Males
Gender,Gender: Female
Gender,Genders Eligible for Study: Both
Gender,Genders Eligible for Study: Female
Gender,Genders Eligible for Study: Male
Gender,If female 
Gender,Inclusion Criteria: Female
Gender,Inclusion Criteria: Female gender
Gender,Inclusion Criteria: Males and Females
Gender,Inclusion/Exclusion Criteria: Male and Female
Gender,Male and female patients will be eligible for enrollment
Gender,male sex
Gender,Males and females
Life Expectancy,Clinical parameters: Life expectancy > 2 months
Life Expectancy,Exclusion Criteria: life expectancy < 24 hours
Life Expectancy,Exclusion Criteria: Life expectancy below 72 hours 
Life Expectancy,Life expectancy < 1 year
Life Expectancy,Life expectancy > 12 weeks
Life Expectancy,Life expectancy > 6 months
Life Expectancy,Life expectancy > 6 months.
Life Expectancy,Life expectancy >12 weeks.
Life Expectancy,Life expectancy greater than 3 months.
Life Expectancy,Life expectancy Not specified
Life Expectancy,life expectancy of at least 12 weeks
Life Expectancy,Life expectancy of at least 2 years.
Life Expectancy,Life expectancy of at least 3 months.
Life Expectancy,Life expectancy of at least 6 months
Life Expectancy,Life expectancy of at least 6 months.
Life Expectancy,Patient life expectancy is less than 12 months
Life Expectancy,Patient must have a life expectancy of at least 3 months
Life Expectancy,Patient with a life expectancy less than the follow-up period (5 years)
Life Expectancy,Patients whose life expectancy is less than 12 months
Life Expectancy,Subject's life expectancy is less than twelve months.
Literacy or Spoken Language,Exclusion Criteria: inability to read or understand English
Literacy or Spoken Language,Exclusion Criteria: Non-English speaking
Literacy or Spoken Language,Ability to read and understand English  Dutch  Danish  Flemish  French  German  Italian  Spanish or Swedish to ensure compliance with cognitive testing and study visit procedures.
Literacy or Spoken Language,Able to read and write in the study related documents translated into the primary local language
Literacy or Spoken Language,Able to speak and read English
Literacy or Spoken Language,Able to understand and speak English
Literacy or Spoken Language,English-speaking
Literacy or Spoken Language,inadequate knowledge of the Swedish language
Literacy or Spoken Language,Inclusion Criteria: English speaking
Literacy or Spoken Language,Non-English or Spanish speaking with no relative present who is fluent in reading and comprehending English or Spanish.
Literacy or Spoken Language,non-english speaking caregivers/parents
Literacy or Spoken Language,poor understanding of French language
Literacy or Spoken Language,Spanish-speaking if individual site allows
Literacy or Spoken Language,Speak English or Spanish
Literacy or Spoken Language,Speaks English
Literacy or Spoken Language,Subjects must be able to read and write in English.
Literacy or Spoken Language,Subjects must have a reliable caregiver who can read  understand and speak English or Spanish.
Literacy or Spoken Language,Subjects must have a reliable caregiver who can read  understand and speak same language.
Literacy or Spoken Language,Unable to understand and speak English
Literacy or Spoken Language,Patient must be able to read and speak English and willing to sign an informed consent in English
Literacy or Spoken Language,Patients must be able to complete a questionnaire in either English or Spanish.
Literacy or Spoken Language,Patients must be able to provide informed consent in English.
Neoplasm Status,Exclusion Criteria: Known or suspect estrogen-dependent neoplasia
Neoplasm Status,Any history of lymphoproliferative disorder.
Neoplasm Status,bone metastasis) as clinically indicated is allowed as long as it is not evidence of progressive disease (see 4.5.2)
Neoplasm Status,Exclusion Criteria: clinical evidence of metastatic disease
Neoplasm Status,Accepts Healthy Volunteers: Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme  anaplastic astrocytoma  or anaplastic oligodendroglioma.
Neoplasm Status,Accepts Healthy Volunteers: Confirmed diagnosis of malignant melanoma
Neoplasm Status,Accepts Healthy Volunteers: Diagnosis of high-risk neuroblastoma  meeting one of the following criteria:
Neoplasm Status,2 before criteria have been replaced by : Patients with colorectal adenocarcinoma which is histologically proved and classified stage II perforated  III or IV  totally removed  in total remission 
Neoplasm Status,If in the opinion of the treating physician  sufficient time has elapsed  such that it is extremely likely that the patient has been cured of a prior malignancy  the patient may be eligible for the protocol.
Neoplasm Status,Other active malignancies requiring systemic therapy.
Neoplasm Status,Inclusion Criteria: Histologically-confirmed diagnosis of breast (females only) or prostate cancer
Neoplasm Status,Phase 2 no previous or concurrent malignancy
Neoplasm Status,Anti-cancer agents (exception: stable doses of hormonal therapy  e.g
Neoplasm Status,Active malignancy requiring chemotherapy.
Neoplasm Status,Any history of malignancy except for surgically cured skin cancer or pilomatricoma (benign tumor of the hair follicle that is associated with DM-1).
Neoplasm Status,Any investigational  anti-cancer therapy within 6 weeks prior to Day 1.
Neoplasm Status,Exclusion Criteria: Previous or current hormonal treatment of prostate cancer
Neoplasm Status,more than two prior anticancer chemotherapy regimens
Neoplasm Status,No prior or concurrent brain metastases (treated or untreated)
Neoplasm Status,patient treated for prostate adenocarcinoma and overexposed during radiotherapy in a prostate adenocarcinoma in the radiation department of the a prostate adenocarcinoma in the radiation department of the Jean MONNET hospital/ service de radiotherapies be
Neoplasm Status,Patients with metastatic disease who have a resectable primary tumor and are deemed a surgical candidate may have undergone prior resection
Neoplasm Status,previous hormonal therapy as adjuvant treatment for breast cancer
Neoplasm Status,Prior irradiation other than basal cell cancer of skin
Neoplasm Status,Proven prostate cancer in need for endocrine treatment  except for neoadjuvant hormonal therapy  but including patients with a rising PSA further to prostatectomy or radiotherapy
Neoplasm Status,Subject is currently being treated for cerebral carcinoma or sarcoma.
Neoplasm Status,Subjects treated for cancer within the previous 5 years except for skin basal cell carcinoma or carcinoma in situ of the cervix  with measures other than a minor  complete surgical excision  .  chemotherapy)  or radiation therapy.
Neoplasm Status,Metastatic disease OR unresectable primary tumor
Neoplasm Status,Accessible disease includes lymph node metastases.
Neoplasm Status,Inclusion Criteria: Clinically documented metastatic or unresectable locally recurrent clear cell renal carcinoma
Neoplasm Status,Inclusion Criteria: Patients with a removed colorectal adenocarcinoma since less than 6 months  in total remission and for whom a monitoring is necessary to detect recurrences precociously.
Neoplasm Status,Previous removal of kidney except if the size of the tumor was less than 5 cm or there was extensive liver or bone metastasis
Neoplasm Status,Subject has a history of neoplastic disease (including leukemia  lymphoma  malignant melanoma)  or myeloproliferative disease  regardless of the time since treatment
Neoplasm Status,unresectable liver metastasis
Neoplasm Status,Histologically confirmed adenocarcinoma of the breast
Neoplasm Status,Histologically or cytologically confirmed renal cell carcinoma (RCC)
Neoplasm Status,Active brain metastasis or patients with meningeal metastases
Neoplasm Status,Airway tumor or airway pathology
Neoplasm Status,Allowed: Basal cell carcinoma of the skin  in situ carcinoma of the cervix  Kaposi's sarcoma.
Neoplasm Status,Any other cancer for which patient has been disease free for 5 years
Neoplasm Status,Available paraffin block or unstained paraffin sections on glass slides containing representative tumor tissue from the most recent tumor biopsy/resection.
Neoplasm Status,Cancer disease within the last 5 years except for prostate cancer and some skin cancers
Neoplasm Status,Central Nervous System (CNS) metastasis if neurologically unstable or requiring steroid use.
Neoplasm Status,Concurrent neoplasms not specifically allowed.
Neoplasm Status,Current CNS metastases or history of CNS metastases
Neoplasm Status,Current or past history of metastasis
Neoplasm Status,Currently have any known malignancy or have a history of malignancy other than non-melanoma skin cancer
Neoplasm Status,Evidence of measurable recurrent or residual primary CNS neoplasm.
Neoplasm Status,Exclusion Criteria: History or evidence of  active malignancy  except for basal cell carcinoma or squamous cell carcinoma of the skin  within the 24 months prior to entry
Neoplasm Status,Exclusion Criteria: Islet cell or neuroendocrine carcinomas of the pancreas.
Neoplasm Status,Exclusion Criteria: Metastatic disease-
Neoplasm Status,Exclusion Criteria: Patient with concurrent malignancy (except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of cervix and/or breast) or patients with prior malignancies that have not been disease-free for five years
Neoplasm Status,Exclusion Criteria: Previous history of excision biopsy of the primary tumour
Neoplasm Status,Exclusion Criteria: Subjects who have brain metastases.
Neoplasm Status,FISH+ HER2 gene amplified breast cancer
Neoplasm Status,Group 2: Patients with inoperable esophageal cancer (adenocarcinoma oe squamous cell CA) with lesions extending beyond the mucosa but limited to the esophageal wall (T1sm or T2N0)
Neoplasm Status,Had Pap smear evidence of atypical squamous cells or adenocarcinoma or other malignancy
Neoplasm Status,has a history of malignancy  excepting basal cell carcinoma and malignancies in remission (greater than 2 years)
Neoplasm Status,Hepatic and/or pulmonary metastasis would have been totally removed since less 6 months before inclusion.
Neoplasm Status,Histological or cytological diagnosis of pancreatic adenocarcinoma
Neoplasm Status,Histologically confirmed myxoid liposarcoma.
Neoplasm Status,Histologically or cytologically documented metastatic breast cancer
Neoplasm Status,histologically proven HR+ operable invasive breast cancer
Neoplasm Status,History of invasive cancer within the past two years (excluding non-melanoma skin cancer)
Neoplasm Status,History of malignancy within the last 5 years (except basal cell carcinoma  which must be in remission for at least 6 months prior to the study.
Neoplasm Status,History of other epithelial/mesenchymal malignant tumours except basal cell carcinoma/squamous cell carcinoma (BCC/SCC) of skin
Neoplasm Status,History of other malignancies within 3 years of Day 1  except for adequately treated carcinoma in situ of the cervix  ductal carcinoma in situ (DCIS) of breast  or basal or squamous cell skin cancer.
Neoplasm Status,History of prior malignancies within 3 years  except for basal cell or squamous cell carcinoma of the skin  carcinoma in situ of the cervix or breast.
Neoplasm Status,History of second cancer (except adequately treated basal cell or squamous cell skin cancer  in situ cervical cancer  or other cancer for which the patient has been disease-free for five or more years).
Neoplasm Status,History of  or evidence of  active malignancy  except for basal cell carcinoma or squamous cell carcinoma of the skin  within the 24 months prior to entry
Neoplasm Status,if metastatic  all metastasis would have been removed  the last surgery dating less 6 months.(amendment 1)
Neoplasm Status,Imaging must show recurrent  unilateral  supratentorial tumor(s)
Neoplasm Status,in situ carcinoma of the cervix
Neoplasm Status,Inclusion Criteria: Histologically confirmed malignant melanoma that is advanced or metastatic.
Neoplasm Status,Inclusion Criteria: Histologically verified breast cancer
Neoplasm Status,Inclusion Criteria: Pathologically confirmed head and neck malignancy
Neoplasm Status,Inclusion Criteria: Patient must have a histologically confirmed unilateral  supratentorial malignant glioma (grade 3 or 4  anaplastic astrocytoma  gliosarcoma  glioblastoma multiforme or malignant oligoastrocytoma)
Neoplasm Status,Inclusion Criteria: Patients must have histologically confirmed thyroid cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
Neoplasm Status,Inclusion Criteria: Patients must have locally advanced  recurrent  or metastatic adenoid cystic carcinoma of the head and neck which is considered incurable by known therapies  as judged by the investigator.
Neoplasm Status,Inclusion Criteria: Unilateral operable palpable breast cancer
Neoplasm Status,Known central nervous system or brain metastases.
Neoplasm Status,Male breast cancer patients
Neoplasm Status,Malignancy other than Kaposi's sarcoma or limited cutaneous basal cell carcinoma.
Neoplasm Status,measurable tumor lesions
Neoplasm Status,Men with prostate cancer may be enrolled at the discretion of the sponsor.
Neoplasm Status,Metastatic disease to the central nervous system.
Neoplasm Status,More than 2 weeks since prior local radiotherapy to the sites of metastatic disease
Neoplasm Status,Must have archived tumor tissue for tissue testing.
Neoplasm Status,No concurrent or prior malignancies within the past 5 years  except adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
Neoplasm Status,No history of prior malignancy  with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer  unless there is a 3-year disease-free interval.
Neoplasm Status,No metastatic disease
Neoplasm Status,No other prior malignancy  except for the following: Adequately treated basal cell or squamous cell skin cancer
Neoplasm Status,No prior malignancy other than curatively treated carcinoma in-situ of the cervix or skin cancer
Neoplasm Status,Non-epithelial ovarian tumors.
Neoplasm Status,NOTE: Patients with malignancies being managed with local therapy  .  Kaposi's sarcoma  basal cell carcinoma) may enroll at the discretion of the site investigator.
Neoplasm Status,or other cancer if the patient has been disease-free for more than 5 years
Neoplasm Status,Other malignancy prior to entry into the study.
Neoplasm Status,Other progressive tumoral affection known  or colorectal cancer in progression.
Neoplasm Status,Past or current history of neoplasm other than breast cancer  except for: curatively treated non-melanoma skin cancer  in situ carcinoma of the cervix  other cancer curatively treated and with no evidence of disease for at least 7 years
Neoplasm Status,Patient has had a malignancy within the past 2 years other than basal cell carcinoma.
Neoplasm Status,Patient has measurable tumor on CT  spiral CT  or MRI scan that meet RECIST criteria.
Neoplasm Status,Patient with a history of prostate cancer
Neoplasm Status,Patients entering the Phase 1 portion of the study must have a histologically or cytologically documented diagnosis of cancer (solid tumors) refractory to conventional therapeutic modalities or for which no conventional treatment exists.
Neoplasm Status,Patients should have cytologically or histologically confirmed adenoid cystic carcinoma of the head and neck.
Neoplasm Status,Patients with a history of another primary malignancy < 5 years
Neoplasm Status,Patients with a history of malignancy of any organ system  treated or untreated
Neoplasm Status,Patients with a prior history of any malignancy with the exception of basal cell carcinoma of the skin treated more than 2 years prior to Screening  unless specific permission/waiver by the Sponsor is granted.
Neoplasm Status,Patients with a T4N0M0 tumour and operated in emergency (because of a tumoral perforation) can be included
Neoplasm Status,Patients with any evidence of cancer or kidney  liver  lung  blood  or brain disorders.
Neoplasm Status,Patients with carcinomatous meningitis are excluded from the study.
Neoplasm Status,Patients with clinical concern for brain metastases must have a negative brain CT scan or MRI within the past 56 days
Neoplasm Status,Patients with known malignancy(ies).
Neoplasm Status,Patients with metastatic and/or unresectable myxoid liposarcoma that is progressive and standard curative measures do not exist or are no longer effective.
Neoplasm Status,Patients with the following are excluded: Active malignancy requiring concomitant chemotherapy.
Neoplasm Status,Personal history of colorectal cancer (CRC) or adenomatous colonic polyps and at least 5 years since last colonoscopy or no sooner than 3 years prior to enrollment date as long as their prior colonoscopy revealed at least one of the following high risk co
Neoplasm Status,Previous diagnosis of noninvasive breast cancer is OK.
Neoplasm Status,previous history of invasive malignancy within the last 5 years  other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix  adequately cone biopsied
Neoplasm Status,Previous or concurrent malignancy except: inactive non-melanoma skin cancer
Neoplasm Status,resectable liver metastasis
Neoplasm Status,Solid enhancing lesions suspicious for pancreatic neuroendocrine tumor(s)
Neoplasm Status,Solid lesions suspicious for microcystic adenoma(s)
Neoplasm Status,Subjects with malignancy (except for prostate ca  or basal cell carcinoma of the skin) diagnosed within the last year  or on concurrent chemotherapy.
Neoplasm Status,The presence of any intracranial tumor(s)  arteriovenous malformation(s) (AVMs)  or aneurysm(s) requiring treatment.
Neoplasm Status,Uncontrolled brain metastases in the judgement of the Investigator.
Neoplasm Status,with other organ metastasis or peritoneum metastasis
Neoplasm Status,without other organ metastasis or peritoneum metastasis
Organ or Tissue Status,Arterial bleeding
Organ or Tissue Status,Menopausal status not specified
Organ or Tissue Status,>= >= 4/5 on manual muscle testing for the deltoid on the affected side if isolated movement is present
Organ or Tissue Status,No visual or vestibular condition that would affect balance
Organ or Tissue Status,ELIGIBILITY CRITERIA include: Post-menopausal women who have used risedronate or alendronate continuously for at least 24 mos prior to enrollment
Organ or Tissue Status,Adequate liver  renal  and bone marrow function
Organ or Tissue Status,Any unstable joints of the lower extremity  recent hip and knee joints or fitted hip or knee pins  bolts and/or plates
Organ or Tissue Status,muscle strength in a distal muscle group (ankle dorsiflexors or deep flexors of the fingers) which is less than or equal to grade 4 (Medical Research Council grade).
Organ or Tissue Status,Normal thyroid function
Organ or Tissue Status,Exclusion Criteria: Cases where one of the molar on either side is grossly carious or restored
Organ or Tissue Status,Inclusion Criteria: Fully erupted bilateral first or second permanent molar teeth.
Organ or Tissue Status,Occlusal fissures of molar teeth.
Organ or Tissue Status,Normal cardiac function 
Organ or Tissue Status,Absent sensation of the affected limb
Organ or Tissue Status,adequate bone marrow  liver and kidney function
Organ or Tissue Status,Affected wrist extensors >= >= 4 on MRC scale
Organ or Tissue Status,Any unstable joints of the lower extremity
Organ or Tissue Status,Have two target fingernails identified at baseline
Organ or Tissue Status,Molar teeth with antagonist tooth not present or extracted
Organ or Tissue Status,muscle strength in a proximal or mid-limb muscle group
Organ or Tissue Status,Must have adequate bone marrow  renal and liver function.
Organ or Tissue Status,Normal cardiac function
Organ or Tissue Status,Patients must have adequate renal  hepatic  cardiac function and hematologic values
Organ or Tissue Status,Patients with significant axial deviation of the knee.
Organ or Tissue Status,Third molars
Patient Preference,In addition  agree to be contacted monthly after week 24 for follow-up  until the entire study has been completed
Patient Preference,Willing to abstain from taking any other medications or substances known to affect appetite or weight gain (eg  steroids [other than those inhaled for treatment of asthmatic conditions]  nutritional supplements [other than vitamins or minerals]  dronabino
Patient Preference,Subjects must agree not to take a monoamine oxidase inhibitor (MAOI) for two weeks (14 days) prior to study participation and for two weeks (14 days) after the end of their study participation.
Patient Preference,Surgeon unwilling to have patient participate in a participate in a perioperative clonidine/ASA trial
Patient Preference,Willing to abstain from any illegal or recreational drug substances for the duration of the trial
Patient Preference,Inclusion Criteria: Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
Patient Preference,Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
Patient Preference,Patients will agree to self-administer topical study medication  and will agree to complete all study procedures
Patient Preference,Subject has confirmed his or her willingness to participate in the study after being informed of all aspects of the trial that are relevant to his or her decision to participate  by signing and dating the IRB / IEC approved informed consent form.
Patient Preference,The informant must see the subject at least once a week for several hours and be available to accompany the subject to the screening and baseline visits  and at a minimum  be accessible by telephone for other scheduled visits.
Patient Preference,The patient has been informed of the nature of the study agrees to its provisions and has provided written informed consent  approved by the appropriate Ethics Committee (EC).
Patient Preference,Exclusion Criteria: Unwilling to consent
Patient Preference,If they refuse to participate.
Patient Preference,Patients and/or their parents (or guardians) who are willing to give written informed consent and willing to participate in and comply with the study protocol.
Patient Preference,Patients who refuse to participate will be excluded.
Patient Preference,Patients who refused to participate
Patient Preference,Refusal to sign the informed consent form
Patient Preference,Willing and able to comply with the protocol  including the inpatient requirements and outpatient visits.
Patient Preference,Willing and able to give written informed consent.
Patient Preference,Patient and patient's physician agree to have the patient return for all the required clinical contacts following study enrollment
Patient Preference,Willing to comply with intensive diabetes management
Patient Preference,Willing to consume one of the nutritional supplements for the study period.
Patient Preference,Willing to participate in 3-day a week monitored strength-training program.
Patient Preference,Have a friend or family member who is willing to participate in the study as an informant
Patient Preference,Inclusion Criteria: Must be willing to participate with an additional blood draw.
Patient Preference,no willingness of follow-up examinations
Patient Preference,Parent/legal representative willing to permit venipuncture for purposes of collecting a blood sample.
Patient Preference,Primary care pediatrician not willing to participate
Patient Preference,The patient is willing to comply with the specified follow-up evaluation
Patient Preference,Willing to return to the National Institutes of Health for follow-up
Patient Preference,Willing to undergo serial non-invasive imaging
Patient Preference,Willingness to be randomized and to commit to the 5-month study period
Patient Preference,Willingness to come to the health facility for the following 28 days
Patient Preference,Willingness to control visits
Patient Preference,Agree to provide a blood and urine sample for submission to central laboratories
Patient Preference,Must agree to have blood samples banked for future research testing
Patient Preference,Patients who are willing to discontinue all non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesic medication taken for any condition  including their knee pain with the exception of acetaminophen  up to 1000 mg (2 tablets) four times a day (q.
Patient Preference,Subject does not require and agrees not to take  for the duration of the study  any medication that is contraindicated with Kaletra?? (list will be in the protocol).
Patient Preference,be willing to switch their current method of contraception
Patient Preference,Willing to use acceptable methods of contraception
Patient Preference,Exclusion Criteria: Refusal of village chief (for village inclusion)  or refusal of parent or guardian (for individual inclusion)
Patient Preference,Agree to come to the clinic up to 2 times per week (according to randomization) for 16 weeks of study drug infusions and to participate in all required follow-up assessments through week 24
Patient Preference,and agree not to use any other steroid hormonal therapy other than topical corticosteroids or inhaled corticosteroids for asthma  during the course of the study.
Patient Preference,Patients must also be willing to abstain from any intra-articular (i.a.) or peri-articular injections to the knee or surgery during the course of the trial  except for the assigned study product.
Patient Preference,Willing to undergo cranial osteopathic manipulation
Patient Preference,These patients must be willing to use only acetaminophen as a rescue pain medication for the knee pain during the study period and refrain from even acetaminophen use 24 hours prior to any office visit
Patient Preference,Willingness not to become pregnant during the first five months of the study for female participants
Pharmaceutical Substance or Drug,> 2 cycles carboplatin  or
Pharmaceutical Substance or Drug,> 2 cycles mitomycin C  or
Pharmaceutical Substance or Drug,Women who do not want the Gardasil vaccination series
Pharmaceutical Substance or Drug,spermicide
Pharmaceutical Substance or Drug,Contre-indication lactose
Pharmaceutical Substance or Drug,Avoid: Drugs with potential to cause peripheral neuropathy or pancreatitis.
Pharmaceutical Substance or Drug,Adjuvant trastuzumab during radiotherapy allowed
Pharmaceutical Substance or Drug,Women who decide they wish to get the Gardasil vaccination series
Pharmaceutical Substance or Drug,Women who had their first Gardasil injection prior to their referring Pap smear
Pharmaceutical Substance or Drug,Patient is not currently receiving  or is not anticipated to receive  concomitant anticancer agent(s) during the course of this study
Pharmaceutical Substance or Drug,Use of a medication such as oral/inhaled glucocorticoids that in the judgment of the investigator will affect the wearing of the sensors or the completion of any aspect of the protocol.
Pharmaceutical Substance or Drug,Being on drugs (a) that affect cortisol synthesis (eg
Pharmaceutical Substance or Drug,Patients with any of the following prior conditions are excluded: History of prior saquinavir (SQV) therapy for more than 14 days.
Pharmaceutical Substance or Drug,Current use of psychotrophic drugs
Pharmaceutical Substance or Drug,Patients on unstable doses of bisphosphonate or patients on stable doses for the past month prior to Screening  and are unwilling to remain on these stable doses throughout the course of the trial.
Pharmaceutical Substance or Drug,Accepts Healthy Volunteers: Have never received smallpox vaccine or previously received an experimental smallpox vectored vaccine (for vaccinia-naive cohorts only)
Pharmaceutical Substance or Drug,You must have been taking the same dose of amitriptyline once daily at bedtime for at least four (4) weeks.
Pharmaceutical Substance or Drug,Exclusion Criteria: Prior treatment with sorafenib or m-TOR inhibitors
Pharmaceutical Substance or Drug,Planned discontinuation or an increase or decrease by more than 30% of the current opioid dose
Pharmaceutical Substance or Drug,Exclusion Criteria : Receipt of any vaccine within the past 7 days (subjects may be deferred until after the seven days has passed.)
Pharmaceutical Substance or Drug,Allowed: Gammaglobulin  intravenous or intramuscular .
Pharmaceutical Substance or Drug,Dosing regimens allowable are continuous (ie  uninterrupted) daily or weekly formulations of risedronate (5 mg once daily [OD] or 35 or 30 mg once a week [OAW]) or alendronate (10 mg OD or 70 mg OAW)  for a minimum of 24 months prior to enrollment into st
Pharmaceutical Substance or Drug,Previous treatment with lamivudine  lobucavir  adefovir  famciclovir  or any other investigational nucleoside for HBV infection
Pharmaceutical Substance or Drug,a drug or treatment known to cause major organ system toxicity during the past four weeks
Pharmaceutical Substance or Drug,Administration of immunoglobulins and/or any blood products within the three months preceding the first study immunization or planned administration during the study period.
Pharmaceutical Substance or Drug,Any concomitant therapy that would preclude use of cidofovir  foscarnet or ganciclovir.
Pharmaceutical Substance or Drug,Any concomitant therapy that would prohibit use of ganciclovir.
Pharmaceutical Substance or Drug,Any current statin therapy at maximum recommended dosage
Pharmaceutical Substance or Drug,At least 28 days since prior antiangiogenesis agents or immunotherapy comprising interferon and/or aldesleukin and recovered
Pharmaceutical Substance or Drug,Beta-blocker treatment at least three months
Pharmaceutical Substance or Drug,Change in treatment with systemic or inhaled corticosteroids within 14 days prior to start of study treatment.
Pharmaceutical Substance or Drug,Concomitant treatment with systemic corticosteroids greater than physiologic doses
Pharmaceutical Substance or Drug,Current or prior therapy with immunomodulators or immunosuppressive drugs and anticoagulant drugs within 30 days prior to study medication administration
Pharmaceutical Substance or Drug,Currently taking a stable dose of antipsychotic
Pharmaceutical Substance or Drug,currently treated with brimonidine
Pharmaceutical Substance or Drug,Depot injection vitamin D >10 000 IU in the past 9 months prior to starting the investigational product
Pharmaceutical Substance or Drug,Exclusion Criteria: Currently receiving antiviral  immunomodulatory or corticosteroid therapy
Pharmaceutical Substance or Drug,Exclusion Criteria: Patients taking greater than 81mg aspirin daily.
Pharmaceutical Substance or Drug,Exclusion Criteria: Patients who have previously not responded to treatment for PHN with gabapentin at doses of >=  1200 mg/day or pregabalin at doses >=  300 mg/day.
Pharmaceutical Substance or Drug,had received any experimental drug or device within 30 days of enrolment
Pharmaceutical Substance or Drug,Have received oral antifungal treatment within 3 months of baseline visit
Pharmaceutical Substance or Drug,Have required recent outpatient IV vasoactive (milrinone  dobutamine  dopamine  nitroglycerin  or open-label Natrecor) therapy as defined as >2 outpatient (excluding emergency room or inpatient) infusions in the last 30 days without a subsequent hospitali
Pharmaceutical Substance or Drug,History of any prior protease inhibitor therapy other than SQV.
Pharmaceutical Substance or Drug,Investigational drug therapy outside of this trial during or within 4 weeks prior the screening assessment
Pharmaceutical Substance or Drug,Maintenance therapy with amphotericin B (l mg/kg) up to 5 days/week.
Pharmaceutical Substance or Drug,Medical treatment arat form antihypertensives and oral anticonceptives
Pharmaceutical Substance or Drug,No prior trastuzumab or bevacizumab therapy
Pharmaceutical Substance or Drug,No prior treatment with other camptothecin drug.
Pharmaceutical Substance or Drug,No prior treatment with systemic anti-EGFR inhibitors or Pemetrexed
Pharmaceutical Substance or Drug,No therapeutic pharmaceutical class changes for at least 1 month
Pharmaceutical Substance or Drug,Other contraindication of steroid treatment
Pharmaceutical Substance or Drug,Patient receiving treatment with ACTH within the 3 months preceding study entry
Pharmaceutical Substance or Drug,Patients on concomitant therapy with anticoagulants (low dose aspirin  not exceeding 325 mg per day as an anti-thrombotic agent is permitted if stable for one month prior to Screening and remains stable throughout the study.
Pharmaceutical Substance or Drug,Patients receiving an intra-articular hyaluronan in any joint within the previous 6 months prior to screening.
Pharmaceutical Substance or Drug,Patients receiving GVHD prophylaxis including cyclosporine or tacrolimus
Pharmaceutical Substance or Drug,Patients who take medications on a chronic basis  such as antihypertensive medications or thyroid replacement therapy  etc
Pharmaceutical Substance or Drug,Previous treatment with D-serine
Pharmaceutical Substance or Drug,Previous treatment with interferon must have ended at least 6 months prior to screening visit
Pharmaceutical Substance or Drug,Previous treatment with polyene or other antifungal active on zygomycete (posaconazole  itraconazole) over 5 days during the month previous inclusion
Pharmaceutical Substance or Drug,previously treated with ezetimibe or participated in a clinical study with ezetimibe
Pharmaceutical Substance or Drug,Prior therapy with anti-VEGF agents.
Pharmaceutical Substance or Drug,Prior treatment with anti-angiogenic agents.
Pharmaceutical Substance or Drug,Prior treatment with glucocorticoids  anabolic steroids  testosterone  growth hormone  or IGF-I within 1 year of entry
Pharmaceutical Substance or Drug,Progression during or following treatment with topotecan or liposomal doxorubicin.
Pharmaceutical Substance or Drug,Receiving a stable medical regimen for CHF for at least 60 days before the study start  including angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs)  and/or beta-blockers.
Pharmaceutical Substance or Drug,Recent or current treatment with any drugs modifying the testosterone level
Pharmaceutical Substance or Drug,requirement for chronic corticosteroid treatment
Pharmaceutical Substance or Drug,Requirement for permanent catheters for IV ganciclovir administration.
Pharmaceutical Substance or Drug,Started antidepressant medication for treatment of depression during past 6 weeks
Pharmaceutical Substance or Drug,Subject has been prescribed ADVATE by their treating physician
Pharmaceutical Substance or Drug,Subject is being treated with aspirin or has used this agent within 3 weeks prior to administration of screening
Pharmaceutical Substance or Drug,Subjects receiving androgen or anti-androgen therapy.
Pharmaceutical Substance or Drug,Subjects who require treatment with an anti-coagulant with the exception of low-dose Aspirin?? (>= >=81 mg/day)  warfarin (>= >=1 mg/day)  or heparin for IV catheter patency.
Pharmaceutical Substance or Drug,subjects with current treatment with typical or atypical neuroleptics which should be changed
Pharmaceutical Substance or Drug,Systemic ketoconazole and acyclovir  or oral nystatin for acute therapy.
Pharmaceutical Substance or Drug,The patient did not improve on earlier alpha-1 blocker treatment
Pharmaceutical Substance or Drug,treatment with a non-approved or experimental drug during 1 month before entry into the study
Pharmaceutical Substance or Drug,Treatment with an investigational drug within 30 days.
Pharmaceutical Substance or Drug,Treatment with antidepressants at entry into the study before 2 weeks.
Pharmaceutical Substance or Drug,Treatment with antiresorptive agents other than risedronate  alendronate  and hormone replacement therapy within the last 36 months before study entry (ie  ibandronate  pamidronate  etidronate  raloxifene  clodronate  or zoledronate)
Pharmaceutical Substance or Drug,Treatment with IV tPA or other thrombolytic agent.
Pharmaceutical Substance or Drug,Treatment with lipid-lowering drug other than Hydroxy-Methylglutaryl Coenzyme A (HMG-CoA)-inhibitor within 3 months prior to inclusion
Pharmaceutical Substance or Drug,Treatment with magnesium sulfate
Pharmaceutical Substance or Drug,Treatment with other antihistamines in the last month before study entry.
Pharmaceutical Substance or Drug,Treatment with psychotropic medication in the previous month.
Pharmaceutical Substance or Drug,Are receiving optimal treatment with long-term oral medications  .  diuretics  angiotensin converting enzyme (ACE) inhibitors  angiotensin II receptor blockers (ARBs)  and beta blockers  unless these are documented to be contraindicated or not tolerated)
Pharmaceutical Substance or Drug,Patients receiving any intra-articular or local peri-articular corticosteroid injections to the study joint/knee within the previous 3 months prior to Screening.
Pharmaceutical Substance or Drug,Patients receiving any intra-articular  intra-muscular or local peri-articular corticosteroid injections to any other joint (beside the study joint) or soft tissue area within the past 3 months.
Pharmaceutical Substance or Drug,Treated with PPAR agonists within 12 weeks prior to study start
Pharmaceutical Substance or Drug,(Was written - Ganciclovir or foscarnet for non-CMV herpes infections within 6 months prior to study entry.)
Pharmaceutical Substance or Drug,(The use of inhaled or intranasal steroids or oral steroids at a dose of >= >=10 mg/day prednisone or its equivalent are permitted.)
Pharmaceutical Substance or Drug,Are on a stable dose of the same AEDs for the 1 month prior to Visit 1.
Pharmaceutical Substance or Drug,Metrifonate during the past three months
Pharmaceutical Substance or Drug,More than 14 days since prior and no concurrent inhibitors or inducers of CYP3A4  including any of the following: Rifapentine
Pharmaceutical Substance or Drug,Ongoing use of thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR ??) agonists  eg  rosiglitazone (Avandia?? or equivalent) or pioglitazone (Actos?? or equivalent).
Pharmaceutical Substance or Drug,Stabilized on atorvastatin 10 mg daily and by subject reported history had taken at least 80% of daily doses for the 4 weeks preceding Visit 1
Pharmaceutical Substance or Drug,Steroid inhalants are permitted if the patient has been on a stable regimen for the past month prior to Screening and remains on this regimen throughout the course of the trial.
Pharmaceutical Substance or Drug,Subject must be currently taking simvastatin 20 mg daily and by history has taken 80% of daily evening doses for the preceding 6 weeks prior to Visit 3 (Baseline Visit).
Pharmaceutical Substance or Drug,Systemic corticosteroid use for <21 days for acute problems is permitted as clinically indicated
Pharmaceutical Substance or Drug,Use of open-label nesiritide within 48 hours of study drug administration.
Pharmaceutical Substance or Drug,Chronic administration of immunosuppressants since birth.
Pharmaceutical Substance or Drug,Fluconazole (doses > 200 mg/day)
Pharmaceutical Substance or Drug,Have had an injection of botulinum toxin in the head or neck within 6 months prior to enrollment
Pharmaceutical Substance or Drug,Have used any topical cosmetics or medicated products on the affected nails within 2 weeks of baseline visit
Pharmaceutical Substance or Drug,Recommended: Standard immunizations
Pharmaceutical Substance or Drug,Allowed: Erythropoietin  G-CSF  or GM-CSF.
Pharmaceutical Substance or Drug,Allowed: G-CSF and GM-CSF.
Pharmaceutical Substance or Drug,Excluded: G-CSF (filgrastim).
Pharmaceutical Substance or Drug,Planned discontinuation of opioids during the study
Pharmaceutical Substance or Drug,Prescription or herbal muscle stimulants  relaxants  etc
Pharmaceutical Substance or Drug,Subject has been prescribed or has taken amphetamine products in the past  including childhood
Pharmaceutical Substance or Drug,Clofazimine.
Pharmaceutical Substance or Drug,Currently taking diabetes mellitus medications  St
Pharmaceutical Substance or Drug,Exclusion Criteria: Planned discontinuation of opioids during the study.
Pharmaceutical Substance or Drug,For atorvastatin  fluvastatin  lovastatin  pravastatin and simvastatin 80 mg QD at the time of the index event and for rosuvastatin 20 mg QD to 40 mg QD
Pharmaceutical Substance or Drug,However  chronic systemic corticosteroid use should be avoided.
Pharmaceutical Substance or Drug,If using sleep medications  medication and dosage have not been changed in the past month  and will remain unchanged for the duration of the acute treatment phase of the study  .  4 weeks)
Pharmaceutical Substance or Drug,In general  patients should be using opioids on a daily basis.
Pharmaceutical Substance or Drug,Individuals on a tapering dose schedule of oral steroids lasting < 7 days may be included in the trial as long as they have not received more than one course within the last two weeks prior to enrollment.
Pharmaceutical Substance or Drug,Opiates.
Pharmaceutical Substance or Drug,Patients currently taking Organic germanium  or who have taken Organic germanium within the past three months
Pharmaceutical Substance or Drug,Patients enrolled in ACTG 128 and ACTG 138 must meet study end points or meet protocol definitions for being permanently off zidovudine (AZT) before enrolling in this study.
Pharmaceutical Substance or Drug,Patients taking unstable doses of glucosamine- or chondroitin sulfate-containing compounds  or patients taking stable dose for less than 4 months prior to Screening  or patients taking stable dose for at least 4 months prior to and unwilling to remain on 
Pharmaceutical Substance or Drug,Patients who  if they are currently taking low dose aspirin (325 mg/day or less)  are willing to remain on a stable dose throughout the study and are willing to refrain from any aspirin dose 24 hours prior to any office visit.
Pharmaceutical Substance or Drug,Used investigational compound within 30 days.
Pharmaceutical Substance or Drug,> 2 opioid and/or nonopioid analgesic for shoulder pain  .  > 2 regardless of class)
Pharmaceutical Substance or Drug,A depot injection or an implant of any drug (other than contraceptives) within 3 months prior to administration of study medication.
Pharmaceutical Substance or Drug,A history of non-response to an adequate course of l-dopa or a dopamine agonist 
Pharmaceutical Substance or Drug,A minimum of four weeks washout of antidepressant medication should occur prior to screening
Pharmaceutical Substance or Drug,Acyclovir (up to 1000 mg/day).
Pharmaceutical Substance or Drug,Administration of immune globulin or other blood products within the last three months  or injected or oral corticosteroids or other immunomodulator therapy within six weeks of the study vaccine
Pharmaceutical Substance or Drug,Aerosol ribavirin for short-term treatment of RSV.
Pharmaceutical Substance or Drug,All other analgesic medications for any chronic condition must be stopped (see exceptions for acute treatment of transient flares of pain)
Pharmaceutical Substance or Drug,Allowed: Atovaquone  IV pentamidine  trimethoprim-dapsone  clindamycin-primaquine  trimetrexate  or TMP/SMX for acute PCP.
Pharmaceutical Substance or Drug,Allowed: Topical and/or antifungal agents  except ketoconazole.
Pharmaceutical Substance or Drug,Alternative medications including megadose vitamins  herbal preparations  tonics  extracts  etc
Pharmaceutical Substance or Drug,Amikacin.
Pharmaceutical Substance or Drug,amitriptyline  nortriptyline  imipramine)
Pharmaceutical Substance or Drug,Amphotericin B.
Pharmaceutical Substance or Drug,Analgesics.
Pharmaceutical Substance or Drug,Antacids within 2 hours of zidovudine (AZT) dose.
Pharmaceutical Substance or Drug,Antibiotics for bacterial infections.
Pharmaceutical Substance or Drug,Anticonvulsants  SNRIs  opiates and benzodiazepines should be tapered appropriately  using product label instructions as a guide.
Pharmaceutical Substance or Drug,antidepressant medication during the past four weeks.
Pharmaceutical Substance or Drug,Antiemetics.
Pharmaceutical Substance or Drug,Antiepileptics (phenobarbital and other barbiturates).
Pharmaceutical Substance or Drug,Antifungal prophylaxis with oral fluconazole or ketoconazole.
Pharmaceutical Substance or Drug,Antihypertensive medication other than diuretics.
Pharmaceutical Substance or Drug,Antipyretics.
Pharmaceutical Substance or Drug,Antiviral prophylaxis with a maximum of 1 gram of oral acyclovir per day.
Pharmaceutical Substance or Drug,any medication or supplement use
Pharmaceutical Substance or Drug,Any nephrotoxic agent.
Pharmaceutical Substance or Drug,Any sulfonamide medications.
Pharmaceutical Substance or Drug,Are on their first combination of stable anti-HIV drugs (have not changed drugs for at least 6 months  except for reasons other than failing treatment or short interruptions of less than 7 days).
Pharmaceutical Substance or Drug,Are receiving investigational drugs or are participating in a clinical trial involving anti-HIV medications
Pharmaceutical Substance or Drug,Are receiving medications and/or medications at certain doses that might interfere with the study.
Pharmaceutical Substance or Drug,Are taking a stable Videx-containing anti-HIV regimen  using Videx tablets either once or twice a day  for at least 2 weeks prior to the screening visit.
Pharmaceutical Substance or Drug,Are taking Videx in liquid form  nelfinavir  or amprenavir.
Pharmaceutical Substance or Drug,Aspirin.
Pharmaceutical Substance or Drug,Azithromycin.
Pharmaceutical Substance or Drug,Benadryl and/or aspirin.
Pharmaceutical Substance or Drug,Benzodiazepines (diazepam  triazolam).
Pharmaceutical Substance or Drug,Beta-blockers.
Pharmaceutical Substance or Drug,Biologic response modifiers such as interferon and IL-2.
Pharmaceutical Substance or Drug,Biologic response modifiers.
Pharmaceutical Substance or Drug,-Biological response modifiers  such as G-CSF  within 3 week prior to study entry
Pharmaceutical Substance or Drug,Carafate.
Pharmaceutical Substance or Drug,Carbamazepine
Pharmaceutical Substance or Drug,Change in intranasal medications (including use of corticosteroids  cromolyn  ipratropium bromide  phenylephrine  or oxymetazoline) within 14 days prior to start of study treatment.
Pharmaceutical Substance or Drug,Chloramphenicol.
Pharmaceutical Substance or Drug,Cholestyramine resin.
Pharmaceutical Substance or Drug,Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first immunization
Pharmaceutical Substance or Drug,Chronic systemic antibiotic use
Pharmaceutical Substance or Drug,Chronic use of steroids or other immunosuppressive agents for other conditions.
Pharmaceutical Substance or Drug,Chronic use of systemic steroids or immunosuppressive agents
Pharmaceutical Substance or Drug,Cimetidine.
Pharmaceutical Substance or Drug,Ciprofloxacin.
Pharmaceutical Substance or Drug,Clarithromycin
Pharmaceutical Substance or Drug,Clarithromycin.
Pharmaceutical Substance or Drug,Clindamycin.
Pharmaceutical Substance or Drug,Clinically indicated antibiotics  unless excluded.
Pharmaceutical Substance or Drug,Concomitant application with another alpha-1 blocker
Pharmaceutical Substance or Drug,Concomitant use of felbamate or use of felbamate within 2 months prior to Visit 1.
Pharmaceutical Substance or Drug,Concomitant use or use within the 4 weeks prior to Visit 1 of neuroleptics  monoamine oxidase (MAO) inhibitors  barbiturates (except for seizure control indication)  benzodiazepines (other than occasional intermittent use)  and narcotic analgesics.
Pharmaceutical Substance or Drug,Concurrent Medication: Allowed
Pharmaceutical Substance or Drug,Concurrent Medication: Excluded
Pharmaceutical Substance or Drug,Concurrent Medication: Required
Pharmaceutical Substance or Drug,Concurrent Medication: The following medications / substances may NOT be ingested up to one hour before or 4 hours after a Nevirapine dose:
Pharmaceutical Substance or Drug,Concurrently taking (within the past 30 days) phenytoin  cimetidine  rifampin  cyclosporin or tacrolimus.
Pharmaceutical Substance or Drug,Conditions requiring use of H2 blockers or other antacids.
Pharmaceutical Substance or Drug,Corticosteroids.
Pharmaceutical Substance or Drug,Coumadin
Pharmaceutical Substance or Drug,Current use of corticosteroids or erythropoietin
Pharmaceutical Substance or Drug,Current use of MAO inhibitors  tricyclic antidepressant medications  or cyclopropane or halothane anesthetic agents.
Pharmaceutical Substance or Drug,Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).
Pharmaceutical Substance or Drug,Currently taking monoamine oxidase inhibitors or bupropion (Zyban or Wellbutrin)
Pharmaceutical Substance or Drug,Currently taking NSAIDs (with the exception of aspirin).
Pharmaceutical Substance or Drug,Currently taking psychostimulant medication
Pharmaceutical Substance or Drug,Currently taking warfarin or other anticoagulants.
Pharmaceutical Substance or Drug,Currently treated with clozapine  lamotrigine or carbamazepine  or defined as treatment refractory
Pharmaceutical Substance or Drug,Cyclosporine trough blood level < 110 ng/ml
Pharmaceutical Substance or Drug,Dapsone.
Pharmaceutical Substance or Drug,darbopoeitin [Aranesp??] is permitted)
Pharmaceutical Substance or Drug,Dicumarol  warfarin  and other anticoagulant drugs.
Pharmaceutical Substance or Drug,Dicumarol  warfarin  and other anticoagulant medications.
Pharmaceutical Substance or Drug,Didanosine (ddI).
Pharmaceutical Substance or Drug,Digitoxin.
Pharmaceutical Substance or Drug,Diltiazem
Pharmaceutical Substance or Drug,Doxycycline.
Pharmaceutical Substance or Drug,Drugs that are potent inhibitors of cytochrome P450 unless they can be withdrawn
Pharmaceutical Substance or Drug,Erythromycin
Pharmaceutical Substance or Drug,Erythropoietin.
Pharmaceutical Substance or Drug,Estrogens)  (b) any form of glucocorticoid which would inhibit CRH and ACTH secretion.
Pharmaceutical Substance or Drug,Ethambutol.
Pharmaceutical Substance or Drug,examples of inhibitors: antidepressants (SSRI)  cimetidine  diltiazem  macrolides  imidazoles  neuroleptics  verapamil  fluoroquinolones  antihistamines) within 30 days prior to administration of the study medication.
Pharmaceutical Substance or Drug,Exceptions are products containing glucosamine/Chondroitin/methylsulfonylmethane (MSM) if stable for 4 months prior to Screening and remain stable throughout study and fulfill the VAS pain entry criteria).
Pharmaceutical Substance or Drug,Excluded Medications: Experimental drugs
Pharmaceutical Substance or Drug,Excluded within 20 days prior to study entry: G-CSF (filgrastim).
Pharmaceutical Substance or Drug,Excluded within 30 days of study entry: Antiretroviral agents other than zidovudine (AZT).
Pharmaceutical Substance or Drug,Excluded within 30 days prior to study entry: Anti-HIV medication other than zidovudine (AZT).
Pharmaceutical Substance or Drug,Excluded within 4 weeks of study entry: Any approved or investigational antiretroviral  immunosuppressive or cytotoxic drugs.
Pharmaceutical Substance or Drug,Excluded: Antiretroviral agents other than zidovudine (AZT) or dideoxycytidine (ddC) within 4 weeks of study entry.
Pharmaceutical Substance or Drug,Excluded: Antiretrovirals other than study drugs.
Pharmaceutical Substance or Drug,Excluded: Any approved or investigational antiretroviral  immunosuppressive  or cytotoxic drugs.
Pharmaceutical Substance or Drug,Excluded: Immunomodulators  biologic response modifiers  interferon  or investigational agents that may influence course of CMV infection.
Pharmaceutical Substance or Drug,Excluded: Immunomodulators.
Pharmaceutical Substance or Drug,Excluded: Non-nucleoside reverse transcriptase inhibitors.
Pharmaceutical Substance or Drug,Excluded: Oral contraceptives.
Pharmaceutical Substance or Drug,Excluded: PER AMENDMENT 4/25/96: Use of IV ganciclovir  foscarnet or cidofovir within 6 months prior to study enrollment
Pharmaceutical Substance or Drug,Excluded: Zidovudine (AZT)  other antiretroviral agents  biological modifiers  and investigational medications.
Pharmaceutical Substance or Drug,Exclusion Criteria: Previous vaccination with a investigational vaccine or a rabies vaccine
Pharmaceutical Substance or Drug,Exclusion Criteria: Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine  or planned use during the study period.
Pharmaceutical Substance or Drug,Failure to observe the designated washout periods for any of the prohibited medications
Pharmaceutical Substance or Drug,Flucytosine.
Pharmaceutical Substance or Drug,Fluvoxamine
Pharmaceutical Substance or Drug,for those on Coumadin  INR > 3.0
Pharmaceutical Substance or Drug,Foscarnet.
Pharmaceutical Substance or Drug,Frequent need of rescue benzodiazepines (two or more times a month).
Pharmaceutical Substance or Drug,Ganciclovir.
Pharmaceutical Substance or Drug,G-CSF.
Pharmaceutical Substance or Drug,Glucocorticoids and steroid hormones (including oral contraceptives).
Pharmaceutical Substance or Drug,Had received medroxyprogesterone acetate injection <=12 weeks prior to enrolment
Pharmaceutical Substance or Drug,Had used barbiturates  antiepileptics  rifampin  griseofulvin  or other hepatic enzyme inducing drugs within 30 days of enrolment
Pharmaceutical Substance or Drug,Have ever taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs).
Pharmaceutical Substance or Drug,Have had treatment with any nonnucleoside reverse transcriptase inhibitor (NNRTI).
Pharmaceutical Substance or Drug,Have received a vaccine within 30 days prior to study entry.
Pharmaceutical Substance or Drug,Have received any other investigational agent during this study
Pharmaceutical Substance or Drug,Have taken any nucleoside reverse transcriptase inhibitors (NRTIs) for more than 2 weeks.
Pharmaceutical Substance or Drug,Have taken medications that affect your immune system within 30 days prior to study entry.
Pharmaceutical Substance or Drug,Have used any HIV vaccine or drugs affecting the immune system within 30 days prior to entering the study.
Pharmaceutical Substance or Drug,Have used any investigational drug within the previous 1 month or 5 half-lives of the investigational agent  whichever is longer  or 3 months for any biologic of unknown half-life
Pharmaceutical Substance or Drug,Having received any approved or investigational antiretroviral  immunosuppressive  or cytotoxic drugs or any other experimental drug with 4 weeks of study entry.
Pharmaceutical Substance or Drug,HIV protease inhibitors
Pharmaceutical Substance or Drug,Hypericum perforatum (St
Pharmaceutical Substance or Drug,Ibuprofen.
Pharmaceutical Substance or Drug,If patients are not taking any analgesic/anti-inflammatory medication or have not taken any pain medication (prescription [Rx] or over-the-counter [OTC]) in the previous 3 days from Screening then they should have a VAS pain score after walking on a 50 ft
Pharmaceutical Substance or Drug,If using other psychotropic medications  medication and dosage have not been changed in the past 2 months  and will remain unchanged for the duration of the acute treatment phase of the study  .  4 weeks)
Pharmaceutical Substance or Drug,Immunoglobulin  IV (IVIG).
Pharmaceutical Substance or Drug,Immunoglobulin.
Pharmaceutical Substance or Drug,Immunomodulating agents such as interferons  isoprinosine  or interleukin-2 within 2 weeks of entry.
Pharmaceutical Substance or Drug,Immunomodulators.
Pharmaceutical Substance or Drug,Immunosuppressive agents: prednisone and other corticosteroids (taken orally or by injection)  methotrexate  cyclophosphamide  cyclosporin  tacrolimus  etc.
Pharmaceutical Substance or Drug,Insulin
Pharmaceutical Substance or Drug,Interferon.
Pharmaceutical Substance or Drug,Interferons.
Pharmaceutical Substance or Drug,Interleukins.
Pharmaceutical Substance or Drug,Investigational drugs not specifically allowed.
Pharmaceutical Substance or Drug,Isoniazid.
Pharmaceutical Substance or Drug,Itraconazole
Pharmaceutical Substance or Drug,Itraconazole.
Pharmaceutical Substance or Drug,John's Wort  appetite suppressants  ephedrine-containing medications  theophylline  clonidine  reserpine  methyldopa  or anti-anginal medications  .  beta-blockers  calcium channel blockers  nitroglycerin preparations)
Pharmaceutical Substance or Drug,Ketoconazole
Pharmaceutical Substance or Drug,Ketoconazole  acyclovir  or nystatin for prophylaxis.
Pharmaceutical Substance or Drug,Ketoconazole  etomidate) or protein binding (eg
Pharmaceutical Substance or Drug,Ketoconazole.
Pharmaceutical Substance or Drug,Live attenuated vaccines within 60 days of study [NOTE: Medically indicated sub-unit or killed vaccines  .  influenza  pneumococcal  hepatitis A and B) are not exclusionary  but should be given at least 4 weeks away from HIV immunizations]
Pharmaceutical Substance or Drug,Lupron  estrogen  are permitted)
Pharmaceutical Substance or Drug,May not be receiving any other investigational agents.
Pharmaceutical Substance or Drug,mefloquine  artesunate  quinine  tetracycline  or clindamycin
Pharmaceutical Substance or Drug,Metronidazole for up to 14 days.
Pharmaceutical Substance or Drug,Mitomycin-C or nitrosurea within 42 days.
Pharmaceutical Substance or Drug,Modafinil
Pharmaceutical Substance or Drug,More than 28 days since prior investigational agents
Pharmaceutical Substance or Drug,More than 4 months of prior ganciclovir or foscarnet  or within 4 weeks prior to study entry.
Pharmaceutical Substance or Drug,More than 6 months since prior and no concurrent amiodarone
Pharmaceutical Substance or Drug,Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis).
Pharmaceutical Substance or Drug,Need for psychoactive medications other than the study drugs  except for one benzodiazepine or hypnotic given at a stable dose.
Pharmaceutical Substance or Drug,Nefazodone
Pharmaceutical Substance or Drug,Neuroleptics and lithium
Pharmaceutical Substance or Drug,Nitroglycerin
Pharmaceutical Substance or Drug,Nitroglycerin.
Pharmaceutical Substance or Drug,No concomitant medications may be taken during the study
Pharmaceutical Substance or Drug,No prior investigational drug within the last 30 days
Pharmaceutical Substance or Drug,No prior trastuzumab (Herceptin??)
Pharmaceutical Substance or Drug,No prior tubule  DNA  or mitosis-targeting agents for RCC
Pharmaceutical Substance or Drug,Non-nucleoside reverse transcriptase inhibitor or protease inhibitor.
Pharmaceutical Substance or Drug,Ofloxacin.
Pharmaceutical Substance or Drug,Omalizumab within 3 months.
Pharmaceutical Substance or Drug,or any investigational agent within 60 days of entry.
Pharmaceutical Substance or Drug,Oral corticosteroids within one month  cromolyn sodium or nedocromil within 14 days  theophylline  LABA  ZYFLO  or leukotriene modifiers  warfarin or propranolol  inhaled anti-cholinergics  or combination LABA/ICS.
Pharmaceutical Substance or Drug,other cholinergic drugs  .  donepezil  tacrine  succinylcholine-type muscle relaxants) during the past two weeks (topical pilocarpine will be permitted)
Pharmaceutical Substance or Drug,Other medications
Pharmaceutical Substance or Drug,Oxcarbazepine
Pharmaceutical Substance or Drug,Patient has used injected anesthetics or steroids within 30 days of baseline.
Pharmaceutical Substance or Drug,Patient ingesting body building/anabolic steroids within the last 6 months preceding the study
Pharmaceutical Substance or Drug,Patient is currently taking an alpha-2 agonist  alpha methyldopa  reserpine  clopidogrel  or ticlopidine
Pharmaceutical Substance or Drug,Patient is not maintained on a stable corticosteroid regimen
Pharmaceutical Substance or Drug,Patient must have a minimum washout period of greater than 5 times the half-life of the drug of any of the following medications: benzodiazepines  skeletal muscle relaxants  orally administered steroids  capsaicin  mexiletene  centrally acting analgesics 
Pharmaceutical Substance or Drug,Patient must not have received other investigational drugs within 14 days before enrollment.
Pharmaceutical Substance or Drug,Patient received Mannitol prior to placement of ICP monitor
Pharmaceutical Substance or Drug,Patient receiving androgens  immunoglobulins  cyclophosphamide  cyclosporin A  or other immunosuppressive agents  except azathioprine  methotrexate  and hydrochloroquine within the last 3 months
Pharmaceutical Substance or Drug,Patient treated with azathioprine  methotrexate  or hydrochloroquine must be on a stable dose with no change in dose for at least 6 weeks preceding the study
Pharmaceutical Substance or Drug,Patient using any investigational agents within the longer of 30 days or 10 half-lives of the agent
Pharmaceutical Substance or Drug,Patients currently receiving Neurontin?? (gabapentin)  glutamine supplements  Elavil?? (amitriptyline)  Dilantin??  Tegretol??  tricyclic antidepressants or other similar medications during the study period
Pharmaceutical Substance or Drug,Patients currently treated with gabapentin or pregabalin at screening may be eligible for the study  but must have a tapering period wherein the dose of gabapentin or pregabalin is reduced gradually over a period of at least 7 days plus a 2-day or 3-day w
Pharmaceutical Substance or Drug,Patients must not have any prior anthracyclines (doxorubicin  epirubicin  daunorubicin  idarubicin) or mitoxantrone  or bortezomib.
Pharmaceutical Substance or Drug,Patients receiving an intra-articular hyaluronan in the study joint within the previous 9 months prior to screening.
Pharmaceutical Substance or Drug,Patients receiving any oral corticosteroid within the previous month
Pharmaceutical Substance or Drug,Patients taking a stable dose of selective serotonin reuptake inhibitor antidepressant (except fluvoxamine) will be allowed.
Pharmaceutical Substance or Drug,Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin  during the last two weeks.
Pharmaceutical Substance or Drug,Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin.
Pharmaceutical Substance or Drug,Patients taking any of the following medications for less than 3 months  or who plan to take them for the first time during the next 3 months: ACE-inhibitors  angiotensin receptor blockers  calcium channel blockers  or statins.
Pharmaceutical Substance or Drug,Patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within 2 months prior to the study or during the study
Pharmaceutical Substance or Drug,Patients taking nonsteroidal anti-inflammatory agents will be asked to discontinue these medications 3 days prior to muscle biopsy.
Pharmaceutical Substance or Drug,Patients who have received investigational drugs < 28 days prior to registration.
Pharmaceutical Substance or Drug,Patients will not be eligible for this study if they: Are receiving high doses of testosterone
Pharmaceutical Substance or Drug,Patients with chronic non-cancer pain that necessitates the use of non- injectable opioid analgesics.
Pharmaceutical Substance or Drug,Phenobarbital
Pharmaceutical Substance or Drug,Phenytoin
Pharmaceutical Substance or Drug,Plan to change their medications within 8 weeks following the screening visit.
Pharmaceutical Substance or Drug,Prednisone dose in patient's receiving alternate day therapy will be the mean daily prednisone dose
Pharmaceutical Substance or Drug,Previous exposure to a Ras pathway inhibitor (including herceptin  EGFr inhibitors  farnesyl transferase inhibitors or MEK inhibitors)
Pharmaceutical Substance or Drug,Previous lack of response to two or more antidepressants at adequate dosage.
Pharmaceutical Substance or Drug,Prior ddI  ddC  3TC or d4T (more than 2 weeks total).
Pharmaceutical Substance or Drug,Prior Medication: Allowed
Pharmaceutical Substance or Drug,Prior Medication: Excluded within 20 days prior to study entry
Pharmaceutical Substance or Drug,Prior Medication: Excluded within 30 days of study entry
Pharmaceutical Substance or Drug,Prior Medication: Excluded within 30 days prior to study entry
Pharmaceutical Substance or Drug,Prior Medication: Excluded within 4 weeks of study entry
Pharmaceutical Substance or Drug,Prior Medication: Excluded
Pharmaceutical Substance or Drug,Prior Medication: Excluded: PER AMENDMENT 4/25/96
Pharmaceutical Substance or Drug,Prior receipt of HIV-1 vaccine in a previous HIV vaccine trial
Pharmaceutical Substance or Drug,Probenecid.
Pharmaceutical Substance or Drug,propylthiouracil  methimazole  iodides).
Pharmaceutical Substance or Drug,Protease inhibitors except IDV.
Pharmaceutical Substance or Drug,Pyrazinamide.
Pharmaceutical Substance or Drug,Pyrimethamine.
Pharmaceutical Substance or Drug,Rapamycin intolerability
Pharmaceutical Substance or Drug,Recombinant erythropoietin (rEPO) and granulocyte-colony stimulating factor (G-CSF  filgrastim).
Pharmaceutical Substance or Drug,regular intake of pain medications for any other chronic pain
Pharmaceutical Substance or Drug,Regularly prescribed medications  such as antipyretics  antidepressants  oral contraceptives  megestrol acetate  testosterone  or any other medication.
Pharmaceutical Substance or Drug,Related investigational agents.
Pharmaceutical Substance or Drug,Required: Stable prescribed dosage of zidovudine (AZT)  = or > 500 mg/day.
Pharmaceutical Substance or Drug,Requirement for anticoagulation with IV heparin or warfarin in the first 48 hours after enrollment.
Pharmaceutical Substance or Drug,requirement for concurrent immunosuppressive drug(s)
Pharmaceutical Substance or Drug,Requirement for intravenous diuretic whilst either an inpatient or in an emergency room setting with intravenous diuretics  vasodilators or inotropes
Pharmaceutical Substance or Drug,Requirement for systemic aminoglycoside antibiotics within 14 days prior to start of study treatment.
Pharmaceutical Substance or Drug,Requires beta-blockers  MAO inhibitors  tricyclic antidepressants  oral or intranasal anticholinergics
Pharmaceutical Substance or Drug,Rifabutin
Pharmaceutical Substance or Drug,Rifabutin and rifampin.
Pharmaceutical Substance or Drug,Rifabutin.
Pharmaceutical Substance or Drug,Rifampin
Pharmaceutical Substance or Drug,Rifampin.
Pharmaceutical Substance or Drug,Should repeat MMR 3 months after discontinuing study.
Pharmaceutical Substance or Drug,Simvastatin consumption meant that subjects must be currently taking simvastatin 20mg daily  and by history have taken at least 80% of daily evening doses for the preceding 6 weeks prior to baseline visit
Pharmaceutical Substance or Drug,Stable medications for 4 weeks prior to screening
Pharmaceutical Substance or Drug,steroid injections to the shoulder in the last 6-wks
Pharmaceutical Substance or Drug,Steroids other than topical.
Pharmaceutical Substance or Drug,Subject has received an investigational drug within 30 days prior to the initiation of study dosing.
Pharmaceutical Substance or Drug,Subject is being treated with coumadin  heparin  clopidogrel or has used these agents within 2 weeks of screening
Pharmaceutical Substance or Drug,Subject must not be taking any medication that could interact with Kaletra?? to enhance hepatic toxicity.
Pharmaceutical Substance or Drug,Subjects must be actively taking ZDV for at least 4 continuous weeks up to the time of study entry.
Pharmaceutical Substance or Drug,Subjects must not be currently taking an approved statin
Pharmaceutical Substance or Drug,Subjects taking antihypertensive medication.
Pharmaceutical Substance or Drug,Subjects taking antithyroid medication  
Pharmaceutical Substance or Drug,Subjects taking MAO inhibitors.
Pharmaceutical Substance or Drug,Subjects taking topical or oral decongestant products within 7 days of Visit 2.
Pharmaceutical Substance or Drug,Subjects taking trycyclic antidepressants  
Pharmaceutical Substance or Drug,Subjects that have received any other investigational agents within 28 days of first day of study drug dosing.
Pharmaceutical Substance or Drug,Subjects who are taking concomitant immunomodulatory agents including  but not limited to  interferons  interleukins  systemic steroids  cyclosporine  tacrolimus  calcineurin inhibitors  chronic low-dose methotrexate  or azathioprine
Pharmaceutical Substance or Drug,Subjects who have been receiving monoamine oxidase inhibitors
Pharmaceutical Substance or Drug,Subjects who have been receiving monoamine oxidase inhibitors.
Pharmaceutical Substance or Drug,Subjects who have not observed designated washout periods for prohibited medications (eg  potent inhibitors of CYP3A4  prescription or over-the-counter agents know to lower lipid levels  corticosteroids)  or have been on a stable regimen of any cardiovasc
Pharmaceutical Substance or Drug,Subjects who have not observed the designated washout periods for any of the prohibited medications
Pharmaceutical Substance or Drug,Subjects who have received an investigational drug within 30 days prior to study dosing.
Pharmaceutical Substance or Drug,Subjects who have taken any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
Pharmaceutical Substance or Drug,Subjects who have taken prescription medication 14 days preceding administration of study medication or over-the-counter products 7 days preceding administration of study medication  except for topical products without systemic absorption
Pharmaceutical Substance or Drug,Subjects who have taken prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication  except for topical products without systemic absorption
Pharmaceutical Substance or Drug,Subjects with a previous history of statin use must have not used a statin for at least 6 months prior to Visit 3 (Baseline Visit).
Pharmaceutical Substance or Drug,Sucralfate.
Pharmaceutical Substance or Drug,Sulfa drugs.
Pharmaceutical Substance or Drug,Sulfadiazine.
Pharmaceutical Substance or Drug,Systemic acyclovir or any nephrotoxic agent  specifically aminoglycosides  amphotericin B  and parenteral pentamidines.
Pharmaceutical Substance or Drug,Systemic acyclovir.
Pharmaceutical Substance or Drug,Systemic steroids.
Pharmaceutical Substance or Drug,Taken any of the following substances: An investigational drug during the past four weeks
Pharmaceutical Substance or Drug,Taking any drug except penicillin-V  folate or iron supplementation  hydroxyurea
Pharmaceutical Substance or Drug,Taking any medications (including over the counter products)  herbal products  mineral supplements or vitamins (other than a daily multivitamin preparation)  other than contraceptives (for women)  within 2 weeks of start of the study
Pharmaceutical Substance or Drug,Terfenadine  astemizole  cisapride  triazolam and midazolam.
Pharmaceutical Substance or Drug,The equivalent dose of 300 mg morphine per day is the maximum opioid analgesic dose allowed
Pharmaceutical Substance or Drug,The following medications / substances may NOT be ingested up to one hour before or 4 hours after a Nevirapine dose: Antacids (particularly those containing calcium carbonate).
Pharmaceutical Substance or Drug,They should only be given nevirapine as part of an initial study regimen if resistance testing can be done to confirm that they do not have nevirapine resistance.
Pharmaceutical Substance or Drug,This includes any dose level of oral steroids or inhaled steroids  but not topical steroids
Pharmaceutical Substance or Drug,Tolbutamide.
Pharmaceutical Substance or Drug,Topical (but not at the proposed vaccination sites) or inhalational steroids are permitted
Pharmaceutical Substance or Drug,Topical antifungals  clotrimazole  ketoconazole  fluconazole  and amphotericin B for mucosal and esophageal candidiasis.
Pharmaceutical Substance or Drug,Topical steroids.
Pharmaceutical Substance or Drug,Treated with antipsychotic medications for at least 6 months in the past  and on a stable dose of the same antipsychotic medication over the past month
Pharmaceutical Substance or Drug,treated with any other investigational drug within 30 days prior Visit 1
Pharmaceutical Substance or Drug,Treated with investigational drug or device within last 30 days
Pharmaceutical Substance or Drug,Trimethoprim / sulfamethoxazole (Bactrim).
Pharmaceutical Substance or Drug,Troleandomycin
Pharmaceutical Substance or Drug,Use of a investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study immunization  or planned use up to 30 days after the third immunization
Pharmaceutical Substance or Drug,Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates  carbamazepine  phenytoin glucocorticoids   omerprazole
Pharmaceutical Substance or Drug,--Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates  carbamazepine  phenytoin glucocorticoids  omerprazole
Pharmaceutical Substance or Drug,Use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication
Pharmaceutical Substance or Drug,Use of any estrogen  progestin  androgen containing medications or tibolone within 12 weeks before screening.
Pharmaceutical Substance or Drug,Use of any investigational agents within 30 days prior to screening
Pharmaceutical Substance or Drug,Use of any medication within one month prior to study start  except occasional use of acetaminophen or ibuprofen.
Pharmaceutical Substance or Drug,Use of any prescription or over-the-counter medications or dietary/herbal supplements (with the exception of oral or implanted contraceptives) within 1 week or 5 half-lives  whichever is longer  of the study.
Pharmaceutical Substance or Drug,Use of bimatoprost or an ocular prostaglandin (eg  latanoprost  travoprost) within 6 weeks prior to baseline (Day 0)
Pharmaceutical Substance or Drug,Use of carbamazepine  phenytoin  phenobarbital
Pharmaceutical Substance or Drug,Use of combination alendronate and risedronate  either simultaneously or sequentially  within 60 months prior to enrollment  or use of any anti-resorptive agent in combination with risedronate or alendronate
Pharmaceutical Substance or Drug,Use of cyclosporin
Pharmaceutical Substance or Drug,Use of excluded concomitant medications
Pharmaceutical Substance or Drug,Use of herbal or anabolic supplements
Pharmaceutical Substance or Drug,Use of ketoconazole  itraconazole  and ritonavir
Pharmaceutical Substance or Drug,Use of or requirement for inhaled gentamicin or amikacin within 14 days prior to start of study treatment or during study treatment.
Pharmaceutical Substance or Drug,Use of prescription medication within 14 days prior to administration of a study medication or over the counter products (including natural food supplements  vitamins  garlic as a supplement) within 7 days prior to administration of study medication  exce
Pharmaceutical Substance or Drug,Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products within 7 days prior to administration of study medication  except for topical products without systemic absorption
Pharmaceutical Substance or Drug,Valproic acid.
Pharmaceutical Substance or Drug,Verapamil
Pharmaceutical Substance or Drug,Vitamin D (25-hydroxyvitamin D) between 16 ng/ml and 80 ng/ml
Pharmaceutical Substance or Drug,Voriconazole
Pharmaceutical Substance or Drug,With a previous use of tegaserod within 3 months prior to baseline.
Pharmaceutical Substance or Drug,You are currently taking an anticonvulsant  cisapride (Propulsid)  or if you have taken an opioid for three or more consecutive days during the 14 days prior to Visit 2.
Pharmaceutical Substance or Drug,Subject uses insulin  PPAR gamma agonists (rosiglitazone or pioglitazone)  exenatide (Byetta)  acarbose (Prandase  Precose) or dipeptidyl-peptidase 4 (DPP-4) inhibitors (JANUVIA>= 1)
Pregnancy Related,Hormonal contraceptives (starting al least 4 weeks prior to study administration)
Pregnancy Related,Use of oral contraceptives  insulin sensitizers  d-chiro inositol  or any other supplements affecting weight or insulin sensitivity during the preceding two months
Pregnancy Related,Inclusion Criteria: Female subjects may not be pregnant and/or will agree to use appropriate method of contraception beginning at least 2 weeks prior to administration of the first dose of study drug in the first treatment period  throughout the study and
Pregnancy Related,Both women and men must take adequate precautions to prevent pregnancy during treatment.
Pregnancy Related,Male and female patients of reproductive potential must agree to use adequate contraception  
Pregnancy Related,Women of childbearing potential must have a pre-treatment pregnancy test
Pregnancy Related,Female patients of child bearing age who have a positive pregnancy test on admission.
Pregnancy Related,Have a positive urine pregnancy test (for women of child-bearing capacity)
Pregnancy Related,a negative urine pregnancy test at admission
Pregnancy Related,Negative pregnancy test (for females of childbearing potential).
Pregnancy Related,Negative pregnancy test for female patients
Pregnancy Related,Negative urine pregnancy test for females (to be confirmed at screening and prior to every dose of study medication)
Pregnancy Related,Positive urine pregnancy screen
Pregnancy Related,Positive urine pregnancy test at screening (performed on all females)
Pregnancy Related,Positive urine pregnancy test at screening.
Pregnancy Related,Be breast feeding a child
Pregnancy Related,Intent to breastfeed infant
Pregnancy Related,The presently used contraceptive method were any of condoms alone  abstinence  withdrawal  or a rhythm method
Pregnancy Related,<12 months post-partum*>= ???>= 
Pregnancy Related,A reliable method for this study is defined as one of the following: oral or injectable contraceptives  IUD  contraceptive implants  tubal ligation  hysterectomy  a barrier method (diaphragm with spermicidal foam or jelly  or a condom).
Pregnancy Related,All forms of contraceptive medication are permissible for this study and would not result in a female's exclusion from participation
Pregnancy Related,Inclusion Criteria: women admitted to the postpartum floor during the study period
Pregnancy Related,Give birth to the target child at participating hospitals
Pregnancy Related,Have a negative pregnancy test within 14 days of study entry  if a woman able to have children.
Pregnancy Related,Exclusion Criteria: Multiple birth greater than twins
Pregnancy Related,If abstinent  women must agree to use double-barrier contraception throughout the study period should they become sexually active.
Pregnancy Related,The acceptable methods of contraception are condom + spermicide (at least 14 days prior to study drug administration)  diaphragm + spermicide (at least 14 days prior to study drug administration)or intrauterine contraceptive device (placed at least 4 week
Pregnancy Related,>= ???>= 'Partum' is defined as a delivery or other termination that occurs after 20 weeks gestation.
Pregnancy Related,they do not use an effective method of contraception until all follow-up procedures are complete
Pregnancy Related,Had a desire to conceive in the subsequent 9 months of enrolment
Pregnancy Related,Non-surgically sterilized women or non-menopaused women.
Pregnancy Related,vasectomized partner (six months minimum)
Pregnancy Related,(Methods of contraception considered effective are an oral  injectable or implanted contraceptive agent  or an intra-uterine device with a failure rate of 1% per year  and abstinence).
Pregnancy Related,Pregnant or has not completed child bearing*
Pregnancy Related,Acceptable methods of contraception: Intra-uterine contraceptive device
Pregnancy Related,Additionally  participants who were menopausal
Pregnancy Related,both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial
Pregnancy Related,Acceptable methods of birth control include oral or transdermal contraceptives  condom  spermicidal foam  intrauterine device (IUD)  progestin implant or injection  abstinence  vaginal ring  or sterilization of partner
Pregnancy Related,Male subjects must also agree to use one or more of the above forms of birth control for either themselves or their partner  as appropriate throughout the course of the study
Pregnancy Related,Females who are nursing  pregnant  or intend to become pregnant during the time of the study  or females of child-bearing potential who have a positive pregnancy test during screening evaluation
Pregnancy Related,women of childbearing potential and men able to father children must use non-hormonal-based birth control while on study.
Pregnancy Related,Women of child-bearing potential must also use a reliable method of birth control during the study and for 1 month following completion of therapy
Pregnancy Related,Women who are pregnant  breast feeding  or of child bearing potentials
Pregnancy Related,Acceptable methods of contraception: Intra-uterine contraceptive device (place al least 4 weeks prior to study drug administration)
Pregnancy Related,Agree to use a barrier method of birth control  men and women  while receiving study drugs and for 3 months afterwards.
Pregnancy Related,Agree to use an effective barrier method of birth control during the study.
Pregnancy Related,Also  male patients whose sexual partners are women of child bearing potential not using effective birth control will be excluded.
Pregnancy Related,Breast- feeding subject.
Pregnancy Related,Breast-feeding subject
Pregnancy Related,Female of childbearing age not practicing contraception
Pregnancy Related,Female patients of child-bearing potential must have a negative pregnancy test within 14 days before initiation of study drug dosing
Pregnancy Related,Female subjects must be postmenopausal or otherwise unable to have children
Pregnancy Related,If subjects who are not sexually active with members of the opposite sex become so during the study  these subjects must agree to use a medically accepted method of contraception.
Pregnancy Related,Patient is a nursing mother.
Pregnancy Related,Post-menopausal women must be amenorrheic for at least 12 months to be considered non-child-bearing potential
Pregnancy Related,Sexually active female subject who is not surgically sterile or 2 years post menopausal must agree to use contraception/birth control measure while on study  .  oral contraceptives  diaphragms with spermicide  condoms with spermicide  intrauterine devices
Pregnancy Related,Subjects of child-bearing potential must be willing to practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment (about 5 half lives).
Pregnancy Related,Those females using hormonal contraceptives must also be using an additional approved method of contraception  .  a barrier method plus spermicide or IUD) starting with the Baseline Phase and continuing throughout the entire study period.
Pregnancy Related,Women must use a medically acceptable form of contraception (steroidal contraceptive  double-barrier  or intra-uterine device) during the entire study period  or they must be surgically sterilized or post-menopausal
Pregnancy Related,Women of child-bearing age who are sexually active and not practicing an acceptable form of contraception
Pregnancy Related,Women of child-bearing potential  must be non-lactating and agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug
Pregnancy Related,Non-pregnant  non-breastfeeding females
Pregnancy Related,All patients (males and females) who are fertile must agree to use an effective barrier method of birth control  .  latex condom  diaphragm  cervical cap  etc) to avoid pregnancy.
Pregnancy Related,All WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant .
Pregnancy Related,Are male or female without child-bearing potential  .  surgically sterilized [via bilateral tubal ligation bilateral oophorectomy  or hysterectomy]  at least one year postmenopausal  or using adequate birth control).
Pregnancy Related,Are pregnant or breast-feeding.
Pregnancy Related,Are pregnant  nursing  or planning pregnancy prior to study enrollment
Pregnancy Related,Be pregnant or breast-feeding
Pregnancy Related,Breast feeding
Pregnancy Related,Current pregnancy or breast-feeding
Pregnancy Related,Exclusion Criteria: Are pregnant or nursing
Pregnancy Related,Exclusion Criteria: Breast feeding female subjects
Pregnancy Related,Exclusion Criteria: Pregnancy
Pregnancy Related,Exclusion Criteria: Pregnancy or lactation
Pregnancy Related,Exclusion Criteria: pregnant or breast feeding women  or with a reproductive potential and no practicing an effective method of contraception during the second part of ovarian cycle ( PET is realised during the first part of ovarian cycle)
Pregnancy Related,Exclusion Criteria: Pregnant or lactating women.
Pregnancy Related,Exclusion criteria: Pregnant women.
Pregnancy Related,Exclusion Criteria: Women of childbearing potential may not be entered if:
Pregnancy Related,Female patient of childbearing potential (not surgically sterile or at least 2 years postmenopausal) has a negative pregnancy test at baseline/day 1 and is not lactating
Pregnancy Related,Female patients who are pregnant or breast feeding or patients of reproductive potential not using an effective method of birth control will be excluded
Pregnancy Related,Female patients who are pregnant or breast feeding.
Pregnancy Related,Female subject is pregnant or lactating.
Pregnancy Related,Female subjects of childbearing potential having unprotected sexual intercourse with any non- sterile male partner  
Pregnancy Related,Female subjects of childbearing potential must be using medically acceptable birth control measures.
Pregnancy Related,Female subjects of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing
Pregnancy Related,Female subjects of childbearing potential who have had unprotected sexual intercourse with any non-sterile male partner  
Pregnancy Related,Female subjects who are pregnant or breast-feeding.
Pregnancy Related,Female volunteers who are not documented to be surgically sterile must be willing to abstain from sexual intercourse during the study or be willing to use intrauterine devices or 2 forms of barrier contraception for at least 7 days prior to the initial do
Pregnancy Related,Females must have the urine or serum pregnancy test (HCG) that is negative at Screening and Day 1 of Period 1.
Pregnancy Related,Females should be either of nonchildbearing potential as a result of surgery or menopause (1 year after onset)  or of childbearing potential and practicing a medically acceptable method of contraception  .  abstinence  a barrier method plus spermicide  or
Pregnancy Related,Females who are pregnant  nursing or unwilling to use/practice adequate contraception (hormonal  I.U.D.  barrier method  etc.).
Pregnancy Related,Females whom are pregnant or nursing>= ???>= ???>= ???>= ???>= 
Pregnancy Related,Fertile patients must use effective contraception
Pregnancy Related,General exclusion criteria: Women who are pregnant or women of childbearing potential who do not use adequate contraception
Pregnancy Related,If female subject  is not currently pregnant and has stated that she has no intention of becoming pregnant during the study.
Pregnancy Related,If female  must not be of childbearing potential or must agree to use one or more of the following forms of contraception during screening and throughout the study: hormonal  .  oral  transdermal  implant or injection)
Pregnancy Related,If female  not be pregnant  including negative serum pregnancy test
Pregnancy Related,If female  subject must have a negative pregnancy test and agree to use  for the duration of the study  a barrier method of birth control that has a history of proven reliability as judged by the investigator.
Pregnancy Related,In addition  men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control
Pregnancy Related,Inclusion Criteria: Negative pregnancy test for women of childbearing potential within 3 days prior to baseline evaluation and use of an acceptable means of contraception (condom  hormonal or mechanical method) for one month prior to immunization and the 
Pregnancy Related,Inclusion Criteria: Pregnant between 32-36 weeks estimated gestation
Pregnancy Related,is pregnant or breast-feeding.
Pregnancy Related,known or suspected pregnancy
Pregnancy Related,Male and female subjects of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 7 days following discontinuation of study drug.
Pregnancy Related,Negative pregnancy test
Pregnancy Related,Non-childbearing potential female subjects is defined as post-menopausal state: absence of menses for 12 months prior to drug administration or hysterectomy with bilateral oophorectomy  or tubal ligation at least 6 months prior to drug administration
Pregnancy Related,non-pregnant and
Pregnancy Related,not breastfeeding
Pregnancy Related,Not pregnant or lactating
Pregnancy Related,Not pregnant or nursing
Pregnancy Related,Not pregnant  if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.
Pregnancy Related,others: pregnant or breast-feeding patients
Pregnancy Related,Patient has no childbearing potential or has negative pregnancy tests within one week prior to procedure.
Pregnancy Related,Patient with the potential for pregnancy or impregnating their partner and who do not agree to follow an acceptable birth control method to avoid conception
Pregnancy Related,Patients of childbearing potential must have a negative urine pregnancy test at screening/randomization  and must use medically acceptable methods of birth control
Pregnancy Related,Patients who are pregnant or plan to become pregnant during the study
Pregnancy Related,Patients will not be eligible for this study if they: Are pregnant or breast-feeding.
Pregnancy Related,Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Pregnancy Related,Pregnancy
Pregnancy Related,Pregnancy (based on urine test)  since this group of patients receives other drugs for malaria treatment in accordance with Peruvian national guidelines.
Pregnancy Related,Pregnancy and breast-feeding.
Pregnancy Related,Pregnancy on going or planned within 3 years
Pregnancy Related,Pregnancy or breastfeeding
Pregnancy Related,Pregnancy or breast-feeding
Pregnancy Related,Pregnancy or breast-feeding.
Pregnancy Related,Pregnancy or lactation
Pregnancy Related,Pregnancy or lactation.
Pregnancy Related,Pregnancy  breast feeding
Pregnancy Related,Pregnancy  breast feeding 
Pregnancy Related,Pregnancy  breast-feeding
Pregnancy Related,Pregnancy.
Pregnancy Related,Pregnant (positive pregnancy test) or lactating.
Pregnancy Related,Pregnant female patients  females of childbearing potential who are unwilling or unable to use adequate contraception methods.
Pregnancy Related,Pregnant female.
Pregnancy Related,Pregnant or breast feeding females
Pregnancy Related,Pregnant or breast feeding.
Pregnancy Related,Pregnant or breastfeeding
Pregnancy Related,Pregnant or breast-feeding women or planning to become pregnant during the study period or within 30 days of discontinuing study drug
Pregnancy Related,pregnant or lactating
Pregnancy Related,Pregnant or lactating females
Pregnancy Related,Pregnant or lactating females not allowed.
Pregnancy Related,Pregnant or lactating females or females of childbearing potential who are unwilling to use reliable  medically accepted methods of contraception
Pregnancy Related,Pregnant or lactating females.
Pregnancy Related,Pregnant or lactating women
Pregnancy Related,Pregnant or lactating women  as treatment involves unforeseeable risks to the participant and to the embryo or fetus
Pregnancy Related,Pregnant or lactating women.
Pregnancy Related,Pregnant or nursing women
Pregnancy Related,Pregnant patients
Pregnancy Related,Pregnant women are excluded from this
Pregnancy Related,Prior to study enrollment  women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy
Pregnancy Related,Subject is pregnant
Pregnancy Related,Subjects who are women of childbearing potential and sexually active males must be willing to use effective contraception while on study.
Pregnancy Related,The reason for non-childbearing potential  such as bilateral tubal ligation  bilateral oophorectomy  hysterectomy  or postmenopausal for >=  1 year  must be specified in the patient's case report form (CRF).
Pregnancy Related,they are nursing
Pregnancy Related,Willingness of male and female patients  if not surgically sterile  to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and follow-up periods.
Pregnancy Related,Women able to become pregnant must have a negative pregnancy test
Pregnancy Related,Women of childbearing potential (included women who were less than 1 year postmenopausal and women who became sexually active) must have been using an acceptable method of birth control (for example  hormonal contraceptive  medically prescribed IUD  condo
Pregnancy Related,Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who became sexually active) must be using an acceptable method of birth control (eg  hormonal contraceptive  medically prescribed IUD  condom in combination 
Pregnancy Related,Women of childbearing potential (includes women who are less than 1 year postmenopausal and women who become sexually active) must be using an acceptable method of birth control  .  hormonal contraceptive  medically prescribed IUD  condom in combination w
Pregnancy Related,Women of childbearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment
Pregnancy Related,Women of childbearing potential could not be pregnant or nursing
Pregnancy Related,Women of childbearing potential had to agree to use effective contraception for the duration of the study and for two weeks after the last dose
Pregnancy Related,Women of childbearing potential may not be entered if: their pregnancy tests (urine test) are positive 
Pregnancy Related,Women of childbearing potential must have a negative serum pregnancy test within 2 weeks of the first administration of chemo
Pregnancy Related,Women of childbearing potential not using a medically acceptable means of contraception.
Pregnancy Related,Women of childbearing potential who are not using effective birth control
Pregnancy Related,women of non-childbearing potential or using acceptable method of birth control.
Pregnancy Related,Women who are pregnant currently trying to conceive
Pregnancy Related,women who are pregnant or lactating.
Pregnancy Related,Women who are pregnant or nursing.
Pregnancy Related,Women who become pregnant again during study follow-up will not be eligible for re-enrollment in the trial
Pregnancy Related,Women who were pregnant or nursing
Pregnancy Related,hormonal or barrier method of birth control)
Pregnancy Related,Fecund women not currently using barrier methods of contraception
Pregnancy Related,Sexually active
Pregnancy Related,Inclusion Criteria: Healthy females  who were sexually active and at risk of pregnancy were eligible to participate in this study provided that they had regular menses occurring every 25 to 35 days (except for those women using medroxyprogesterone acetate
Receptor Status,Hormonal receptor status assessed
Receptor Status,Hormone receptor status not specified
Receptor Status,hormone receptor status: estrogen receptor positive 
Receptor Status,epidermal growth factor receptor (egfr) positive 
Receptor Status,estrogen and progesterone receptor positive 
Receptor Status,estrogen receptor positivity 
Receptor Status,estrogen receptor and / or progesterone receptor positive (by laboratory / institutional standard) at the time of initial diagnosis or determined during subsequent biopsy / surgery of metastases 
Special Characteristic of Patient,Inclusion Criteria: Patients must be adults 
Special Characteristic of Patient,Be an emancipated minor
Special Characteristic of Patient,Contact with an immunosuppressed individual.
Special Characteristic of Patient,Included in Neonatal Research Network Generic Database
Special Characteristic of Patient,NOTE: Protocol is approved for prisoner enrollment.
Special Characteristic of Patient,Premature groups: Preterm-born (32-34 weeks of gestation)
Special Characteristic of Patient,male who has not been sterilized by vasectomy for al least 6 months) within 14 days prior to study drug administration
Special Characteristic of Patient,male who has not been sterilized by vasectomy for at last 6 months) within 14 days prior to the study drug administration
Special Characteristic of Patient,Born after a gestation period of >=  32 weeks 
Special Characteristic of Patient,Inclusion Criteria: Attendance at out-patients clinics at Bristol Royal Hospital for Children  Southmead Hospital in Bristol  Weston General Hospital  The Royal United Hospital in Bath  Gloucestershire Royal Hospital in Gloucester or the Musgrove Park bra
Special Characteristic of Patient,Receive their prenatal and well-baby care from MediCal
Special Characteristic of Patient,Fewer than four years of formal education.
Special Characteristic of Patient,20 healthy subjects
Special Characteristic of Patient,Inclusion Criteria: Subjects with a live twin living in the same household who is also enrolled in this study.
Special Characteristic of Patient,Healthy subjects
Special Characteristic of Patient,Inclusion Criteria: Patients
Special Characteristic of Patient,Inclusion Criteria: All workers from a specific company  including administrative and production sections.
Special Characteristic of Patient,Inclusion Criteria: healthy subjects
Special Characteristic of Patient,Students from the Nova Southeastern University Colleges of Osteopathic Medicine and Optometry
Special Characteristic of Patient,General good health based on history and clinical examination
Special Characteristic of Patient,NOTE: This protocol is approved for prisoner participation.
Special Characteristic of Patient,elderly patients hospitalised in the internal medicine department of a suburban Parisian hopital
Special Characteristic of Patient,Accepts Healthy Volunteers: ELIGIBILITY CRITERIA include:
Special Characteristic of Patient,Accepts Healthy Volunteers: General inclusion criteria
Special Characteristic of Patient,Donors must meet one of the following criteria: Matched  related donor (6/6 or 5/6) (bone marrow donor allowed)
Special Characteristic of Patient,Inclusion Criteria: Subjects enrolled in the study will be members of the community at large
Special Characteristic of Patient,Homeless or travelers who may not be followed-up
Special Characteristic of Patient,Inclusion Criteria: Healthy volunteers
Special Characteristic of Patient,Non member of the social security or CMU
Special Characteristic of Patient,Patient non-affiliated to the social security and the protected people
Special Characteristic of Patient,Accepts Healthy Volunteers 
Special Characteristic of Patient,Anyone who does not meet the inclusion criteria.
Special Characteristic of Patient,Exclusion Criteria: Workers absent from the workplace during all the study period.
Special Characteristic of Patient,Inpatient population
Special Characteristic of Patient,Military returnees from OIF/OEF
Special Characteristic of Patient,Accepts Healthy Volunteers. Basic Inclusion Criteria:
Special Characteristic of Patient,Accepts Healthy Volunteers  
Special Characteristic of Patient,Accepts Healthy Volunteers: Inclusion/Exclusion Criteria:
Special Characteristic of Patient,Accepts Healthy Volunteers: Inclusion:
Special Characteristic of Patient,Accepts Healthy Volunteers: Key Inclusion Criteria:
Therapy or Surgery,Patients with the following symptoms or conditions are excluded: Malignancy requiring systemic cytotoxic chemotherapy.
Therapy or Surgery,All subjects requiring radiotherapy to the head and neck for a poor-prognosis malignancy will be eligible.
Therapy or Surgery,Have had systemic treatment for cancer within 30 days of entering the study.
Therapy or Surgery,if no metastatic  removed surgery must have been done since less 6 months
Therapy or Surgery,Patients with a history of tracheostomy
Therapy or Surgery,14 days or more since prior therapy and recovered from all side effects
Therapy or Surgery,Patients unable to be withdrawn for 2 weeks from AT-II antagonist or ACE- inhibitor therapy
Therapy or Surgery,Patients that are receiving or performing physical therapy regimen during the previous month from Screening  and/or will not or cannot maintain a stable physical therapy regimen throughout the course of the trial.
Therapy or Surgery,No prior allogeneic hematopoietic stem cell transplantation
Therapy or Surgery,>=  21 days since completion of prior chemotherapy  >= 6 weeks since prior Mitomycin-C
Therapy or Surgery,A minimum time period of 4 weeks should elapse between the completion of prior chemotherapy and enrollment in the study.
Therapy or Surgery,More than 2 weeks must have elapsed since previous radiation therapy and prior radiation must be less than or equal to 15% of the bone marrow.
Therapy or Surgery,Prior tandem autologous stem cell transplantations (according to clinical trial COG-ANBL0532) allowed
Therapy or Surgery,Also  chemotherapy as part of initial potentially curative therapy  
Therapy or Surgery,In VGPR or PR after salvage therapy
Therapy or Surgery,More than 2 weeks must have elapsed since previous chemotherapy and 6 weeks from previous treatment with nitrosoureas or mitomycin-C.
Therapy or Surgery,More than 3 weeks since prior chemotherapy  immunotherapy (including anti-GD2 regimen)  or biologic response modifiers and recovered
Therapy or Surgery,Prior chemotherapy is allowed as long as the patient has recovered from any toxicity
Therapy or Surgery,Radiotherapy for the treatment of a symptomatic  
Therapy or Surgery,Allowed: Local radiation therapy.
Therapy or Surgery,An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy  and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery  radiotherapy  or chemotherapy.
Therapy or Surgery,Any non-investigational  anti-cancer therapy within 4 weeks prior to Day 1.
Therapy or Surgery,Are receiving or plan to receive chemotherapy for cancer.
Therapy or Surgery,At least 21 days since prior radiotherapy and recovered
Therapy or Surgery,Candidate for curative treatment such as prostatectomy or radiotherapy
Therapy or Surgery,Cannot have received any prior chemotherapy for this disease or cannot have received chemotherapy for any other cancer in the past 5 years.
Therapy or Surgery,Chemotherapy Not specified
Therapy or Surgery,Chemotherapy within four weeks prior to study drug administration.
Therapy or Surgery,Chemotherapy  if given  should have been given post-operatively  ie  patients who received neoadjuvant chemotherapy are ineligible
Therapy or Surgery,Cytotoxic chemotherapy.
Therapy or Surgery,Excluded within 20 days prior to study entry: Radiation therapy.
Therapy or Surgery,Excluded within 30 days prior to study entry: Radiation therapy.
Therapy or Surgery,Excluded: Chemotherapy  hormonal therapy  or other immunotherapy.
Therapy or Surgery,Excluded: Radiation therapy.
Therapy or Surgery,Exclusion Criteria: CNS metastases  Concomitant myelosuppressive radiotherapy  C/T  hormonal therapy or immunotherapy.
Therapy or Surgery,Exclusion Criteria: No prior chemotherapy for recurrent / metastatic adenoid cystic carcinoma
Therapy or Surgery,Exclusion Criteria: Women who have had previous cryotherapy of the cervix  LEEP or cervical conization
Therapy or Surgery,For patients with previous radiosurgery or enhanced radiotherapy  based on neurosurgeon's judgment  the area of enhancement can be removed during the surgery
Therapy or Surgery,high-dose chemotherapy requiring hematopoietic stem-cell reinfusion.
Therapy or Surgery,History of cytotoxic chemotherapy within one month of study entry
Therapy or Surgery,May have had no prior chemotherapy or up to 1 prior treatment regimen with immunotherapy or chemotherapy
Therapy or Surgery,More than 2 months since prior autologous stem cell transplantation  myeloablative therapy  total-body irradiation  whole abdominal radiotherapy  or therapeutic >= I-MIBG
Therapy or Surgery,More than 2 prior chemotherapy regimens for the treatment of advanced melanoma.
Therapy or Surgery,More than 2 weeks since prior radiation therapy
Therapy or Surgery,Must have received either whole or partial breast radiotherapy by external beam or brachytherapy after completion of primary surgery
Therapy or Surgery,Must have undergone complete surgical removal of invasive cancer by mastectomy or lumpectomy with either sentinel or axillary lymph node dissection within the past 84 days
Therapy or Surgery,Mycobacteriosis requiring maintenance chemotherapy.
Therapy or Surgery,No prior chemotherapy
Therapy or Surgery,No prior chemotherapy for this disease
Therapy or Surgery,No radiation therapy  prior biological therapy or surgery within 4 weeks prior to first dose of study agent.
Therapy or Surgery,Other chemotherapy.
Therapy or Surgery,Patients entering the Phase 1 portion of the study may have received up to two prior chemotherapy programs including adjuvant or neoadjuvant therapy.
Therapy or Surgery,Patients entering the Phase 2 portion of the study may have received only one prior chemotherapy program including adjuvant or neoadjuvant therapy for NSCLC.
Therapy or Surgery,Patients heavily pretreated with chemotherapy and radiation  defined as follows: >=  12 cycles of an alkylating agent-containing regimen  or
Therapy or Surgery,Patients likely to undergone chemotherapy  surgery or radiotherapy during 2 weeks before PET-TDM.
Therapy or Surgery,Patients may have received multiple treatments of radioactive iodine  one prior biologic treatment  and at least half of the patients will have had no prior chemotherapy for metastatic disease
Therapy or Surgery,Patients may have received up to 2 prior systemic chemotherapy regimens (including dacarbazine  and alternative dosing schedule of temozolomide)
Therapy or Surgery,patients who have not received chemotherapy and whose primary surgery was completed more than 8 weeks before starting the study treatment
Therapy or Surgery,patients whose chemotherapy was started more than 8 weeks after completion of primary surgery or whose chemotherapy was completed more than 8 weeks before starting the study treatment
Therapy or Surgery,Patients with a planned coronary intervention.
Therapy or Surgery,patients with ray-treatment or chemotherapy within the last three months
Therapy or Surgery,Planned future chemotherapy is also allowed after the one month evaluation.
Therapy or Surgery,Previous bone marrow or stem cell transplant.
Therapy or Surgery,previously irradiated.
Therapy or Surgery,Prior chemo therapy < 21 days prior to registration.
Therapy or Surgery,Prior full field radiotherapy < 28 days or limited field radiotherapy < 14 days prior to registration.
Therapy or Surgery,prior immunotherapy (up to 2 regimens) or prior radiotherapy is permitted but at least 4 weeks must have elapsed prior to enter study
Therapy or Surgery,Prior radiation therapy will be allowed
Therapy or Surgery,Prior surgery  chemotherapy  hormonotherapy for breast cancer
Therapy or Surgery,Prior treatment for another cancer in the last 5 years
Therapy or Surgery,radiation of the ovaries
Therapy or Surgery,radiotherapy during study or within 4 weeks prior to study entry
Therapy or Surgery,Radiotherapy must have been completed at least 4 weeks prior to study drug administration.
Therapy or Surgery,Radiotherapy Not specified
Therapy or Surgery,Received chemotherapy or radiation therapy within 30 days of study entry.
Therapy or Surgery,Scheduled to undergo definitive radiation therapy (either brachytherapy or external beam)
Therapy or Surgery,Subject is receiving systemic chemotherapy.
Therapy or Surgery,Three or fewer prior chemotherapy regimens (including a platinum-based therapy).
Therapy or Surgery,Toxoplasmic encephalitis requiring suppressive therapy.
Therapy or Surgery,Visceral Kaposi's sarcoma requiring chemotherapy and/or irradiation.
Therapy or Surgery,contraindication for dual antiplatelet therapy for the following 6 months
Therapy or Surgery,Use of any investigational therapy within 30 days  or 5 half-lives  whichever is longer  and/or use of AD immunotherapy prior to screening.
Therapy or Surgery,Are currently being treated with one to three (maximum) marketed and approved AEDs and are known to take their medications as directed
Therapy or Surgery,Hormonal therapy for patients with hormone receptor-positive disease allowed
Therapy or Surgery,Patients may have received or be receiving hormonal therapy
Therapy or Surgery,Exclusion Criteria: Patients with a known or suspected difficult intubation
Therapy or Surgery,Patients must have fully recovered from the toxic effects of prior therapy.
Therapy or Surgery,Prior cardiac or renal allografts
Therapy or Surgery,History of cholecystectomy.
Therapy or Surgery,Concurrent Treatment: Allowed:
Therapy or Surgery,Organ allografts.
Therapy or Surgery,Inclusion Criteria: Heart transplantation (> 6 months post-operation)
Therapy or Surgery,Patients having a ligament reconstruction to the study knee.
Therapy or Surgery,Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Therapy or Surgery,PEG feeding
Therapy or Surgery,Women receiving hormonal therapy  including hormone replacement  any estrogen antagonist/agonist  or oral contraceptives  must have been maintained on a stable dose and regimen for at least 8 weeks and be willing to continue the same regimen for the durat
Therapy or Surgery,Recipient of heart transplant
Therapy or Surgery,Inclusion Criteria: Kidney or heart transplant recipients
Therapy or Surgery,Liver transplant patients
Therapy or Surgery,Have received a blood transfusion within the 3 months before administration of study medication
Therapy or Surgery,No prior chemotherapy or prior vaccine or immunotherapy.
Therapy or Surgery,Up to 1 prior biologic/targeted therapy regimen is allowed
Therapy or Surgery,women receiving hormonal therapy  including hormone replacement  any estrogen antagonist/agonist  or oral contraceptives  must have been maintained on a stable dose and regimen for at least 8 weeks and continue same regimen during the study.
Therapy or Surgery,Women receiving hormonal therapy  including hormone replacement  any estrogen antagonist/agonist  or oral contraceptives  must have been maintained on a stable dose and regimen for at least 8 weeks and willing to continue the same regimen for the duration
Therapy or Surgery,Patients for whom previously treatment with dopamine agonists needed to terminate because of induction of psychosis  
Therapy or Surgery,Mechanically-ventilated during the first week of life
Therapy or Surgery,Mechanically-ventilated for at least 48 hours
Therapy or Surgery,At least 4 weeks must have elapsed and patients must have recovered from all side effects associated with surgery.
Therapy or Surgery,Patients requiring fissure sealant due high caries risk.
Therapy or Surgery,Had  or during the course of the study are anticipated to have  any organ transplantation (heart  liver  lung  kidney  or bone marrow)
Therapy or Surgery,If using a vagal nerve stimulator  it must have been implanted at least 5 months prior to Visit 1
Therapy or Surgery,Patient implanted with a wireless-transmission-enabled Medtronic ICD or CRT-D
Therapy or Surgery,Patients having any surgery to the study joint within the previous 12 months prior to Screening  and surgery to the contralateral knee or other weight-bearing joint if it would interfere with the study assessments.
Therapy or Surgery,Patients who can tolerate a hemodialysis treatment with blood flow rates of 300 ml per minute.
Therapy or Surgery,Prior biologic or immunotherapy < 14 days prior to registration
Therapy or Surgery,Patient who has been under a none satisfied antihypertensive treatment  and for whom this treatment was stopped at least 2 weeks prior to inclusion.
Therapy or Surgery,Major surgery and related complications not resolved within 12 weeks prior to Day 1.
Therapy or Surgery,Treatment with any investigational product in the last 1 month before study entry.
Therapy or Surgery,No hormone replacement therapy within the 90 days immediately prior to the screening evaluation.
Therapy or Surgery,requires IOP-lowering therapy in both eyes
Therapy or Surgery,Contraindication to ??-adrenoceptor antagonist therapy or brimonidine therapy
Therapy or Surgery,Patients who underwent major surgery within 3 months prior to screening.
Therapy or Surgery,History of surgical or device  
Therapy or Surgery,Have had implantation of an automated implanted cardiac defibrillator (AICD) or synchronization device within the preceding 7 days
Therapy or Surgery,Have previously undergone destructive ganglionectomy affecting C2/C3 occipital and/or trigeminal distribution or have an occipital blockade or radio frequency procedure currently in effect
Therapy or Surgery,Implanted stimulator (such as a pacemaker)
Therapy or Surgery,Patients must have failed to respond or clearly progress to previous therapy on or before day +100 posttransplant.
Therapy or Surgery,Excluded: Antiretroviral treatment or experimental treatment within 2 weeks of entry.
Therapy or Surgery,Must have been taking a stable regimen of accepted HIV anti-retroviral treatments for at least two weeks prior to study entry
Therapy or Surgery,Patient has had a bare metal stent in the six weeks prior to randomization
Therapy or Surgery,Patient has had a drug eluting stent in the year prior to randomization
Therapy or Surgery,Inclusion Criteria: Coronary artery stenting between March 1  2001 and March 30  2006
Therapy or Surgery,Exclusion Criteria: Presence of ventriculoperitoneal shunt
Therapy or Surgery,Antiretroviral therapy.
Therapy or Surgery,History of allogeneic hematopoietic cell transplant (HCT).
Therapy or Surgery,Inclusion Criteria: Consecutive patients undergoing percutaneous coronary intervention at an enrolling center by study investigators
Therapy or Surgery,Patient requires IOP-lowering therapy in both eyes
Therapy or Surgery,Patients having significant surgery of lower limbs (hip  ankle  foot) that may interfere with knee assessments.
Therapy or Surgery,Planned elective spinal surgery in which the modified Jackson table will be used.
Therapy or Surgery,Received more than one month of prior antiretroviral therapy
Therapy or Surgery,Require IOP-lowering therapy in each eye
Therapy or Surgery,Use of antiretroviral therapy within 3 months of pre-study screening.
Therapy or Surgery,Use of any experimental therapy within 3 weeks prior to baseline evaluations done prior to enrollment.
Therapy or Surgery,Who underwent major surgery within 3 months prior to screening.
Therapy or Surgery,+/- surgery)
Therapy or Surgery,Acceptable candidate for coronary artery bypass surgery (CABG)
Therapy or Surgery,Acute therapy for intercurrent infections so long as that therapy is not an excluded medication of an excluded opportunistic infection.
Therapy or Surgery,Allowed: Blood transfusion.
Therapy or Surgery,Allowed: Blood transfusions for hematologic toxicity.
Therapy or Surgery,Allowed: Blood transfusions.
Therapy or Surgery,Alternatively  patients can enter after refusing standard curative therapy only if therapy was clearly discussed with the treating physician or if they have failed another biologic therapy due to toxicity.
Therapy or Surgery,Anticipated spinal fusion surgery
Therapy or Surgery,Any number of prior systemic therapies is allowed.
Therapy or Surgery,Any other experimental therapy within 1 week of entry.
Therapy or Surgery,Any spinal manipulation within 48 hours
Therapy or Surgery,Aortic surgery within 6 months
Therapy or Surgery,Are currently receiving chronic dialysis or have the expectation that dialysis will be required during the next 12 months.
Therapy or Surgery,At least 28 days since prior surgery and recovered
Therapy or Surgery,At least 3 weeks must have elapsed since prior treatment.
Therapy or Surgery,Be admitted for heart transplant surgery or have had a heart transplant 
Therapy or Surgery,Be an appropriate candidate for the surgical procedures required for this study
Therapy or Surgery,bilateral oophorectomy
Therapy or Surgery,Biologic therapy Not specified
Therapy or Surgery,bone marrow transplant
Therapy or Surgery,Cardiac surgery patients
Therapy or Surgery,cardiopulmonary reanimation on the accident scene or dying immediately after hospital admission
Therapy or Surgery,Chemoprophylaxis for candidiasis and herpes simplex.
Therapy or Surgery,Concurrent Treatment: Excluded:
Therapy or Surgery,Contra-indications to lumbar puncture
Therapy or Surgery,coronary artery bypass graft (CABG)  or
Therapy or Surgery,Currently require mechanical ventilation  ultrafiltration  or hemodialysis 
Therapy or Surgery,Deviation from standardised surgical procedure
Therapy or Surgery,ECT treatment within the past two months
Therapy or Surgery,Eligible for both treatment interventions
Therapy or Surgery,emergency endotracheal intubation
Therapy or Surgery,emergency surgery
Therapy or Surgery,Endocrine therapy Not specified
Therapy or Surgery,Excluded within 14 days prior to study entry: Transfusion.
Therapy or Surgery,Excluded: Prior treatment for CMV retinitis.
Therapy or Surgery,Exclusion Criteria: Have a history of surgery of the affected fingernails
Therapy or Surgery,Exclusion Criteria: Patients who received thrombolytic therapy (intravenous or intraarterial)
Therapy or Surgery,Exclusion Criteria: Previous surgery of the ascending aorta  or surgery planned
Therapy or Surgery,Exclusion Criteria: Recent cervical spine injuries or surgeries
Therapy or Surgery,Exclusion Criteria: Subjects receiving escalating doses of immunotherapy  oral immunotherapy or short course (rush) immunotherapy for rhinitis
Therapy or Surgery,gastric banding) intervention for obesity
Therapy or Surgery,Have had treatment with ABC.
Therapy or Surgery,Have previously been treated with occipital nerve stimulation
Therapy or Surgery,History of non-compliance with other therapies.
Therapy or Surgery,history of percutaneous coronary intervention (primarily PTCA with or without stent placement)
Therapy or Surgery,History of solid organ or hematological transplantation.
Therapy or Surgery,History of splenectomy
Therapy or Surgery,Hormone replacement therapy.
Therapy or Surgery,Hospitalization in the previous 2 weeks for a medical condition or surgery for which recovery overlaps with the study onset and duration
Therapy or Surgery,Immunoglobulin therapy (except single dose or for hypogammaglobulinemia).
Therapy or Surgery,Inclusion Criteria: Elective surgery
Therapy or Surgery,Inclusion Criteria: elective surgery requiring endotracheal intubation
Therapy or Surgery,Inclusion Criteria: Multilevel surgery
Therapy or Surgery,Inclusion Criteria: Patients for elective surgery  requiring general endotracheal anesthesia
Therapy or Surgery,Inclusion Criteria: Patients scheduled for non emergent surgery under either general or regional anesthesia deemed to have moderate to high physiologic stress
Therapy or Surgery,Inclusion Criteria: Patients undergoing noncardiac surgery who fulfill the following criteria:
Therapy or Surgery,INCLUSION CRITERIA: The study population will be drawn from patients undergoing CABG or CABG plus valve surgery using a bypass pump
Therapy or Surgery,indication for bypass surgery
Therapy or Surgery,Intraocular surgery in the study eye within 60 days prior enrollement
Therapy or Surgery,Major elective surgery planned in study period
Therapy or Surgery,Major surgery < 28 days prior to registration.
Therapy or Surgery,Major surgery within 4 weeks prior to Day 1.
Therapy or Surgery,Major surgery within 8 weeks prior to the Baseline Visit
Therapy or Surgery,Major surgical procedure or trauma within 2 months
Therapy or Surgery,Not scheduled for joint replacement surgery during the study period
Therapy or Surgery,Ongoing or chronic dialysis (either hemodialysis or continuous ambulatory peritoneal dialysis)
Therapy or Surgery,OR any 3 of 9 risk criteria: undergoing major surgery [i.e.  intraperitoneal  intrathoracic  or orthopedic surgery]
Therapy or Surgery,Other experimental therapy.
Therapy or Surgery,Other indicated/planned concomitant surgery
Therapy or Surgery,Patient has had gastric reduction surgery.
Therapy or Surgery,Patient has had neurolytic or neurosurgical treatment for PHN.
Therapy or Surgery,Patient must have recovered from toxicity of prior therapy
Therapy or Surgery,Patient received any of the following within the specified time period prior to initiation of treatment in this study: Chemotherapy  major surgery  significant traumatic injury  or irradiation  whether conventional or investigational within 28 days
Therapy or Surgery,Patient undergoing intracranial surgery  carotid endarterectomy  or retinal surgery
Therapy or Surgery,Patients enrolled in the adjuvant setting must have received standard curative therapy  e.g.  surgery  radiation
Therapy or Surgery,Patients may have received prior surgery
Therapy or Surgery,Patients receiving any articular procedures  such as transplants  to the study knee.
Therapy or Surgery,Patients should have recovered from prior surgery or radiation therapy
Therapy or Surgery,Patients undergoing liver resection other than left lateral hepatic sectionectomy.
Therapy or Surgery,Patients who can tolerate a hemodialysis session lasting up to 9 hours.
Therapy or Surgery,Patients who have other cardiac surgeries or procedures planned but not yet performed during the duration of the study
Therapy or Surgery,Patients who have undergone surgery for the treatment of PD 
Therapy or Surgery,Patients with previous gastrointestinal surgery other than appendectomy or cholecystectomy.
Therapy or Surgery,Patients within 6 months of a coronary intervention  including PCI or CABG.
Therapy or Surgery,Percutaneous coronary intervention or cardiac surgery within 90 days of study start
Therapy or Surgery,Planned surgical procedure that can impact the conduct of the study
Therapy or Surgery,predicted difficult intubation
Therapy or Surgery,Pre-treatment with devices other than balloon angioplasty  although direct stenting is allowed
Therapy or Surgery,Previous laser therapy
Therapy or Surgery,previous percutaneous coronary intervention (PCI)  or
Therapy or Surgery,Prior bariatric surgery
Therapy or Surgery,prior CABG
Therapy or Surgery,PRIOR CONCURRENT THERAPY: Biologic therapy
Therapy or Surgery,PRIOR CONCURRENT THERAPY: See Disease Characteristics
Therapy or Surgery,Prior cranial manipulative treatment/craniosacral therapy
Therapy or Surgery,Prior to aortic root surgery
Therapy or Surgery,Prior Treatment: Excluded within 20 days prior to study entry:
Therapy or Surgery,Prior Treatment: Excluded within 30 days prior to study entry:
Therapy or Surgery,receiving physical or occupational therapies for shoulder pain
Therapy or Surgery,Recent intraocular surgery
Therapy or Surgery,requires salvage intervention as defined by the ACC/AHA guidelines as being ongoing cardiopulmonary resuscitation on the way to the operating room
Therapy or Surgery,scheduled for non-emergent abdominal hysterectomy (with or without salpingo-oophorectomy) or myomectomy under general anesthesia
Therapy or Surgery,Six weeks since major surgery (three weeks since minor surgery)
Therapy or Surgery,Subject has had (coronary artery bypass graft) CABG or vascular surgery within 30 days PRIOR TO index procedure (percutaneous coronary intervention is permissible provided cardiac enzymes are normal within 24 hours of index procedure)  OR has planned CABG
Therapy or Surgery,Subject has undergone prior stenting of the ipsilateral carotid artery.
Therapy or Surgery,Subject meets one or more of the high surgical risk criteria .
Therapy or Surgery,Subject must have adequate anticoagulant therapy
Therapy or Surgery,Subjects must have fully recovered from the effects of any prior surgery  chemotherapy  or radiation therapy
Therapy or Surgery,Subjects undergoing spine surgery in the prone position.
Therapy or Surgery,Such patients will receive any appropriate treatment prior to surgery
Therapy or Surgery,Surgery Not specified
Therapy or Surgery,Systemic treatment with glucocorticoids within the 12 months prior to study entry
Therapy or Surgery,Transfusions.
Therapy or Surgery,undergoing emergent/urgent surgery
Therapy or Surgery,undergoing major vascular surgery  .  vascular surgery except arteriovenous shunt  vein stripping procedures  and carotid endarterectomies)
Address,Houston  Texas
Address,Orinda  California
Address,Participants must live within easy commuting distance of Duke Medical Center  Durham  North Carolina
Address,Must live in the United States
Address,Must live in selected communities in eastern Massachusetts
Address,Foreign (non-U.S.) residence
Address,Must live within 50 miles or one hour of the study site and have reliable transportation to the site.
Address,Lives more than 100 miles from alcohol treatment facility.
Address,Homeless or unstable residence.
Address,Lives within 50 miles of the study site.
Address,Lives within 50 miles of the study site  has a stable living situation  and a reliable source of collateral reporting.
Address,Residence in a specific domicile  shelter  or prison cell block within 6 months of a known outbreak of MDR TB.
Address,Living in the geographic area surrounding Kings County Hospital in Brooklyn  New York
Address,Is a resident of the Temple-Belton  Texas area.
Address,INCLUSION CRITERIA: Patients must live in the Metropolitan Washington Area.
Address,Live within adequate commuting distance to the treatment center.
Address,Other: Must reside within 60 km (37.5 miles) of a treatment site
Address,Residence outside of the St
Address,Are a resident of the United States of America.
Address,Residence making follow-up unlikely (eg lives outside U.S.)
Address,resides within 30 miles of Duke University
Address,They reside in the United States and will be available for at least six months of follow up.
Address,Patients living in USA  Puerto Rico  Australia  Brazil  Singapore  and Thailand can be at least 12 years old (need consent of parent or guardian if under 18).
Address,Mary's Hospital  Marianhill  South Africa
Address,polyclinics in Chitungwiza District  Zimbabwe.
Address,Reside within 15 km of Mulago Hospital  the study site.
Address,Live in a commutable distance to the University of Pennsylvania and agree to followup visits.
Address,Lived within a 9-county area surrounding the city of Cincinnati
Address,reside in the Metropolitan Washington  D.C
Address,History of varicella or long-term (greater than or equal to 30 years) residence in the continental USA.
Address,Must be a resident of the Washington DC area.
Address,New York Metro Area resident
Address,Resident of the New York Metro Area
Address,Local residence
Address,Live in the following counties at the time of diagnosis: Churchill  Lyon  Mineral  Storey  Douglas  Carson City  Nevada  and Kings County  California
Address,Live in Ottawa County  Oklahoma
Address,residence in one of the study communities
Address,History of Varicella or long-term resident (greater than or equal to 30 years) in the continental United States.
Address,Exclusion: patients living outside the greater Boston area
Address,Residence within 40 miles of Wills Eye Hospital in Philadelphia  PA
Address,Young population Less than 30 Resident of Kaohsiung metropolitan  Taiwan
Address,Planning to live in the greater New Brunswick  NJ  area for at least 3 years
Address,Live within a one-hour drive of the study site
Address,Residence within 20 km of Kampala city
Address,Resident of Zomba or Blantyre Districts  Malawi
Address,Live in Kisumu District  Kenya
Address,new york city local address
Address,Maximum age 18 years In France and the United Kingdom
Address,Lives in the Kansas City area
Address,reside in targeted counties
Address,Must live in the Northeast Ohio area.
Address,Planning to live in the San Francisco Bay Area in the year following study entry
Address,Smoker lives in the household
Address,Plans to live in the San Francisco Bay Area for the next 12 months
Address,Lives in a nursing home
Address,Single live intrauterine fetus in cephalic presentation
Address,Family lives in the San Jose area
Address,INCLUSION CRITERIA: Patients who self-identify as Hispanic and currently live in the United States.
Address,Live in the USA or Canada.
Address,Place of Residence: Child and participating parents must live in a rural county and within the same house.
Address,plan to live in the area for 9 months  report upset with CR function dependence or behavioral occurrences.
Address,Plans to live in area for 8 months
Address,plan to live in the area for 6 months  and
Address,Participants must live in San Diego and meet all of the following inclusion criteria: Has VA primary care provider for heart failure care
Address,live in a private home
Address,Patients who at admission did not live in the Funen County.
Capacity,Mental incapacity  unwillingness or language barrier precluding adequate understanding or cooperation
Capacity,Confusion or other factors that would impair ability to assess symptoms
Capacity,Unable to sustain a breath-hold for 25 seconds
Capacity,Unable to remain in supine position for at least 60 minutes
Capacity,Able to understand a written informed consent and comply with the study protocol
Capacity,unable to complete neuropsychological testing
Capacity,Subjects must be able to show efficient use with a jet nebulizer
Capacity,Subjects unable to follow up for study visits
Capacity,Subject is willing and able to complete required follow-up
Capacity,Must be able to complete the micturition diary
Capacity,Availability for follow-up during the study.
Capacity,Patient capable of understanding(including) the advantages and the risks of the try
Capacity,Patients who are unable to undergo radical hysterectomy for complication of excessive obesity  liver cirrhosis  or bleeding tendency
Capacity,Ambulatory and able to use a toilet independently and without difficulty.
Capacity,You must be able to swallow the LY317615 tablets
Capacity,Ability to visit the doctor's office for scheduled visits
Capacity,You are a woman of childbearing age and unwilling or unable to use effective contraceptive.
Capacity,Are capable and willing to do specified study procedures
Capacity,Patients must be able to swallow capsules
Capacity,Able to visit the doctor's office at least every 14 days during the actual treatment
Capacity,Ambulatory and capable of self-care(eg  up and about greater than 50% of waking hours)
Capacity,Must be able to come in for follow-up visits for the duration of the study.
Capacity,able to visit the doctor's office every 28 days for at least 6 months
Capacity,Subjects who were available for the duration of the study (from enrollment to study completion).
Capacity,Ability to complete the follow-up period of 84 days
Capacity,who were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period
Capacity,Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol
Capacity,who are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period
Capacity,Ability to complete follow-up period of 188 days as required by the protocol
Capacity,Ability to complete the follow-up period of 90 days (single-dose groups) or 120 days (two-dose group) as required by the protocol
Capacity,Persons being able to participate in the trial for 1 month from the inoculation of the trial vaccine to the completion of the trial.
Capacity,Persons being able to be contacted (by phone  hospital visit or house visit) by the trial staff at the time of testing after 28 days from the inoculation of the trial vaccine.
Capacity,Persons judged to be impossible or difficult to be contacted for requesting hospital visits to carry out clinical evaluation and tests during the trial term.
Capacity,Unable to follow study procedures  illiteracy  or poor comprehension of the language used in the psychometric tests
Capacity,Able to perform activities of daily living without considerable assistance
Capacity,Available for follow-up for up to 5 years
Capacity,Subjects lacks the capacity to provide informed consent
Capacity,the subject is able to return for frequent follow-up care
Capacity,subjects unable or unwilling to comply with study procedures or illiterate
Capacity,Not able to adhere to the protocol.
Capacity,Candidate will not be available for the next 18 weeks (2 weeks run-in  12 weeks study  4 weeks follow-up)
Capacity,Able to be regularly followed up.
Capacity,Patient unable to be regularly followed-up.
Capacity,Subjects who are able to use a Diskus inhaler
Capacity,Subjects or their parent/ guardian who are able to understand and complete a DRC
Capacity,Able to follow 2-step commands
Capacity,Able to walk without assistive devices
Compliance,Subjects must be available for follow-up visits to comply with the requirements of the protocol.
Compliance,Inability to comply with the study protocol
Compliance,History of noncompliance with prior medical care
Compliance,Willing to comply with all study requirements
Compliance,Be able to comply with the requirements of the entire study
Compliance,Able to comply with study procedures
Compliance,Subjects unlikely to comply with study procedures
Compliance,Concerns for subject's compliance with the protocol procedures
Compliance,Concurrent or history of psychiatric disease that would interfere with ability to comply with study protocol or give informed consent
Compliance,Subjects unlikely to comply with protocol
Compliance,Able to comply with study procedures.
Compliance,Willing and able to comply with all study requirements
Compliance,Able to understand and comply with planned study procedures
Compliance,Have demonstrated compliance with the study medication and treatment visits
Compliance,In addition  patients non-compliant with study medication during 2 ?€??? 4 week study periods
Compliance,Must comply with all study procedures and be literate.
Compliance,Understand and sign informed consent document  able to communicate with the investigator  and understand and comply with the requirements of the study.
Compliance,Patients unwilling to  or unable to  comply with the protocol
Compliance,History of non-compliance to medical regimens or patients who are considered potentially unreliable and/or not cooperative
Compliance,Subjects unlikely to comply with the requirements of the protocol
Compliance,Able to comply with study procedures
Compliance,Willing and able to comply with all study requirements
Compliance,Be able to give informed consent and comply with study procedures
Compliance,Ability to understand and comply with planned study procedures
Compliance,Any other clinical condition or prior therapy that  in the opinion of the clinic physician  would make the subject unsuitable for the study or unable to comply with the dosing requirements
Compliance,Able to understand and comply with study requirements
Compliance,Patient compliance doubtful.
Compliance,Subjects must be willing and able to comply with the requirements of the protocol.
Compliance,Patient able to comply with the protocol
Compliance,Willing to comply with all study-related procedures
Compliance,Inability to comply with follow-up visits
Compliance,Able to comply with study procedures and follow-up examinations
Compliance,Able to comply with the protocol
Compliance,Unlikely to comply with protocol.
Compliance,Subjects with high probability for compliance and completion of the study
Compliance,Subject will comply with protocol  in the opinion of the investigator.
Compliance,Persistent non compliance with taking medication
Compliance,Subject can comply with the protocol requirements
Compliance,Inability for treatment compliance.
Compliance,Suspicion that patient compliance will be poor
Compliance,Expect to comply with protocol procedures and schedule
Compliance,Perceived inability to comply with the study protocol
Compliance,Inability to comply with study requirements.
Compliance,History of poor compliance (Missing two or more clinic appointments in the past year).
Compliance,Subject must be willing to comply with study-mandated evaluations
Compliance,Inability to comply to the protocol
Compliance,Able to understand and comply with planned study procedures.
Compliance,History of non-compliance with other therapies
Compliance,A participant whom the investigator believes can and will comply with the requirements of the protocol.
Compliance,Ability to comply with all study requirements
Compliance,Good compliance
Compliance,Expected bad compliance
Compliance,failure to comply with study CLIC477D2303
Compliance,Compliance with taking HU treatment of at least 70 % for 6 months prior to study entry
Compliance,Be likely to comply with the study protocol
Compliance,compliance (pt not taking at least 85% of two week placebo were excluded)
Compliance,Subjects who in the investigator's opinion are unlikely to complete the 48 week study period or unlikely to comply with the dosing schedule and protocol evaluations.
Compliance,Compliance by the patient seems guaranteed  and the patient seems to be able to understand and complete the patient diary.
Compliance,Suspicion of abuse or non-compliance
Compliance,Ensured compliance
Compliance,Participant is likely to comply with the study treatment during the study period
Compliance,would limit compliance with study requirements
Compliance,Probability of poor compliance and termination of the study
Compliance,Be willing to comply with study requirements if they meet study eligibility criteria.
Compliance,Compliance by the patient seems guaranteed  and patient seems to be able to understand and complete the patient diary.
Compliance,Poor compliance with the visit schedule or medication intake in the previous brivaracetam trial
Compliance,Parents of study participants must agree to comply in good faith with the conditions of the study  including attending all of the required baseline and follow-up assessments.
Compliance,Non-pregnant females of childbearing potential must comply with contraceptive restrictions.
Compliance,Able to provide written informed consent and comply with study protocol
Compliance,Non-compliance
Compliance,Are able to comply with study procedures and visits
Compliance,Expectation of protocol compliance
Compliance,Patients with poor compliance
Compliance,Expected non-compliance with follow-up or study treatment
Compliance,Inability to comply with study requirements.
Compliance,Noncompliance with current medical regimen
Compliance,Expect to comply with protocol procedures and schedule
Compliance,Patients unable to comply with the requirements for the trial.
Compliance,Foreseen difficulties with study compliance  especially the long-term follow-up
Compliance,Unable to comply with the protocol.
Compliance,Non compliance
Compliance,Poor compliance to treatment and follow up
Compliance,Patients who cannot comply with the study requirements
Compliance,compliance with daily questionnaire
Compliance,Be able to comply with follow up over two years.
Compliance,able to comply with study procedures and protocol
Compliance,Must understand the requirements of the study and agree to comply with the study protocol.
Compliance,There is a risk of non-compliance with study procedures
Compliance,Problem of compliance
Compliance,Expected to comply with protocol
Compliance,expectation of protocol compliance
Device,Mechanical assist device
Device,intrauterine device (IUD)  oral contraceptives  Depo-Provera
Device,Has intrauterine device (IUD) or subdermal contraceptive implant 
Device,(3) an aneurysm clip in their brain
Device,Presence of pacemaker or ICD
Device,Patients with pacemaker
Device,Catheter likely needed for 2 weeks or less
Device,Patient with an implanted pacemaker or defibrillator
Device,Have other implantable devices such as pacemakers
Device,Implantable cardioverter defibrillator
Device,Subject is implanted with intracranial electrodes.
Device,Subject is under constant medical supervision while implanted with the intracranial electrodes.
Device,Subject is implanted with a medical device that might interfere with the eRNS
Device,intrauterine progesterone contraceptive system
Device,patient requires the use of invasive ventilatory support
Device,patient requires the use of noninvasive ventilatory support while awake and in an upright position
Device,Have a mechanical tricuspid prosthesis
Device,Must receive a commercially available Guidant CRT-P or CRT-D device
Device,A respirator with a device for delivery of gaseous NO to the inspiration gas and equipped with analysis tools for lung mechanics
Device,Cervical cap
Device,8 weeks for oral preparations or progestogen containing intrauterine device (IUD).
Device,Comprehension of PCA and virtual reality device
Device,Has cardiac pacemaker or other electromedical implant
Device,Devices incompatible to MR studies (eg pacemakers  ear implants  etc.)
Device,On Ventilator
Device,intra-uterine device
Device,barrier contraceptive with spermicide
Device,Have a tricuspid prosthesis
Device,Subjects with an existing ICD or CRT device
Device,Patient has received a drug eluting stent within the last 1 year.
Device,Presence of cardiac implants (ie implantable defibrillators)
Device,Presence of previously placed intravascular stent or intravascular graft in the ipsilateral distribution
Device,second or third degree heart block without a pacemaker
Device,No cochlear implant
Device,Permanent pacemaker 
Device,Pre-existing endocardial pacing leads 
Device,Patient has an epicardial ventricular lead system.
Device,Implanted ventricular pacing device
Device,concomitant valve surgery
Device,cardiac pacemaker
Device,Subjects who are able to use a Diskus inhaler
Device,Ureteral stent
Device,Nephrostomy tube
Device,Required pre-operative intra-aortic balloon pump (IABP)
Device,intrauterine device (IUD)
Device,Placement of a permanent central venous line
Device,Currently using a pacemaker
Device,Has an implantable cardioverter defibrillator
Diet,Have no regular care provider present at meals.
Diet,Dietary calcium-to-protein ratio (in mg:g  as assessed by 7-day food diary) does not exceed 13
Diet,Nutritional support (for children with wasting syndrome and/or malnutritional) including hyperalimentation (TPN) of dietary supplements.
Diet,Unable to tolerate the standard diet required for the study.
Diet,Diet will be lactose free  maximum 7 g fat/day with unlimited calorie intake
Diet,EXCLUSION CRITERIA: Subject non-compliance with restricted diet.
Diet,Patient on a regular diet without difficulties.
Diet,Low carbohydrate diet (less than 150 g/day) for 3 days preceding the OGTT
Diet,patients following a low sodium diet
Diet,Ability to eat solid food three meals per day
Diet,Diet
Diet,Usual and customary diet maintained throughout study  eg  medium-chain triglyceride oil
Diet,Must maintain low calcium diet (less than 800 mg calcium daily)
Diet,Gastrointestinal: No requirement for special diet or additives
Diet,No diet that would preclude taking study medications
Diet,Grapefruit juice
Diet,Already on unusually restrictive diet
Diet,Have changes in diet or physical activity that might explain changes in body fat.
Diet,Willing to adhere to dietary restrictions as required during the study.
Diet,Are dieting or doing heavy exercising.
Diet,No concurrent grapefruit juice
Diet,No concurrent grapefruit juice or grapefruit
Diet,No concurrent diet high in soy products
Diet,Other: No concurrent grapefruit or grapefruit juice
Diet,Use of herbs  high-dose vitamins  or non-traditional diets
Diet,Grapefruit juice
Diet,No adherence to vegan diet or other special dietary requirements that would preclude study participation
Diet,No concurrent grapefruit juice
Diet,Omnivorous diet
Diet,Follows the ketogenic diet.
Diet,At least 1 week since prior grapefruit juice
Diet,Able to follow dietary restrictions associated with the protocol.
Diet,Co-morbidity requiring a specific diet
Diet,Medication which contraindicates consuming a high-fiber diet
Diet,regularly eats 3 meals/day
Diet,No concurrent grapefruit juice during the first month of study participation
Diet,No concurrent grapefruit  grapefruit juice  or grapefruit-containing food or vitamins
Diet,Currently following a vegetarian diet
Diet,Dietary soy allowed
Diet,No concurrent grapefruit juice
Diet,Follow a vegan diet
Diet,No concurrent ingestion of high-fat meals
Diet,Normal  balanced diet (20-40% calories from fat)
Diet,Current dietary pattern includes suboptimal total fat  saturated fat and vegetable and fruit consumption
Diet,Dietary patterns meet current recommendations for saturated fat and vegetable and fruit consumption
Diet,Willingness to maintain current activity level and diet
Diet,Limited habitual intake of dairy products according to dietary questionnaire.
Diet,Active dieting
Diet,Dietary restrictions such as bread  dairy  peanut  aspartame  or meat products used in the study
Diet,consuming special diets
Diet,Currently following a vegetarian diet
Diet,medically prescribed or slimming diet
Diet,Prior use of the Atkins diet for more than 1 week
Diet,Prior use of the Atkins diet for over 1 week
Diet,Dietary intake of vitamin K below 120 mcg
Diet,Usual dietary intake of phylloquinone greater than 120 ??g/d
Diet,Usual dietary calcium intake greater than 1500 mg/d
Diet,Usual dietary vitamin D intake greater than 1500 IU
Diet,Currently following a vegetarian diet
Exercise,Exercise less than 20 min/day two days a week
Exercise,The subjects must be relatively sedentary  not currently engaged in strength-training exercises.
Exercise,Amount of physical activity exceeds 120 minutes of moderate exercise per week
Exercise,Moderate exercise examples: brisk walking  golfing  gardening  housework  house painting
Exercise,Current participation in a structured aerobic exercise program
Exercise,Patients for whom exercise is contraindicated or whose physicians believe that exercise is contraindicated.
Exercise,Men should exercise appropriate contraceptive measures while participating on the study.
Exercise,Have evidence of reduced exercise tolerance lasting longer than one week on either the St
Exercise,Have no exercise intolerance
Exercise,No physical handicap that would prevent resistance or aerobic exercise
Exercise,No concurrent regular exercise of 3 or more hours a week
Exercise,Medical conditions for which changes in diet and exercise levels would be contraindicated
Exercise,Cannot avoid strenuous exercise or constant activity for the study period.
Exercise,normal physical activity
Exercise,subjects who exercise vigorously
Exercise,No exercise intolerance
Exercise,History of excessive exercise (greater than 10 hours a week).
Exercise,Significant exercise-restricting disease
Exercise,Participation in an exercise program or strength training within the previous 4 weeks
Exercise,Are dieting or doing heavy exercising.
Exercise,Successful completion of a food and exercise diary over a 5-day period
Exercise,Caffeine  alcohol or strenuous exercise within 24 h before each test period.
Exercise,Major (greater than 3 hours/week) athletic/physical exercise activities.
Exercise,Failure to complete the two-week run-in for dietary intake and exercise.
Exercise,Complex ventricular arrhythmia at rest or with exercise (eg  ventricular tachycardia).
Exercise,They may continue with any ongoing exercise program
Exercise,Perform bicycle exercise test
Exercise,No exercise intolerance
Exercise,Taken exercise class for back pain within past year
Exercise,Individuals unable to exercise independently
Exercise,Health status that prohibits patient from performing graded exercise test
Exercise,Structured exercise more than once per week for 20 minutes or longer during the 3 months prior to study entry
Exercise,Any condition (other than CHF) that could limit exercise
Exercise,Willing to refrain from exercise for 24 hours prior to study entry
Exercise,No contraindications for exercising maximally
Exercise,Have exercise-limited non-cardiac chest discomfort
Exercise,less than 150 minutes regular exercise per week
Exercise,The patient already engages in more than one hour of weekly exercise.
Exercise,Unable to exercise safely
Exercise,Cannot engage in moderate intensity exercise (eg  walking)
Exercise,No contraindication to exercise as determined by a fitness test
Exercise,Physically capable of exercise
Exercise,Able to tolerate a moderate intensity exercise program
Exercise,Able to participate in exercise classes that meet 3 times per week for a minimum of 6 months.
Exercise,Physical challenges such as deformities that would impair ability to perform physical activities
Exercise,Currently exercising for more than 30 minutes  3 times per week
Exercise,Dyspnoea on exertion and a reduced exercise capacity
Exercise,Patients with handicaps for exercising
Exercise,Currently exercising less than 3 times per week
Exercise,Baseline exercise of more than 20 minutes two times per week
Exercise,regular exercise ( participating in 2 or more structured exercise sessions weekly for more than or equal to 6 months prior to enrolment).
Exercise,not currently exercising 120 min/wk or more
Exercise,Concurrent major health problems or disabilities that would limit participation in an exercise program.
Exercise,Not currently participating in 20 minutes or more of physical activity 3 times a week
Gender,Female gender only
Gender,Male sex
Gender,Participants must be female gender.
Gender,Female gender-to evaluate effects in the target population for clinical trials.
Gender,Male gender
Gender,Female sex
Gender,Male adolescents
Gender,Female adolescents
Gender,Male or female gender
Gender,Female gender
Gender,For all subjects female gender
Gender,Males and females
Gender,Female
Gender,Genders Eligible for Study: Female
Gender,Are female.
Gender,Sex distribution: Male and female.
Gender,Male and female subjects.
Gender,Male and female patients will be accepted.
Gender,Sex: Female or male
Gender,Healthy male volunteers
Gender,Genders Eligible for Study: Male
Gender,Genders Eligible for Study: Female
Gender,male/female.
Gender,Male and females
Gender,Subjects may be male or female
Gender,Gender: Patients may be male or female
Gender,male or female  in- or outpatients
Gender,Male or female subjects
Gender,1) Male or female of any race or ethnicity
Gender,Male patient
Gender,Genders Eligible for Study: Male
Gender,Sex Male or female
Gender,Genders Eligible for Study: Female
Gender,Genders Eligible for Study: Male
Gender,Female gender.
Gender,May be male or female
Gender,Genders Eligible for Study: Female
Gender,Sex Female
Gender,Healthy males or females.
Gender,1.Male or female patients.
Gender,Healthy male or female newborn
Gender,Healthy male volunteers
Gender,Female Gender
Gender,Both male and female
Gender,Sex: Male and female
Gender,both mal and female
Receptor Status,Hormone receptor status: Not specified
Receptor Status,Hormone resistant disease required of receptor positive patients
Receptor Status,Progesterone receptor positive or negative
Receptor Status,No concurrent selective estrogen-receptor modulators
Receptor Status,Hormone receptor status: Any status
Receptor Status,Progesterone receptor positive
Receptor Status,Peptide receptor antagonists
Receptor Status,Hormone receptor status: ER/PR status known
Receptor Status,Estrogen receptor (ER) and progesterone receptor status known by immunohistochemistry
Receptor Status,Estrogen receptor negative
Receptor Status,Kit receptor tyrosine kinase by immunohistochemistry using the Dako anti-CD117 antibody
Receptor Status,ER/PR negative
Receptor Status,Hormone receptor status: Estrogen and/or progesterone receptor positive
Receptor Status,Hormone receptor status: Estrogen receptor and/or progesterone receptor positive
Receptor Status,Progesterone receptor status known
Receptor Status,Hormone receptor status: ER status known
Receptor Status,Estrogen receptor and/or progesterone receptor positive (by laboratory/institutional standard) at the time of primary diagnosis or determined during subsequent biopsy/surgery of metastases.
Receptor Status,Selective estrogen receptor modifiers
Receptor Status,Hormone receptor status: Estrogen receptor (ER) status known
Receptor Status,Progesterone status known if ER analysis is negative
Receptor Status,Selective estrogen-receptor modulators
Receptor Status,ER  PgR and HER-2 status not determined.
Receptor Status,Patient already receiving AT1 receptor blocker
Receptor Status,Peptide receptor antagonist
Receptor Status,Positive estrogen and/or progesterone receptors as >10% cells or >10fmol/mg.
Receptor Status,ER and PgR negative
Receptor Status,Hormonal receptor status not determined.
Receptor Status,Erbb2 negative and/or ER and PgR negative
Receptor Status,Hormone receptor status: Estrogen receptor- (ER) or progesterone receptor- (PR) positive or negative tumor
Receptor Status,Hormone receptor status: Estrogen receptor-negative and progesterone receptor-negative tumor
Receptor Status,Patients with hormone receptor (ER and/or PgR) positive or both unknown.
Receptor Status,Previous or current use of ACE-inhibitors or Angiotensin II-receptor blockers
Receptor Status,Estrogen receptor (ER+) positive and/or progesterone receptor (PgR+) positive or ER/PgR unknown
Receptor Status,Patients must be positive for either ER or PR or both
Receptor Status,Unknown ER and PR status
Receptor Status,ER &/or PR positive
Receptor Status,Sample must be positive for ER and/or PR
Receptor Status,Her-2 overexpression and ER and/or PgR positive
Receptor Status,All tumors must be ER-  PR- and HER-2 negative.
Receptor Status,Any receptor status.
Receptor Status,Estrogen and progesterone hormone receptor status  determined before study registration.
Receptor Status,Hormone receptor status: Any receptor status allowed
Receptor Status,T >2 cm  N0  M0  regardless of ER or PR status
Receptor Status,Hormone receptor status: Estrogen receptor (ER)-positive OR ER-negative
Special Characteristic of Patient,Minorities are actively recruited.
Special Characteristic of Patient,Be able to participate as an outpatient.
Special Characteristic of Patient,NOTE: This study is approved for prisoner participation.
Special Characteristic of Patient,Inclusion criteria for minors
Special Characteristic of Patient,The first patient must have an identical twin donor
Special Characteristic of Patient,The patient must be clinically stable enough for outpatient evaluation.
Special Characteristic of Patient,Study is NOT approved for prisoner participation.
Special Characteristic of Patient,All subjects will be outpatients.
Special Characteristic of Patient,Membership in a vulnerable population (eg pregnant woman  prisoner  etc.)
Special Characteristic of Patient,6 years of education or work history
Special Characteristic of Patient,Inpatient or outpatient.
Special Characteristic of Patient,We will also recruit from the outpatient memory clinic
Special Characteristic of Patient,9th grade students who agree to provide profile data
Special Characteristic of Patient,No UCLA students or staff
Special Characteristic of Patient,No inmates or prisoners
Special Characteristic of Patient,Able to participate as an outpatient
Special Characteristic of Patient,Student attending sixth through eighth grades
Special Characteristic of Patient,Classification in school as a special education student
Special Characteristic of Patient,Inpatient admittance to Western Psychiatric Institute and Clinic
Special Characteristic of Patient,Healthy endurance-trained subjects
Special Characteristic of Patient,Subjects must be willing to be treated in the inpatient setting for a minimum of three days
Special Characteristic of Patient,Ability to participate in an outpatient study.
Special Characteristic of Patient,Inclusion: All students who attend Cleveland and Rainier Beach high schools are eligible.
Special Characteristic of Patient,Be able to participate as an outpatient.
Special Characteristic of Patient,Eligibility for care in the military medical system.
Special Characteristic of Patient,Homosexual donors
Special Characteristic of Patient,Postgraduate students
Special Characteristic of Patient,Student in participating school
Special Characteristic of Patient,Less than 10 years of formal education
Special Characteristic of Patient,Discharged by the hospitalist service or other inpatient services
Special Characteristic of Patient,Patients must be inpatients who are expected to stay in the hospital for at least 5 days
Special Characteristic of Patient,No prisoners.
Special Characteristic of Patient,6th or 7th grade students
Special Characteristic of Patient,Military or veterans health care beneficiary.
Special Characteristic of Patient,All subjects will be outpatients.
Special Characteristic of Patient,Must meet same criteria as that of a volunteer blood donor.
Special Characteristic of Patient,Be able to participate as an outpatient.
Special Characteristic of Patient,Undergraduate students at Oxford University
Special Characteristic of Patient,Donor siblings must have: HLA A2+.
Special Characteristic of Patient,INCLUSION CRITERIA: Graduate students and undergraduate students who have completed two years of college.
Special Characteristic of Patient,Require inpatient hospitalization.
Special Characteristic of Patient,History of military service 1989 or earlier.
Special Characteristic of Patient,Same cell type as donor sibling.
Special Characteristic of Patient,Student in grades 1 to 9
Special Characteristic of Patient,Must have ability to set up an outpatient monitoring system.
Special Characteristic of Patient,High school students (grades 9-12) enrolled in participating schools
Special Characteristic of Patient,Healthy volunteers studied as outpatients.
Special Characteristic of Patient,Donor: Partially HLA matched family donor
Special Characteristic of Patient,Students at the excluded colleges
Special Characteristic of Patient,The patient must be clinically stable enough for outpatient evaluation.
Special Characteristic of Patient,Ability to participate in an outpatient study for at least 26 weeks.
Special Characteristic of Patient,Positive cross-match with intended donor and/or ABO incompatible with intended donor.
Special Characteristic of Patient,Patients who are inpatients
Special Characteristic of Patient,exclusion criteria: military service prior to 1989.
Special Characteristic of Patient,No prisoners or institutionalized patients
Special Characteristic of Patient,All regular education students  including students in bilingual classes
Special Characteristic of Patient,The volunteer is currently on active duty in the US military.
Special Characteristic of Patient,Minorities are encouraged to participate.
Special Characteristic of Patient,Outpatient status required
Special Characteristic of Patient,Inpatients at OSF Saint Francis Medical
Special Characteristic of Patient,Minorities: All races and ethnic backgrounds.
Special Characteristic of Patient,VA Medical Center or outpatient clinics with at least 3000 patients.
Special Characteristic of Patient,Prisoners or subjects who are compulsorily detained
Special Characteristic of Patient,Eligible veteran of United States (US) military
Special Characteristic of Patient,Prisoners or incarcerated individuals
Special Characteristic of Patient,No military service prior to 1989 or after January 2003.
Special Characteristic of Patient,No prisoners or parolees
Ethnicity,Urban African Americans with arthritis
Ethnicity,Caucasian
Ethnicity,African American
Ethnicity,Race of all 4 grandparents self-identified either as all Caucasian or all African American.
Ethnicity,Inpatient monitoring will be provided when medically indicated.
Ethnicity,Race of all four grandparents self-identified as either all Caucasian or all African American.
Ethnicity,INCLUSION CRITERIA: Ethnicity: African Americans
Ethnicity,To enroll participants must self-identify as African Americans and be born in the United States  with American born parents or be born in Africa with African born parents
Ethnicity,In the future  we plan to expand the study to include other groups which self-identify as African Americans (ie AfroCarribeans and Hispanic blacks).
Ethnicity,EXCLUSION CRITERIA: African American Ethnicity other than American or West African ancestry
Ethnicity,In the future  we will expand the study to include other African American groups such as individuals of Afro-Caribbean and Hispanic blacks.
Ethnicity,Alcohol consumption during the inpatient pharmacokinetic portion of the study.
Ethnicity,Caucasian (at least 2 generations originating in any of the original peoples of Europe  North Africa  or the Middle East) OR
Ethnicity,African American (at least 2 generations originating in any of the black racial groups of Africa)
Ethnicity,African Americans are eligible if they had a non-cardioembolic ischemic stroke at lease 7 days  but no more than 90 days before entering the trial.
Ethnicity,Although this condition is rare amongst African-Americans  every effort will be made to recruit such individuals.
Ethnicity,African-American  Hispanic  or Caucasian Self stated  plus the same for all 4 grandparents
Ethnicity,African American (self-identified)
Ethnicity,Male and females African American subjects over 18 years of age.
Ethnicity,Full Japanese  African American  and Taiwanese ancestry
Ethnicity,Hispanics and Native Americans are oversampled  but non-Hispanic whites will be included for comparison purposes
Ethnicity,Black/African American or White/Caucasian
Ethnicity,Participant is of Ashkenazi Jewish ethnicity and either has had breast cancer or has 1 first-degree or 2 second-degree relatives with breast cancer (including ductal carcinoma in situ) or ovarian cancer
Ethnicity,African-American or Hispanic
Ethnicity,Adults of Caucasian and Japanese Ethnicity
Ethnicity,African American
Ethnicity,African-American or Caucasian
Ethnicity,African Americans
Ethnicity,Caucasian
Ethnicity,64 African-Americans
Ethnicity,56 Caucasians 
Ethnicity,African-Americans: Individuals will be considered to be African-American if they self-identify as African-American and were born in the United States
Ethnicity,Further they must describe both parents as being African-American and born in the United States.
Ethnicity,Asians and Pacific Islanders.
Ethnicity,Ashkenazi Jewish ethnicity and meets criteria for 1 of the following: Prior breast cancer diagnosis
Ethnicity,The patient population is expected  however  to be predominantly minority in composition (mainly African-American and Latino  with some Asian  European and Native American patients as well) as function of demographics and genetics of these diseases
Ethnicity,Self-identify as African American or Caucasian
Ethnicity,African  Caucasian  or Hispanic heritage
Ethnicity,Minority individuals  particularly African Americans and English speaking Hispanics will be included
Ethnicity,American Indian
Ethnicity,Patients other than African American
Ethnicity,White and Latino patients in a safety net hospital
Ethnicity,Male or female of African descent
Ethnicity,Self-identifies as all or part Latino
Ethnicity,Self-identifies as African American
Ethnicity,Caucasian race
Ethnicity,African American
Ethnicity,Unable to read English  Korean  or Chinese
Ethnicity,Self identification of Black  White or Hispanic Ethnicity
Ethnicity,African American or Latino
Ethnicity,African American
Ethnicity,must be fluent in either English or Chinese (Mandarin or Cantonese)
Ethnicity,unable to speak English or Chinese
Ethnicity,African Americans with stage 1-2 hypertension
Ethnicity,African American Men and Women
Ethnicity,Asian origin.
Ethnicity,Chinese speaking  capable to understand the study
Ethnicity,African American
Ethnicity,African American men and women with concurrent hypertension and dyslipidemia that is either treated or untreated
Organ or Tissue Status,Renal Not specified
Organ or Tissue Status,Pulmonary
Organ or Tissue Status,Menopausal status Not specified
Organ or Tissue Status,Hepatic Not specified
Organ or Tissue Status,Renal Not specified
Organ or Tissue Status,Normal lung function
Organ or Tissue Status,Menopausal status See Disease Characteristics
Organ or Tissue Status,Lung function normal
Organ or Tissue Status,No nasopharyngeal primaries
Organ or Tissue Status,Intact uterus (womb).
Organ or Tissue Status,Adequate renal function
Organ or Tissue Status,Adequate hepatic function
Organ or Tissue Status,Adequate organ function and bone marrow reserve.
Organ or Tissue Status,Palpable axillary lymph nodes
Organ or Tissue Status,Adequate pulmonary function
Organ or Tissue Status,No compromised pulmonary function
Organ or Tissue Status,Adequate hepatic  renal  and cardiac function.
Organ or Tissue Status,Normal heart and lung evaluations
Organ or Tissue Status,Adequate organ function
Organ or Tissue Status,Oral cavity
